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Abstract 
 
In this thesis, two potential applications of transdermal iontophoresis in the field 
of sports medicine were studied: (1) the local delivery of dexamethasone 
phosphate (Dex-Phos), a corticosteroid used to treat musculoskeletal 
inflammation, and (2) the extraction of systemic amino acids (AAs), potential 
biological markers of fatigue in athletes. 
 The iontophoretic delivery of Dex-Phos was studied, in vitro, in order to 
evaluate the effects of competing ions and electroosmosis, and identify the 
optimal conditions for its delivery. The iontophoretic extraction of AAs from the 
skin was first studied in vitro, before evaluating the method in a group of human 
volunteers. 
 Dex-Phos was best delivered by iontophoresis from the cathode in 
absence of background electrolyte in the drug solution. In this situation, the 
delivery of Dex-Phos is limited principally by the competition with counter-ions 
(mainly Na+) present subdermally and the small mobility of the drug inside the 
membrane. The accumulation of Cl-, released by the Ag/AgCl cathode in the 
drug solution during current passage, can also reduce Dex-Phos delivery. 
 The extraction of zwitterionic AAs from the skin during iontophoresis 
was highly influenced by their presence in the outermost layer of the skin, the 
stratum corneum (SC). In the pig skin model, the amount of the AAs extracted 
during a short extraction period (1 hour) correlated with their abundance in the 
SC. Once this ‘reservoir’ was emptied (after ∼3 hours of iontophoresis), the 
subdermal compartment could be sampled, suggesting that the method could 
be used to monitor systemic levels of AAs. The experiments in human 
volunteers revealed, however, that a 4-hour iontophoretic extraction period was 
insufficient to deplete the AAs SC ‘reservoir’. It follows that the method can be 
used to evaluate the abundance of AAs in the SC, but is unpractical for the 
clinical monitoring of their systemic levels.   
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Introduction 
 
Sports medicine is the branch of medicine that oversees the medical care of the 
exercising individual. It is a wide-range discipline that includes: the prevention, 
diagnosis, treatment and rehabilitation of injury and illness; the enhancement of 
performance through training, nutrition and psychology; and ethical issues, such 
as the problem of drug abuse in sport [1]. This underlies the need for medical 
methods for both treatment and diagnosis of injury and illness. On one hand, 
methods to treat locally musculoskeletal injury-related pain and/or inflammation 
would certainly be welcomed by clinicians and athletes. On the other hand, non-
invasive clinical monitoring tools could help, for example, either the athletes to 
maintain optimal physical fitness by following the level of biological markers of 
fatigue, or the sporting regulator agencies to detect the presence of prohibited 
substances in athletes. 
Iontophoresis is a minimally-invasive technique that enhances the 
transport of charged and polar molecules across the skin by the application of a 
mild electrical current (resulting usually in a current density <0.5 mA/cm2) [2]. 
The symmetrical nature of iontophoresis makes it useful for the delivery of 
therapeutic molecules in the body through the skin [3] or inversely (often called 
‘reverse iontophoresis’ in that context), for the transdermal extraction of 
endogenous substances of clinical relevance [4].  
Sports medicine could, therefore, strongly benefit from iontophoresis to 
both deliver drugs and monitor endogenous substances across the skin in a 
minimally-invasive manner. This research project concerns the development 
and optimization of iontophoresis in the field of sports medicine. Some 
examples of possible applications of iontophoresis in this field are summarized 
in Table 1. From these potential uses of iontophoresis in sports medicine, two 
are more specifically the subject of this thesis: (1) the optimization of local 
delivery of corticosteroids to inflamed joints using iontophoresis, and (2) the 
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evaluation of reverse iontophoresis as a clinical monitoring tool of biological 
markers of overtraining. 
 
Table 1. Examples of possible applications of iontophoresis in the field of sports 
medicine. 
Drug delivery Clinical monitoring 
Pain management 
- Reduce injury-related pain with local 
administration of: 
   + NSAIDs
a
 (piroxicam, diclofenac...) 
   + Local anesthetics (lidocaine) 
- Reduce post-operative pain with systemic 
administration of: 
    + Opioids (fentanyl, morphine…) 
Prevention of overtraining 
- Monitor overtraining biological markers 
- Non-invasive method 
- Many potential markers:       
     lactate, cortisol, testosterone, glutamine, 
tryptophan, branched-chain amino 
acids… 
Treatment of soft tissue inflammation 
- Treatment of musculoskeletal injuries 
- Local administration limiting side-effects 
- Wide range of possible drugs:     
   + Corticosteroids (cortisone,  prednisolone, 
dexamethasone…) 
   + NSAIDs
a
 (ketoprofen, diclofenac...) 
Anti-doping control 
- Control of prohibited substances 
- Systemic concentration and skin reservoir  
- Many potentially detectable doping agents:     
    caffeine, ephedrine, anabolic steroids... 
 
a
NSAIDs stands for non-steroidal anti-inflammatory drugs 
 
1. Iontophoresis of corticosteroids 
 
Corticosteroids are commonly used for the treatment of musculoskeletal injuries 
[1, 5-9]. The rationale of its use is to reduce pain and inflammation sufficiently to 
allow the commencement of a strengthening program. Local administration of 
corticosteroids by injection maximizes the clinical effect of the drug at the site of 
injury and minimizes the systemic side effects associated with the 
administration via the oral route [1, 6-10]. While the delivery of corticosteroids 
by injection is generally considered safe, the use of a needle is the source of 
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disadvantages and risks of complications. Indeed, corticosteroid injections are 
commonly the cause of postinjection pain and flares. As any invasive method, 
there is also a risk of infection at the site of injection. Furthermore, the efficiency 
of the treatment relies on the accuracy of the needle placement and an 
experienced health-care professional is required to perform the injection [1, 6, 
10].  
Iontophoresis represents an alternative to the needle to deliver locally 
corticosteroids [11-13]. Amongst the corticosteroids available, dexamethasone 
phosphate (Dex-Phos, MW: 472.4), a phosphorylated prodrug of 
dexamethasone (Dex), has undoubtedly been the most studied corticosteroid 
for iontophoretic delivery [12]. Dex-Phos is a potent corticosteroid (equivalent 
potency 25-fold higher than hydrocortisone and ∼6-fold higher than 
prednisolone), meaning that a smaller amount needs to be delivered to obtain a 
clinical effect [6]. Furthermore, Dex-Phos is available in the form of a disodium 
salt, dexamethasone sodium phosphate (MW 516.4) which is water soluble, and 
at physiological pH is essentially doubly negatively charged (pKas: 1.9 and 6.4). 
Many clinical studies have been conducted to evaluate iontophoresis of Dex-
Phos for the treatment of a variety of musculoskeletal problems [14-26]. A 
majority of these studies report at least subjective positive outcome [14-24]. 
However, improvement in the patient’s condition is not always seen [25, 26]. 
Moreover, the design of some of these clinical studies is questionable, 
preventing the true causes of the clinical outcomes to be identified [11]. The 
limited evidence supporting the iontophoretic delivery of Dex-Phos for the 
management of inflammatory musculoskeletal conditions is possibly the 
principal reason that the method has not yet been generally adopted by 
clinicians to replace the injection of corticosteroids. From a drug delivery 
perspective, it can be observed that a variety of iontophoretic conditions are 
employed in these studies. Indeed, the formulation of the drug solution and 
even the polarity of the electrode chosen for delivery vary from one study to 
another. Clearly, the optimal conditions for Dex-Phos iontophoretic delivery 
have not been identified and this could, at least partially, explain the results 
obtained in clinical studies. While the assessment of the effectiveness of the 
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method will ultimately require additional, better-designed clinical studies, it 
seems logical to determine the optimal delivery conditions beforehand.  
Hence, there is a need to find the optimal conditions for Dex-Phos 
iontophoresis that is addressed in this thesis. The goal is to better understand 
the effects of: (1) the ions present in the formulation and/or subdermally that are 
competing with Dex-Phos for the transport of current, and (2) the electroosmotic 
flow which normally occurs in the anode-to-cathode direction; that is against the 
electromigration of Dex-Phos delivered from the negative electrode (cathode). 
 
2. Reverse iontophoresis of markers of overtraining 
 
The other potential use of iontophoresis in sports medicine explored in this 
thesis is the monitoring of biological markers of overtraining. The overtraining 
syndrome can be defined as a state of prolonged fatigue and underperformance 
caused by the failure to recover from hard training and competition [1, 27]. It is 
most common in endurance athletes, touching, for example, as many as 10 to 
20% of elite swimmers per year [27]. Unfortunately, there is no single test that 
can detect overtraining in the athlete, but rather a number of clinical and 
laboratory parameters, which in combination can be used for the prevention of 
overtraining [1].  
Variations in the blood levels of some molecules have been linked to 
overtraining in athletes: lactate, cortisol, testosterone, glutamine, tryptophan 
and the branched-chain amino acids (BCAAs: isoleucine, leucine and valine) 
are examples of such overtraining biomarkers [1, 27-29]. Blood lactate 
increases exponentially as exercise intensity is increased. The lactate 
production during exercise is principally due to the anaerobic production of 
adenosine triphosphate (ATP), the chemical energy used in muscle, from 
glycogen [30]. In overtrained athletes, decreased blood lactate concentrations 
at maximal work rate have been observed [1, 31]. Cortisol and testosterone are 
hormones associated respectively with catabolic and anabolic activity. A 
decrease in the free blood testosterone to cortisol ratio is therefore an indication 
that the training load is too intensive to allow sufficient recovery (insufficient 
anabolic acitivity) and have been suggested as a marker of overtraining [1, 29]. 
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Glutamine is the most abundant amino acid in plasma and is used as a 
substrate by the cells of the immune system. When the body is placed under a 
catabolic stress, like during illness or exercise, the glutamine stores may be 
depleted. Indeed, a decrease in plasma glutamine has been observed in 
overtrained athletes and is proposed as a marker of fatigue in athletes [1, 27, 
29, 32].  
Tryptophan and the BCAAs (isoleucine, leucine and valine) are other 
primary amino acids that are linked with overtraining. Indeed, it has been 
suggested that overtraining can result in chronically diminished levels of BCAAs 
and increased free tryptophan plasma levels. During prolonged exercise, 
BCAAs are metabolized in skeletal muscles to generate energy and their 
plasma levels decrease as a result. The increase in free tryptophan plasma 
levels during sustained exercise originates indirectly from an increase in blood 
levels of free fatty acids (FFAs), used as a source of energy by the muscles, as 
the glycogen stores are depleted. As both tryptophan and FFAs are competing 
for the same binding sites on the protein albumin, some of the albumin-bound 
tryptophan is therefore released. Serotonin is a neurotransmitter metabolized in 
the brain directly from tryptophan and an increase in its concentration in the 
brain is believed to result in central fatigue. Since the transport of tryptophan 
across the blood-barrier is in competition with the transport of large neutral 
amino acids (BCAAs, phenylalanine and tyrosine), an increase in the free 
tryptophan-BCAAs concentration ratio in blood facilitates the entry of tryptophan 
into the brain. The free tryptophan to BCAAs ratio is therefore proposed as a 
marker of overtraining (or central fatigue) in athletes [1, 29, 33, 34]. 
To be really efficient, these biomarkers should be monitored on a regular 
basis in individual athletes, before and after exercise, because variation in 
levels, rather than absolute levels, gives an indication of overtraining [1, 29]. 
This is where an iontophoretic device capable of extracting non-invasively (and 
eventually analysing in situ) a biological marker of overtraining could be very 
practical. Indeed, the frequent blood samples would be avoided. The use of this 
transdermal technique to monitor biological markers of overtraining represents a 
novel application at the stage of evaluation and development. To date, the only 
work related to the subject, to the best of our knowledge, is a preliminary study 
on the monitoring of lactate by reverse iontophoresis, where it was 
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demonstrated that reverse iontophoresis could be used to extract lactate in vitro 
and in vivo [35]. However, considerable more research is required to evaluate 
this technique as a tool for the monitoring of biological markers of overtraining.  
In this thesis, the reverse iontophoresis of amino acids (AAs) in general 
is evaluated. As previously mentioned, glutamine, tryptophan and the BCAAs 
are all AAs that could be potential biological markers of overtraining. Central 
fatigue being present in other conditions than overtraining, a tool to monitor the 
free tryptophan to BCAAs ratio could find applications in other spheres of 
medicine. For example, it could be useful to follow patients after a surgery [36]. 
Furthermore, the similitude between many signs and symptoms of central 
fatigue observed in overtrained athletes and in patients suffering from clinical 
depression suggests that patients followed for depression could also benefit 
from the method to monitor their free tryptophan to BCAAs ratio [37, 38]. Since 
AAs fulfill a multitude of other functions essential to life [39], their clinical 
monitoring could find even more applications outside sports medicine. For 
example, hereditary metabolic diseases, such as phenylketonuria which 
concerns specifically the metabolism of phenylalanine, can result in mental 
retardation and early death if left untreated [39, 40]. Screening for these 
metabolic diseases in neonates currently requires a blood sample to be 
collected invasively, which could be avoided with a method like reverse 
iontophoresis [41, 42].  
Moreover, iontophoresis being a transdermal method, the AAs present 
inside the skin are also expected to be extracted during current passage. It is 
well documented that AAs are essential for skin’s health. Indeed, AAs and their 
derivatives are the main constituents of natural moisturizing factors (NMF), a 
mixture of highly hydroscopic molecules present in the stratum corneum (SC) to 
ensure that it retains an appropriate level of hydration [43-45]. Reduced levels 
of NMF in the SC are associated with diseased or abnormally dry and scaly skin 
[43, 46-48]. It follows that information from skin’s condition could also be 
obtained by reverse iontophoresis of AAs. On the other hand, it is also essential 
to verify if this expected ‘reservoir’ of AAs in the skin compromises the 
possibility of using reverse iontophoresis to monitor their systemic levels.   
This thesis aims at evaluating reverse iontophoresis for the clinical 
monitoring of AAs with in vitro and in vivo studies. The in vitro experiments are 
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necessary to verify that iontophoresis can extract detectable amounts of the 
AAs in a reasonable period of time and that the iontophoretic fluxes correlate 
with the subdermal concentration. The effect of the skin reservoir on the 
extraction fluxes can also be determined. Then, in vivo experiments are 
performed to confirm that the findings obtained in the in vitro study are 
applicable in human. 
 
3. Organization of the thesis 
 
In the first chapter, the literature on transdermal iontophoresis pertinent to the 
two applications studied here is reviewed.  
Chapters 2 and 3 concern the in vitro experiments performed to optimize 
and better understand the delivery of Dex-Phos by iontophoresis.  
In Chapters 4 and 5, the in vitro study evaluating reverse iontophoresis 
as a clinical monitoring tool of AAs is presented. First, in Chapter 4, the AAs 
‘reservoir’ in the SC is quantified and the possibility to use reverse iontophoresis 
to sample it is explored. Then, the possibility to correlate the extraction fluxes of 
AAs with their concentration in the subdermal compartment is evaluated in 
Chapter 5. The effect of the SC ‘reservoir’ previously characterized on the AA 
extraction fluxes is also investigated. 
Finally, reverse iontophoresis is evaluated for the extraction of AAs in 
human volunteers in Chapter 6. Again, the SC ‘reservoir’ in AAs is quantified in 
order to determine its effect on the iontophoretic extraction of endogenous AAs.  
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Transdermal iontophoresis for drug delivery and clinical 
monitoring: a review 
 
 
1. Introduction 
 
Iontophoresis generally refers to the use of an electric field to transfer charged 
and neutral, polar molecules through a biological membrane [1-4]. While the 
technique has been applied for ocular, buccal, tympanic and nail drug delivery 
[4-8], it is most commonly used for transdermal applications. Since the 
applications of iontophoresis in sports medicine considered in this thesis are 
related to the electrotransport of compounds across the skin, it is specifically 
transdermal iontophoresis that is covered in this review. More precisely, the 
objective of this chapter is to understand how transdermal iontophoresis can be 
used in sports medicine for the management of injury-related pain and tissue 
inflammation, and to monitor, without the use of a needle, compounds of 
interest in athletes such as markers of overtraining or doping agents.  
First, the transdermal route is described. Then, the theoretical basis of 
transdermal iontophoresis and some practical considerations are covered. 
Examples of iontophoretic drug delivery for the management of pain and 
treatment of inflammation follows and includes an overview of previous 
experimental research attempting to quantify the iontophoretic delivery of 
corticosteroids. Finally, the use of reverse iontophoresis for clinical monitoring is 
reviewed.  
 
2. The transdermal route 
 
2.1. Structure and function of the skin 
The skin is the largest organ of the body with an area of approximately 2 m2 and 
accounts for more than 10% of body mass [9, 10]. As illustrated in Figure 1, the 
skin consists of three distinct layers, the hypodermis (or subcutaneous tissue), 
the dermis and the epidermis, and several associated appendages: hair follicles 
and their associated sebaceous glands, eccrine sweat glands, apocrine sweat 
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glands and nails. The deepest layer of the skin is the subcutaneous tissue and 
is constituted of fat cells arranged in lobules and linked to the dermis by 
collagen and elastin fibres. In addition to the fat cells, the hypordermis also 
contains fibroblasts and macrophages. The principal functions of the 
subcutaneous tissue are to act as an insulator, a shock absorber, an energy 
storage region and to carry the vascular and neural systems for the skin [10].  
The dermis is made up of connective tissue elements and forms the bulk 
of the skin. Dermis is highly vascular and includes dermal adipose cells, nerve 
endings as well as sebaceous and sweat gland. It plays an important role in the 
regulation of temperature, pressure and pain, and provides nutritive and 
immune support to the epidermis [9, 10].  
The overlaying, avascular epidermis is composed essentially of 
keratinocytes (∼95%), but also contains melanocytes, Langerhans cells and 
Merkel cells. The total thickness of the epidermis is ∼100 to 150 µm and is 
constituted of four distinct layers (Figure 2). The keratinocytes originate from a 
layer called stratum basale, located at the interface between the dermis and the 
epidermis, and undergo continuous differentiation during the course of migration 
upward through the layers of spinosum and granulosum.  
Finally, the outermost layer of the epidermis, called the stratum corneum 
(SC), is composed of corneocytes (terminally differentiated keratinocytes) and 
the secreted contents of the lamellar bodies (elaborated by the keratinocytes). 
The epidermis has, above all, a function of protection, which covers physical, 
chemical (including water loss), immune, pathogen, UV radiation and free 
radical defences. It is the stratum corneum, and more precisely the highly 
tortuous path (due to its brick-and-mortar organization) through which 
substances have to traverse in order to cross it, that is the most efficient barrier 
against chemical penetration in the body and water loss from the skin [9, 10]. 
 The barrier function of the SC is further facilitated by the continuous 
desquamation of its top layer, resulting in a total turnover every 2-3 weeks. The 
controlled loss of corneocytes from the surface of the skin is regulated by the 
water content of the SC. Critical in maintaining the SC hydrated despite the 
desiccating action of the environment are the natural moisturizing factors 
(NMFs). NMF is exclusively found in the SC and comprises water soluble and 
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hydroscopic compounds capable of retaining water (Table 1). As it can be 
observed in Table 1, the principal constituents of NMF are the free amino acids 
(AAs) and their derivatives (pyrrolidone carboxylic acid and urocanic acid). 
These AAs are derived from a protein precursor system: the profilaggrin-
filaggrin system [11-13]. As seen in Figure 2, the profilaggrin is first expressed 
in the stratum granulosum as a large highly phosphorylated protein (>500 kDa) 
composed of multiple filaggrin repeats linked by short hydrophobic peptides. As 
the keratinocytes mature into corneocytes and form the SC, the profilaggrin is 
dephosphorylayed in filaggrin (37 kDa), which is itself proteolyzed to NMF within 
the corneocytes [11-13].    
 
 
Figure 1. Illustration of the principal structures of the skin (http://www. 
healthsystem.virginia.edu/uvahealth/adult_derm/images/ei_0390.gif). 
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Figure 2. Illustration of the epidermis [12]. 
 
Table 1. Chemical composition of natural moisturizing factor [13]. 
Chemical Composition (%) 
Free amino acids 40 
Pyrrolidone carboxylic acid 12 
Lactate 12 
Sugars 8.5 
Urea 7 
Chloride 6 
Sodium 5 
Potassium 4 
Ammonia, uric acid, glucosamine and creatine 1.5 
Calcium 1.5 
Magnesium 1.5 
Phosphate 0.5 
Citrate and formate 0.5 
 
 
2.2. Advantages and limitations of the transdermal route 
It follows that trying to deliver or extract compounds from the skin in a 
minimally-invasive manner is against the very nature of this formidable barrier 
and represents, therefore, a real challenge. In the case of clinical monitoring, 
transdermal extraction relying exclusively on passive diffusion is not sufficiently 
efficient for practicable use unless the barrier is compromised [14, 15]. For a 
limited number of very potent drugs, with appropriate physicochemical 
properties (MW < 500 Da, aqueous solubility > 1 mg/mL and 10 < Ko/w < 1000), 
it is possible to rely only on passive diffusion for their transdermal delivery [16]. 
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Transdermal drug delivery is accompanied with many advantages: avoidance of 
first-pass effect and/or gastro-intestinal metabolism or degradation, easy 
access, non-invasive and consequently improved patient acceptance and 
compliance [16].  
 
2.3. Pig skin as a model of human skin 
As excised human skin is often difficult to obtain, animal skin is extensively 
used as a model, with pig skin being the most reliable [17]. Indeed, porcine skin 
is a well-established model of human skin and is often used to assess 
transdermal transport either in vivo, or in vitro [18, 19]. The skin model remains 
representative of the in vivo situation even if it was kept frozen before use [20]. 
Recently, it was demonstrated that pig skin could also be used as an in vitro 
model for its in vivo human counterpart during tape-stripping procedure, either 
to assess drug permeability in this membrane or its barrier function [21, 22]. 
Again, storage of the skin in the freezer until its use had no apparent 
detrimental effect on the tape-stripping procedure [23, 24]. 
 Pig skin is also an established model of human skin for iontophoresis 
studies. For example, the transport fluxes of lithium measured with the pig skin 
in vitro model could be directly used to predict those observed in vivo in man 
[25]. Furthermore, the pig skin model is a cation-permselective membrane as its 
human counterpart (with a similar pI), meaning that it can also be used to model 
the electrotransport of neutral molecules by electroosmosis [26]. 
 
3. Transdermal iontophoresis 
 
3.1. Description of iontophoresis 
Iontophoresis is one of many methods that have been developed in order to 
improve the efficiency of transdermal delivery and expand the range of 
compounds that could be transported through the skin. Most of these methods 
(chemical enhancers, microneedles, needless injections, sonophoresis etc.) 
increase the permeability of the skin via direct effects on the skin barrier itself, 
such as the disruption or the extraction of SC lipids for example [27, 28]. In 
iontophoresis, an electrical field is applied across the skin, generally via a mild 
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constant current (≤0.5 mA/cm2),  in order to act principally on the molecules 
themselves rather than on the skin’s barrier [1-4]. Indeed, the major 
perturbations of the SC observed after application of iontophoresis are limited to 
an increase in hydration and a moderate disorganisation of the lipid bilayers 
(not always observed [29]), which are hardly modifying the barrier function of 
the skin [30]. Furthermore, the viable skin is also minimally affected during 
current application as evidenced by only mild erythema and fast skin recovery 
usually observed after iontophoresis [30, 31]. In summary, when used correctly, 
iontophoresis is considered as a safe and minimally-invasive technique. 
Iontophoresis should not be confused with electroporation, another electrically-
assisted transdermal technique that applies high voltage (>100 V) pulses of 
short duration (µs-ms) in order to increase the skin’s permeability [32].  
 The principal advantage of iontophoresis is to open the way to the 
transdermal transport of polar and/or charged molecules whose passive skin 
permeation is severely restricted [16]. Other advantages include the possibility 
to control the extent of transdermal passage by simple adjustment of current 
intensity, and to limit the effect of skin’s condition on its efficiency [1-4, 33, 34]. 
 
3.2. The electrical circuit of iontophoresis 
A basic iontophoretic system is composed of a power supply and two electrodes 
placed on the skin via a conducting electrolytic medium (Figure 3). The 
electrical current passed in the circuit determines how much of the charged 
species are carried across the skin. The electrochemistry occurring at the 
electrode/electrolyte interface permits the transition from a current of electrons, 
in the external circuit, to a current of ions in the electrolyte and the skin. There 
are two types of electrodes: non-consumable and consumable [35]. When non-
consumable electrodes, made of inert materials (e.g., platinum, glassy carbon, 
stainless steel), are used in an aqueous electrolyte solution, electrolysis of 
water is likely to occur. The respective electrochemical reactions at the anode 
and cathode are: 
)2.(222:
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As it can be seen from eq.1 and 2 respectively, each electron flowing in the 
circuit generates a proton at the anode and a hydroxyl ion at the cathode. This 
can lead to pH shifts during iontophoresis unless the solutions are sufficiently 
buffered. Furthermore, the gases generated can accumulate on the electrode or 
skin surface and may interfere with the uniformity of current distribution [35]. In 
order to avoid reaction of water at the electrodes, materials with lower redox 
potential can be used. Ag/AgCl is an example of consumable electrode very 
popular for iontophoresis due to its biocompatibility, its reversability and the fact 
that pH shifts are avoided [35, 36]. The electrochemical reactions of Ag/AgCl at 
the anode and cathode are respectively: 
)4.(:
)3.(:
)()()(
)()()(
eqClAgeAgClcathode
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As one chloride is consumed at the anode for each electron flowing in the 
circuit, the electrolyte in contact with this electrode needs to have sufficient 
chloride for the duration of the experiment. Otherwise, Ag+ are released in the 
anodal compartment and can lead to competition with the delivery of cationic 
drugs and apparition of stains on the skin. At the cathode, one chloride is 
released for each electron. The flux of anionic drugs delivered from the cathode 
may therefore decrease progressively due to the increasing chloride 
concentration in the donor solution [35, 37-40]. 
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Figure 3. Schematic diagram of molecular transport during iontophoresis. 
Electromigration is represented by the thick black arrows and the electroosmotic 
flow by the grey arrows (inspired from [1]). 
 
3.3. Mechanisms of transport 
Three mechanisms can contribute to the transport of a molecule across the skin 
during iontophresis: (1) the direct interaction of the (charged) molecule with the 
electrical field (electromigration), (2) the convective transport due to the solvent 
flow (electroosmosis), and (3) the diffusion related to a concentration gradient 
(passive diffusion) [3]. The total flux of a molecule being transported 
transdermally (Jtot) is therefore the sum of these three contributions: 
)5.(eqJJJJ PEOEMtot ++=  
where JEM represents the flux attributable to electromigration, JEO, that obtained 
by electroosmosis, and, JP, the contribution of passive diffusion. For many 
compounds, however, passive diffusion can be neglected and the two main 
mechanisms of transport are electromigration and/or electroosmosis [1, 2].  
Electromigration can be thought of as the repulsion of solute ions by an 
electrode of like charge and their migration towards an electrode of opposite 
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charge (Figure 3). The reality is slightly more complicated and is a direct result 
of the application of an electrical. As seen previously, the electrical current 
imposed through the electrodes results in electrochemical reactions at the 
surface of the electrodes resulting in the release or consumption of charges 
species. Ionic transport occurs through the skin in order to maintain 
electroneutrality in the electrode compartments. The speed of migration of an 
ion is determined by its physicochemical characteristics and the properties of 
the media through which the ion is progressing. The sum of the electrical 
current carried by each ion must equal to the electrical current supplied by the 
power source. Practically, as far as drug delivery is concerned, this means that 
the drug will compete for the current delivery with all the other ions present in 
the system [41]. The efficiency of transport, or in other words the fraction of the 
total charge transported by a given drug, can be evaluated by determining its 
transport number, td: 
)6.(eq
zc
zc
t
i
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ddd
d
∑
=
µ
µ
 
where c, z and µ refer respectively to the concentration, valence and mobility 
inside the skin of either the drug (d) or ion (i) [41]. It can be seen from this 
equation that a small ionic (highly mobile) drug will have a higher transport 
number than a larger (less mobile) one. Electromigration is thus considered to 
be an efficient mechanism of transport for relatively small ions. Experimentally, 
the transport number of the drug can be deduced from the measurement of the 
ionic flux of the drug, Jd, using the relation: 
)7.(eq
zF
tI
J
d
d
d
⋅
⋅
=  
where I is the electrical current passed, F, the Faraday’s constant and zd, the 
valence of the drug [20].  
Electroosmosis has its origin in the fact that the skin is a negatively 
charged membrane at physiological pH. When an electrical potential is applied 
across a membrane containing fixed charge, a bulk flow of solution (volume 
flow) occurs in the direction of the counter-ion flow [42]. This means that for the 
negatively charged skin, the electoosmotic flow is oriented in the direction of the 
cations, in the anode-to-cathode direction (Figure 3). This will have as an effect 
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to assist the transport of cations and retard that of anions. This flow of solvent 
will carry through the skin any dissolved solute and is therefore the mechanism 
enhancing the transdermal delivery of neutral, but polar, molecules. The 
electroosmotic flow is proportional, at least in first approximation, to the 
concentration of the solute and is the dominant mechanism of transport for the 
delivery of larger molecules [1]. The pH and the ionic strength are the main 
parameters of the formulation that can be used to modulate electroosmosis by, 
respectively, modifying  and screening the skin’s charge (the isoelectric point is 
∼4.8 for human skin) [26, 43].  
 
3.3. Pathways of transport 
The electric current follows the routes of least resistance and the presence of 
appendages in the skin (i.e. hair follicles and sweat glands) raises the question 
whether ionic transport is localized in these natural ‘pores’ during iontophoresis 
[44]. Many techniques have been used in order to identify the principal routes of 
ionic transport across the skin. A method, involving the scanning of the skin 
surface with a vibrating probe electrode, revealed that the current is highly 
localized in structures related with skin appendages [45]. This was further 
confirmed with scanning electrochemical microscopy (SECM) during 
iontophoresis of ionized and neutral compounds, suggesting that significant 
transport during both electromigration and electroosmosis is associated with 
appendageal pathways [46-50]. Another technique proposed to evaluate the 
contribution of the appendageal routes is the skin sandwich, which consists in 
the superposition of two pieces of epidermis and virtually ensures that 
appendages of the two layers do not superpose  [51, 52]. The transport or ionic 
and neutral compounds across the skin sandwich was importantly decreased 
compared to the transport measured in the single-epidermis case, suggesting 
that the ‘shunts’ in the skin are important pathways during iontophoresis [51, 
52]. On the other hand, X-ray microanalysis after iontophoresis of mercuric 
chloride demonstrated that the mercuric ions are also transported through the 
intercellular route [53].  Confocal microscopy analysis of the skin, after the 
delivery of fluorescent compounds, also confirmed the appendageal and 
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intercellular routes, and suggests that their role is dependant on the physico-
chemical properties of the compound being delivered [54-56].   
 
3.4. Parameters affecting iontophoresis 
The iontophoresis of a compound across the skin is affected by its 
physicochemical properties, the electrical parameters applied and the 
composition of the electrode compartments. The charge, the molecular weight, 
the mobility and the lipophilicity of a compound are physicochemical properties 
of great importance in iontophoresis. The charge determines the amplitude and 
direction of electrostatic force acting on the molecule and higher fluxes are 
usually observed for charged compounds. Due to the cationic permselectivity of 
the skin, cations are usually better transported during iontophoresis [38]. The 
iontophoretic fluxes of charged molecules have been shown to decrease rapidly 
with molecular weight and aqueous mobility [4, 57]. For neutral compounds 
transported mainly by electroosmosis, the fluxes are only slightly affected by the 
molecular weight at least for compounds in the range 60-400 Daltons [58]. An 
increase in lipophilicity usually results in a decrease of the iontophoretic flux [4]. 
 From equation 7, it can be seen that the iontophoretic flux of a 
compound is proportional to the intensity of current applied and this has been 
verified for many charged compounds [3, 59]. Similar comportment has also 
been observed for electroosmosis [43, 60]. The current intensity that can be 
applied is however limited by the maximal current density that is tolerable in 
human (∼0.5 mA/cm2) [31]. Obviously, the quantity of a compound transported 
through the skin will also be linearly proportional to the time of current 
application. 
 Finally, the ionic composition of the electrode compartment can have an 
important effect on the iontophoretic transport. In the case of delivery of a 
charged drug, the inclusion in the donor of co-ions usually results in decreased 
efficiency in its transport due to competition [1, 2]. In presence of co-ions, the 
flux of the drug is increased by increasing its concentration (molar fraction) in 
the donor [59, 61]. In absence of co-ions, however, increase of drug 
concentration has usually no significant effect [59, 61]. Increase in ionic strength 
of the donor also results in decreased transport of neutral compounds from the 
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anode due to a reduction of the solvent flow [42, 43]. Similarly, the extraction 
efficiency of a neutral analyte at the cathode also decreases with an increase in 
ionic strength of the extraction solution for the same reason. The pH is another 
parameter of importance. Firstly, the pH of the solution may have an effect on 
the charge of the molecule iontophoresed (dependant of the pKa of the 
compound). Moreover, the pH can change the charge of the skin, which can 
result in a modification of its permselectivity and the amplitude (and direction) of 
the net electroosmotic flow [26, 42, 43].   
  
4. Transdermal iontophoretic drug delivery 
 
Iontophoresis has been used to deliver across the skin a wide range of 
compounds including peptides and proteins [62, 63], oligonucleotides [64, 65], 
anti-Parkinson drugs [59, 66, 67], anti-viral agents [68-70] and pilocarpine (for 
the diagnosis of cystic fibrosis) [71]. The following sections will focus on the 
drug delivery for the management of pain and inflammation. 
 
4.1. Iontophoresis for administration of local anesthetics 
Local anesthetics are used to locally inhibit sensation. Lidocaine is a positively 
charged local anesthetic that has been successfully delivered by iontophoresis 
prior a variety of invasive interventions, e.g. insertion of a needle, catheter or 
cannula, laser surgery and shave biopsy [72-76]. The delivery of lidocaine by 
iontophoresis was compared to its topical application and subcutaneous 
infiltration. It was found that iontophoresis was more efficient than topical 
application and resulted in a quicker onset of action in addition to a longer 
duration and improved depth of anesthesia [77, 78]. Anesthesia induced by 
iontophoresis was of slightly shorter duration than that obtained by 
subcutaneous injection, but was better tolerated than the latter by patients [78, 
79]. Pharmacokinetics studies in weanling pigs showed that the addition of a 
vasoconstrictor (e.g., epinephrine, norepinephrine) in the lidocaine donor 
solution resulted in increased residence time at the site of delivery and a lower 
systemic delivery [80, 81]. This conclusion was supported by an in vivo study in 
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human showing that the addition of epinephrine increased the duration of 
anesthesia [82].  
These positive results led to commercialization of devices designed to 
deliver mixtures of lidocaine and epinephrine. The first FDA approved 
iontophoretic delivery system for lidocaine/epinephrine has been the 
IONTOCAINE from IOMED (Salt Lake City, UT), which consists in a gel 
electrode that requires to be filled with a solution of the drugs before 
iontophoresis with IOMED’s Phoresor drug delivery system. Vyteris (Fair 
Lawn, NJ) now commercializes a recently FDA approved, disposable pre-filled 
electrode system that is used with a reusable power supply (Figure 4).  
 
 
Figure 4. The LidoSiteTM iontophoretic system for topical delivery of lidocaine 
(http://www.vyteris.com/home/Our_Products/Lidosite.php) 
 
Recently, the specific use of lidocaine iontophoresis for the pain 
management of (sport-related) soft tissue injuries has been considered [83, 84]. 
One prospective study found that the iontophoreis of lidocaine was more 
effective than the oral administration of non-steroidal anti-inflammatory 
medication for the pain management of acute soft tissue injuries in the 
emergency department setting [83]. Another study, where the iontophoresis of 
lidocaine was part of larger treatment algorithm for five patients with ‘tennis 
elbow’, showed clinical improvement of the patients over time [84]. While the 
results of these prospective studies are encouraging, more studies are required 
to substantiate the use of lidocaine iontophoresis for such applications.    
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4.2. Iontophoresis for systemic administration of opioids 
Opioids are a class of molecules (MW 300-500) with analgesic properties that 
are administered systemically to alleviate acute pain, such as post-operative 
pain. Surgery has an important role to play in the management of both acute 
and overuse sport-related injuries [85]. The iontophoretic delivery of opiods is 
therefore relevant to sports medicine. The size, positive charge under 
physiological conditions and relatively high potency makes these molecules 
good candidates for systemic delivery by iontophoresis. The iontophoretic 
delivery of hydromorphone, morphine, buprenorphine, nalbuphine, sufentanil 
and fentanyl has been studied [86-92].  
The pharmacokinetics of fentanyl have been investigate extensively, as a 
function of the current intensity and profile, the dosing regiment, the site of 
application and demographics (sex, age, race and weight) of the patient, using 
an iontophoretic delivery platform developed by ALZA Corporation (Mountain 
View, CA), the E-TRANS [34, 93-97]. The results showed that the plasma 
concentration increased continuously during the fentanyl delivery by 
iontophoresis over a 24-hour period, and that the maximum plasma 
concentration of the drug increased in direct proportion with the intensity of the 
current applied [93]. Furthermore, when the iontophoretic system was used in 
the intermittent mode to deliver fentanyl during 20 minutes at the beginning of 
each hour over a 24-hour period, the plasma profiles obtained for iontophoresis 
paralleled those obtained with intravenous (IV) infusion (Figure 5) [93]. 
Moreover, the dose administered was found to be linearly related with the 
intensity of current applied and independent of the patient’s demographics, such 
as age, bodyweight, race and sex, and whether the device was placed on the 
chest or the outside of the upper arm [95, 96]. It was also found that the 
equivalent dose obtained from a single 10 minutes current application was 
independent of the frequency and total number of doses applied [97]. The 
safety and efficacy of the delivery system were also assessed in clinical trials. 
The device was well tolerated, and importantly, it was more efficient than 
placebo and of equivalent efficiency than the on-demand intravenous infusion of 
morphine for the management of post-surgery pain [98, 99].  
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These positive results led to the recent commercialization of a device 
based on the E-TRANS platform: the IONSYSTM (Janssen-Cilag), an FDA 
approved needle-free, patient-controlled, iontophoresis fentanyl delivery system 
(Figure 6). The device, of the size of a credit card, is installed on intact skin of 
the upper outer arm or chest of hospitalized patients for their pain management. 
By pressing twice on the ‘on-demand button’, the patient receives a 40µg dose 
of fentanyl delivered over a 10 minutes period, a process that can be repeated 
80 times over a 24 hours period [http://www.ionsys.net]. 
 
IV infusion 50 µg
Ionto 0.25 mA
Ionto 0.20 mA
Ionto 0.15 mA
 
Figure 5. Mean serum concentration of fentanyl as a function of time for three 
iontophoretic currents applied for 20 minutes at the beginning of each hour for 
24h, compared to the IV infusion of 50 µg (per 20 minutes application period) of 
the drug using an identical delivery regiment [93]. 
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Figure 6. IONSYSTM iontophoresis fentanyl delivery system [92]. 
 
4.3. Iontophoresis for local administration of NSAIDs 
Non-steroidal anti-inflammatory drugs (NSAIDs) are pharmacologic agents with 
analgesic, antipyretic and anti-inflammatory effects that are widely used in the 
treatment of sporting injuries [85]. Most of these drugs, when administered 
orally, provoke adverse effects in the gastrointestinal tract, which may result in 
ulceration of the mucosa and bleeding. The rationale of using iontophoresis is 
therefore to deliver directly the molecules at the target (inflamed) site, while 
limiting the systemic side effects of the drug. As these compounds are acidic 
and usually negatively charged under physiological conditions, it is expected 
that iontophoresis from the cathode can result in an increased delivery 
compared to passive diffusion [2, 100]. 
 This hypothesis was tested for numerous NSAIDs in both in vitro and in 
vivo studies [39, 40, 101-109]. In the case of piroxicam, a 6-hours iontophoresis 
period from solutions or gels of the drug, in vitro, resulted in a 100-1000 fold 
increase of its transdermal delivery compared to passive diffusion [39]. In an in 
vivo study in man, it was found that iontophoresis also enhanced the amount of 
piroxicam present in the stratum corneum compared to passive diffusion [101]. 
The in vitro iontophoresis of ketorolac from the cathode, using current densities 
ranging from 0.11 to 0.5 mA/cm2, through rat skin was also found to be much 
more efficient (10-100 fold increase) than its passive delivery [102]. A study in 
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rats, using two microdialysis probes located respectively in the dermis and 
subcutaneous tissue underneath the delivery electrode (cathode), demonstrated 
that 15 minutes of current application (0.4 mA/cm2) was sufficient to deliver a 
high amount of flurbiprofen in the dermis and underlying tissue while 
maintaining a low plasma concentration [103]. Deep (3-4 mm) penetration of 
salicylic acid in rats underneath the donor electrode was also attributed to its 
direct cathodic delivery (0.38 mA/cm2, 120 minutes), while deeper penetration 
(>3-4 mm) was due to systemic redistribution of the drug [104]. Ketoprofen was 
also delivered more efficiently from the cathode than by passive diffusion [105]. 
Furthermore, ketoprofen was present in the venous blood collected close to the 
delivery site after iontophoresis in human and rat, demonstrating that the drug 
was delivered transcutaneously [105-107]. The local transcutaneous delivery 
was further demonstrated in an in vivo study in pig where the drug was 
quantified in the skin and underlying muscles after iontophoresis [108]. The 
transdermal delivery of the sodium, potassium and ammonium salts of 
diclofenac from the cathode were also more efficient than their respective 
passive delivery [109]. The local increase in concentration after iontophoresis of 
underlying tissues (as deep as muscle) was also demonstrated for sodium 
diclofenac administered to rabbits [40]. 
 The efficiency of iontophoretic delivery of NSAIDs to treat 
musculoskeletal conditions has been evaluated in clinical studies in man. Table 
2 (updated from [100]) summarizes the delivery conditions and clinical outcome 
for the treatment of articulation dysfunctions using iontophoresis of NSAIDs. All 
of the clinical investigations demonstrated at least subjective positive clinical 
outcome.  
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Table 2. Clinical investigations of NSAIDs iontophoresis  [100, 110-115]. 
Dysfunction Delivery 
electrode 
Current dose 
(mA⋅min) 
NSAID Number of 
treatments 
Outcome 
Joint or tendon 
inflammation 
Cathode ? Diclofenac 10 
Clinical 
improvement 
[110] 
Upper 
extremity 
periarthritis 
Cathode 100-240 Diclofenac 20 
Subjective pain 
relief [111] 
Upper 
extremity 
periarthritis 
Cathode 100-240 Pirprofen 10 
Subjective pain 
relief [112] 
Rheumatic 
dysfunction 
Cathode 41 
Pirprofen or 
Lys-aspirin
a
 
10 
Subjective pain 
relief [113] 
Rheumatic 
dysfunction 
Cathode 40 Ketorolac 5 
Subjective pain 
relief [114] 
Lateral 
epicondylitis 
Cathode 120-220 
Diclofenac or 
salicylic acid 
18 
Subjective pain 
relief [115] 
a
 Lysine soluble aspirin 
 
4.4. Iontophoresis for local administration of corticosteroids 
Corticosteroids are another type of drugs with anti-inflammatory effect and are 
also commonly used in the treatment of musculoskeletal injuries [85]. The 
rationale behind the use of iontophoresis for the delivery of these 
pharmacological agents is the same than that discussed for NSAIDs: local 
delivery of the drug at the inflamed site to obtain an anti-inflammatory effect with 
minimal systemic exposition of the drug, therefore limiting the adverse effects. 
While corticosteroids are chemically neutral molecules at physiological pH, it is 
possible to chemically modify them in order to form prodrugs containing an 
acidic group (e.g., sulphate or phosphate) that are negatively charged in 
physiological conditions. For example, dexamethasone phosphate (Dex-Phos) 
is a prodrug of the corticosteroid dexamethasone (Dex) and is essentially 
doubly charged at physiological pH (pKas: 1.9 and 6.4). Iontophoresis from the 
cathode is therefore expected to increase the delivery of these anionic 
prodrugs. In the two following sections, the clinical studies performed to 
evaluate iontophoresis of corticosteroids for the treatment of musculoskeletal 
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conditions and the experimental studies carried to quantify their transcutaneous 
delivery are reviewed.  
 
4.4.1. Clinical studies 
Many studies have been conducted in human to evaluate the clinical relevance 
of corticosteroid iontophoresis to treat acute soft tissue inflammation (e.g. 
bursitis, tendonitis, carpal tunnel syndrome). The iontophoretic conditions used 
in these studies are summarized in Table 3 together with the clinical outcome 
obtained. It can be observed that the clinical outcome was not always positive. 
Moreover, a variety of iontophoretic conditions were used (and in some cases 
were not clearly described), strongly suggesting that the optimal conditions 
have not been clearly identified yet. 
 
Chapter 1 
 44 
Table 3. Clinical studies of corticosteroid iontophoresis [100, 116-129]. 
Dysfunction Delivery 
electrode 
Current 
dose 
(mA⋅min) 
Drug 
formulation 
RX
a 
Outcome 
Musculoskeletal 
inflammation 
Anode 85 Dex/Lido
b
 1-3 
Subjective pain relief 
[117] 
Tendinitis 
inflammation 
? 45 Dex/Lido
b 
4 
Subjective & objective 
improvements [118] 
Musculoskeletal 
dysfunction 
Anode 3-7 Triam-Ace
c 
11 
56% subjects pain relief 
[116] 
Muscle 
soreness 
Anode 65 Dex/Lido
b
 1 
Subjective improvement 
[119] 
Infrapatellar 
tendinitis 
? 40-80 Dex/Lido
b
 6 
Subjective & objective 
improvements [120] 
Carpal tunnel 
syndrome 
? 40-45 Dex/Lido
b
 3 
58% subjective & object- 
tive improvements [121] 
TMJ
d
 
dysfunction 
Cathode 40 Dex/Lido
b
 3 
No improvement from 
iontophoresis [122] 
Rheumatic 
knee 
Cathode 80 
Dex-Phos 
0.2%
e 
3 
Subjective improvement 
[123] 
TMJ
d
 
dysfunction 
? 40 Dex/Lido
b
 3 
Objective improvement, 
but no pain relief [124] 
Plantar fasciitis Cathode 40 
Dex-Phos 
0.4%
e
 
6 
Enhanced rehabilitation 
[125] 
Lateral 
epicondylalgia 
Cathode 40 
Dex-Phos 
0.4%
e
 
4 
No improvement from 
iontophoresis [126] 
Achilles tendon 
pain 
? ? Dex
f
 4 
Subjective improvement 
[127] 
Acute 
epicondylitis 
Cathode 40 
Dex-Phos 
0.4%
e
 
6 
Subjective improvement 
[128] 
Carpal tunnel 
syndrome 
Cathode 40-45 
Dex-Phos 
0.4%
e
 
3 
Subjective improvement 
[129] 
a
RX, number of treatments 
b
Dex/Lido, mixture of injectable Dex-Phos 0.4% in citrate:lidocaine HCl (1:2) 
c
Triam-Ace, Triamcinolone-acetonide (Kenacort-A) 
d
TMJ, temporomandibular joint 
e
Dex-Phos solution, the presence of other ionic species is unknown 
f
Solution of unknown composition 
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4.4.2. Quantitative Studies 
Quantitative studies have been performed in order to evaluate the actual 
amount of corticosteroids delivered during iontophoresis and to optimize the 
iontophoretic conditions. Similarly to clinical studies, most quantitative studies 
were carried with Dex-Phos with only few studies performed with different 
corticosteroids. One study looked at a variety of commercially available water-
soluble corticosteroids (including triamcinolone-acetonide, prednisolone sodium 
tetrahydrophthalate, hydrocortisone sodium succinate, dexamethasone sodium 
phosphate, prednisolone sodium succinate and methylprednisolone sodium 
succinate) and failed to demonstrate the transcutaneous migration during 
iontophoresis of the corticosteroids using an in vitro model [116]. This result is 
in contradiction with another study performed in human with a donor solution of 
radiolabeled prednisolone sodium phosphate delivered from the anode. It was 
found that the plasma concentration of the drug 15 minutes after the treatment 
was about one third than that obtained after the oral administration of 10 mg of 
prednisolone [130]. A reservoir of the drug was also found in the epidermis, 
most likely situated in the SC, as evidence by the presence of the drug in this 
tissue even 24 hours after the iontophoretic treatment [130]. The 
transcutaneous delivery from the anode of the neutral hydrocortisone by the 
electroosmotic flow was enhanced compared to passive diffusion or delivery 
from the cathode, and increased linearly with current density [131, 132]. The 
following studies all concern the iontophoretic delivery of Dex-Phos. 
An early study performed over five joints of a single monkey established 
that iontophoresis from the positive electrode (5 mA, 20 minutes) of a mixture of 
0.4% radiolabeled dexamethasone sodium phosphate and 4% lidocaine HCl 
resulted in local tissue concentrations of Dex-Phos (in the µg/g range) higher 
than those that would be obtained by systemic therapy, but lower than would be 
obtained by local injection [133]. These results should be interpreted with care 
however, firstly because the current density used in this study (0.94 mA/cm2) 
was much higher than the accepted maximal value (0.5 mA/cm2) used in 
human, and second, because the hairs were clipped before the experiment, two 
possible sources of barrier alteration. On the other hand, the use of the anode 
(positive electrode) as the electrode for delivery is questionable considering that 
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Dex-Phos is negatively charged. A later in vitro study, using hairless mouse 
skin, demonstrated that the delivery of Dex-Phos from the cathode was indeed 
slightly more effective than from the anode [134].  
Two subsequent in vivo studies, the first one in horse tibiotorsal joint 
[135], the other in human wrist [136], were conducted to quantify the amount of 
Dex-Phos delivered with iontophoresis from the cathode. The end-points of the 
studies were the Dex-Phos concentration in the synovium of the joint and in the 
plasma of local venous blood for the study in horse, and the concentration of 
Dex-Phos in plasma of local venous blood for the study in human. Both studies 
used clinically relevant current densities and the concentration of Dex-Phos and 
Dex (measured in order to account for the possible dephosphorylation of the 
pro-drug in vivo) were assayed using HPLC. Both studies failed to demonstrate 
the presence of Dex-Phos in the fluids analyzed, a fact due, perhaps, to the 
insufficient sensitivity of the analytical method (HPLC, ∼0.2 µg/ml). This seems 
a plausible explanation when we look at the serum concentration of Dex-Phos 
one hour after iontophoresis obtained in another study performed in the patellar 
tendon of rabbits (∼6 ng/ml) [137]. The latter study also confirmed the presence 
of Dex-Phos in the patellar tendon one hour and 24 hours after the application 
of the current. Another study using iontophoresis to administer Dex-Phos, from 
a 10 mg/ml drug donor, into tarsocrural joint in 5 horses found a mean 
concentration of ∼1 ng/ml in the synovial fluid 30 minutes after the treatment 
[138]. The drug was undetectable in the plasma in this condition. When the 
concentration of the donor solution was reduced to 4 mg/ml, the Dex-Phos was 
undetectable in the synovial fluid [138]. In all these four studies however, it is 
not clear if the Dex-Phos solution was prepared in pure water or in buffered 
electrolyte, so the possibility of co-ions in the formulation cannot be completely 
discarded. 
Finally, two more studies aimed at the optimization of the delivery of Dex-
Phos were performed [139, 140]. The first suggests that for a given current 
dose, a low current administered over a longer period seems to result in deeper 
penetration of the drug than a higher current applied for a shorter period [139].  
This is based on results obtained in an in vitro study where the amount of Dex-
Phos delivered through an artificial membrane (cellulose ultrafiltration 
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membrane), into an agarose gel, was quantified as a function of the distance in 
the gel, and an in vivo study were the temperature at the surface of the skin was 
measured to give an indication of the vasoconstriction occurring due to the 
presence of Dex-Phos in local tissue. Both results must be regarded with great 
care: in vitro, because the artificial membrane allows for a non-negligible 
amount of passive diffusion to occur, so a longer period will just allow for more 
drug to diffuse passively; in vivo, due to the fact that erythema (a sign of 
vasodilatation) will be more important at higher electrical current, and this may 
mask the antagonist effect (vasoconstriction) of the drug being measured. 
Nevertheless, the result is in good agreement with previous studies showing 
that the main effect of iontophoresis is to enhance the transport of molecules 
through the epidermis (the barrier of the skin), and from there, it is mainly 
passive diffusion (together with the microcirculation in vivo) that is the main 
mechanism of distribution [4]. Finally, an in vitro study (with an artificial 
membrane again) reported that the absence of background electrolyte in the 
drug formulation resulted in a drug flux four-fold higher than when citrate anions 
were present [140]. The quantity of Dex-Phos delivered in vivo was 
approximated (1.4 mg) by measuring the concentration of the drug in the donor 
solution before and after the treatment (80 mA⋅min over a 24h period). Here 
again, the methodology used (artificial membrane for the in vitro study and 
quantification method for in vivo study) is questionable.  
 In summary, therefore, the optimal iontophoretic delivery conditions for 
Dex-Phos have not yet been clearly identified. 
 
5. Reverse iontophoresis for clinical monitoring 
 
The symmetrical nature of iontophoresis means that ions and polar molecules 
are not only delivered from the electrode compartments into the body, but can 
also be extracted from the skin into these compartments (Figure 3). In this latter 
situation, the method is generally referred to as ‘reverse iontophoresis’. The 
method can be used to monitor, in a minimally-invasive manner, endogenous 
molecules or drugs present in the subdermal compartment [141]. 
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5.1. Monitoring of endogenous substances 
Glucose is the endogenous molecule that has received the most attention due 
to the obvious benefit that a minimally-invasive method to monitor blood sugar 
would bring to diabetics. The proof-of-concept to use reverse iontophoresis to 
extract subdermal glucose was established in preliminary in vitro and in vivo 
studies [142, 143], and led to the development of the GlucoWatch Biographer 
(Animas Corporation, West Chester, PA). The biographer is a wristwatch device 
(Figure 7) capable of sampling glucose using reverse iontophoresis and 
detecting it in situ using an on-board amperometric detector. The device 
requires one conventional ‘finger-stick’ blood sample to be taken for its 
calibration. Once this calibration is performed, blood glucose can be monitored 
in a nearly continuous manner (up to 6 readings per hour for the second 
generation of the device) for up to 13 hours. Clinical studies have demonstrated 
the efficiency of the device to track changes in the blood sugar levels of 
diabetics over the entire range of glycemia (Figure 8) [144]. The system was the 
first device based on reverse iontophoresis to be approved by the FDA. 
 
 
Figure 7. The GlucoWatch Biographer [144].  
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Figure 8. Representative results obtained in two subjects with the GlucoWatch 
biographer (filled symbols) compared to blood glucose measurements (empty 
symbols) [144].  
 
Another endogenous substance that was extracted by reverse 
iontophoresis is prostaglandin E2 (PGE2). The negatively charged PGE2 was 
extracted from the skin of hairless guinea pigs, at the anode, following the 
application of several skin irritants. It was found that the amount extracted of 
PGE2 correlated with the intensity of skin irritation observed [145]. The 
extraction, at the cathode, of the zwitterionic amino acid phenylalanine, a 
molecule of interest for the detection of phenylketonuria, was also investigated 
in vitro. The method showed promise as the fluxes correlated with the 
subdermal concentration, but the range of concentrations explored (1-10 mM) 
was higher than the usual in vivo levels for this molecule [146]. Very recently, 
the reverse iontophoresis of lactate, a marker of the tissue distress in critically ill 
patients and of sport performance in athletes was investigated. The in vitro 
experiments demonstrated a linear relationship between subdermal levels and 
extraction fluxes. The in vivo results were also encouraging as the fluxes 
followed the blood concentrations in some subjects, but as this was not the 
case in all volunteers more research is necessary to facilitate the interpretation 
of the data [147]. Finally, the extraction of urea and potassium, interesting to 
diagnose chronic kidney diseases, was evaluated in vitro, and again the 
extraction fluxes correlated with the subdermal concentrations [148]. 
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5.2. Monitoring of therapeutic drugs 
Some drugs have a narrow therapeutic window and reverse iontophoresis could 
be use to monitor their systemic levels in order to adjust the dose accurately 
[141]. The potential of the method was fist explored with caffeine and 
theophylline using tape-stripped pig skin as a model of the underdeveloping SC 
found in premature neonates. While the extraction across an intact membrane 
of the two compounds was increased by iontophoresis compared to passive 
diffusion, this was not the case for the stripped skin. The results suggest that 
the reverse iontophoresis of neutral compounds could be of interest in infants 
with a fully-developed SC, but not in premature neonates [15].  
The reverse iontophoresis of two anti-convulsant drugs, valproate and 
phenytoin, known to be approximately 90% protein-bound in plasma, was 
investigated. As the complex drug-protein is expected to be too large to be 
extracted efficiently, extraction fluxes are expected to reflect the free-form of the 
drugs. The results indicated that the extractions fluxes were indeed dependant 
on the concentration of the free-fraction of the drugs [149, 150].  
Finally, lithium is a drug commonly used in bipolar disorders. In vitro and 
in vivo studies demonstrated that reverse iontophoresis can be used to extract 
this small cation in a concentration dependant manner [151, 152]. 
 
5.3. Skin reservoir 
Reverse iontophoresis being a transdermal method, the presence of the analyte 
of interest in the skin can affect the extraction fluxes, more so if the ‘skin 
reservoir’ is important. This reservoir should be emptied before a linear 
correlation between the extracted fluxes and the plasma concentration can be 
obtained. The GlucoWatch Biographer, for example, requires a ‘warm up’ 
period of 2 hours to deplete the skin content before reporting on the glycemia 
[143]. The extraction of lithium in bipolar patients required a 30 minutes period 
before reliable information from the systemic level of the drug could be 
obtained, a fact attributed to a reservoir of drug ‘stored’ in the skin [152]. Recent 
studies investigating the reverse iontophoresis of lactate and urea, two 
compounds present in high concentration in the SC (Table 1), further 
demonstrated the interfering effect of the reservoir on the fluxes [147, 148, 153]. 
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The extraction flux of a compound abundant in the SC, such as urea (Figure 9), 
is higher at the beginning of current passage and decreases to achieve a stable 
value. As amino acids are known to be abundant in the SC (Table 1), a similar 
effect can therefore be expected during the reverse iontophoresis of these 
molecules. 
 
 
Figure 9. Reverse iontophoresis extraction fluxes as a function of time obtained 
in healthy volunteers (A-H) and patients with chronic kidney disease (X,Y and Z) 
[153]. 
 
5.4. Internal standard 
As previously mentioned, the GlucoWatch Biographer requires one 
conventional blood sample to be obtained in order to calibrate the device, a step 
that has been perceived as an inconvenient. The concept of internal standard 
has been developed to avoid this invasive procedure. During reverse 
iontophoresis, ions and small neutral molecules (including the compound of 
interest) are extracted non-specifically. The internal standard concept is based 
on the simultaneous detection of two compounds: the molecule of interest, the 
temporal change in whose concentration is of interest, and a second one, with 
known and essentially fixed physiological concentration [154]. Assuming that 
the iontophoretic transport of the analyte (A) and the latter internal standard (IS) 
are independent one another, the ratio of their fluxes (JA/JIS) should therefore 
follow the relationship: 
[ ]
[ ]
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where [A] and [IS] are the concentrations in the blood of the analyte and the 
internal standard respectively and K is a proportionality constant. 
 This concept was validated in vitro for glucose with Na+, sucrose, 
mannitol, glycerol and urea as internal standards [58, 154]. An in vivo study, 
however, indicated that Na+ was not a suitable internal standard for glucose and 
that an electroosmotically-extracted internal standard should be identified in 
order to avoid the need for blood sampling [155]. The neutral urea was tested in 
another study for that purpose and performed reasonably well as an internal 
standard, but more research is required to better understand the inter-individual 
variability observed [156]. 
 The validity of the internal concept was further validated in a variety of 
situations in vitro. Sodium was found to be a good internal standard for lithium 
[151], acetate for phenytoin [150], mannitol for phenylalanine [157], and 
glutamate for valproate [149]. Finally, when sodium was used as the internal 
standard during the extraction of lithium in man, increased precision on the 
predicted serum values of the drug could be obtained [152].  
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Abstract 
 
Purpose: To evaluate the effects of competing ions and electroosmosis on the 
transdermal iontophoresis of dexamethasone phosphate (Dex-Phos), and to 
identify the optimal conditions for its delivery. 
Methods: The experiments were performed using pig skin, in side-by-side 
diffusion cells (0.78 cm2), passing a constant current of 0.3 mA via Ag/AgCl 
electrodes. Dex-Phos transport was quantified for donor solutions (anodal and 
cathodal) containing different drug concentrations, with and without background 
electrolyte. Electrotransport of co-ion, citrate, and counter-ions, Na+, K+ and 
Ca2+, was also quantified. The contribution of electroosmosis was evaluated by 
measuring the transport of the neutral marker, mannitol. 
Results: Electromigration was the dominant mechanism of drug iontophoresis 
and reduction in electroosmotic flow directed against the cathodic delivery of 
Dex-Phos did not improve drug delivery. The Dex-Phos flux from the cathode 
was found to be optimal (transport number of ∼0.012) when background 
electrolyte was excluded from the formulation. In this case, the transport of the 
drug is limited principally by the competition with counter-ions (mainly Na+ with 
a transport number of ~0.8) and the mobility of the drug in the membrane. 
Conclusion: Dex-Phos must be delivered from the cathode and formulated 
rationally, excluding mobile co-anions, to achieve optimal iontophoretic delivery.  
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1. Introduction 
 
The use of corticosteroids for the treatment of a variety of musculoskeletal 
conditions is common practice [1-6]. Local administration of the drug by 
injection usually results in improved clinical outcome, at least temporarily, and 
limits the systemic effects associated with oral delivery [2-6]. However, while 
injections are generally safe,  they present some disadvantages and risks (for 
example, postinjection pain and flare, infection, difficulty to place accurately the 
needle, and the need for an experienced health-care professional to perform the 
injection) [2, 3].  
Alternatively, iontophoresis is also used in clinical practice to deliver 
locally corticosteroids [7-9]. Iontophoresis is a minimally invasive technique that 
enhances the transport of charged and highly polar molecules across the skin 
by the application of a small electrical current (with a current density < 0.5 
mA/cm2). The two main mechanisms of transport of this electrically enhanced 
method are electromigration and/or electroosmosis [8, 10, 11].  
Electromigration originates from the direct interaction of the electrical 
field and the ions present in the formulation and the skin and will therefore 
enhance the transport of cationic drugs from the anode and, inversely, 
negatively charged drugs from the cathode. Conservation of charge requires 
that the sum of the electrical current carried by each ion equals the total 
electrical current supplied by the power source. Practically, as far as drug 
delivery is concerned, this means that the drug competes with all the other ions 
present in the system [10, 11]. The efficiency of transport, i.e., the fraction of the 
total charge transported by a given drug (its transport number, tD), can be 
determined experimentally by measuring its flux (JD) and applying the relation: 
)1.(eq
zF
tI
J
d
d
d
⋅
⋅
=  
where I is the total current passed, F is the Faraday’s constant and zd is the 
valence of the drug [12]. 
Electroosmosis has its origin in the fact that the skin is a negatively 
charged membrane at physiological pH. When an electrical potential is applied 
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across a membrane containing fixed charge, a bulk volume flow of solution 
occurs in the direction of the counterion movement [13]. This means that for the 
negatively charged skin, the electoosmotic flow is in the anode-to-cathode 
direction. This assists the transport of cations and retards that of anions. This 
flow of solvent carries through the skin any dissolved solute and is therefore the 
mechanism enhancing the transdermal delivery of neutral, polar, molecules. 
The electroosmotic flow is the dominant mechanism of transport for the delivery 
of larger molecules [11]. The drug flux due to the electroosmotic mechanism 
(JD
EO) is proportional to the concentration (CD) of the solute: 
)2.(eqCJ D
EO
D ⋅=υ  
where υ is the solvent volume flow [14]. The pH and the ionic strength are the 
main parameters of the formulation that can be used to modulate 
electroosmosis by, respectively, modifying  and screening the skin’s charge [11, 
15, 16].  
Dexamethasone phosphate (Dex-Phos, MW: 472.4), a phosphorylated 
prodrug of dexamethasone (Dex), has undoubtedly been the most studied 
corticosteroid for iontophoretic delivery [8]. Its disodium salt, dexamethasone 
sodium phosphate (Dex-Na2-Phos, MW 516.4), is water soluble and at 
physiological pH is present mainly in its dianionic form (pKas: 1.9 and 6.4). The 
iontophoretic treatment of various musculoskeletal problems with Dex-Phos has 
been the subject of clinical studies [17-29], many of which have reported 
subjective beneficial effects [17-27]. However, improvement in the patient’s 
condition is not always seen [28, 29], a fact due, perhaps, to the variety of 
iontophoretic conditions employed [8], and to the fact that the optimal conditions 
for Dex-Phos delivery have not been identified. Hence, there is a need to 
optimize the conditions for Dex-Phos iontophoresis.  
The primary objective of this research was therefore to identify the 
optimal iontophoretic conditions to deliver Dex-Phos. It was a further goal to 
better understand the effects of: (1) the ions present in the formulation and/or in 
the subdermal compartment that are competing with Dex-Phos to transport the 
current, and (2) the electroosmotic flow, which normally occurs in the anode-to-
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cathode direction; that is, against the electromigration of Dex-Phos delivered 
from the cathode. 
 
2. Materials and methods 
 
2.1. Materials 
Dex (>98%) and Dex-Na2-Phos (>98%) were purchased from Sigma-Aldrich 
Co. (Gillingham, UK). Solutions of injectable Dex-Na2-Phos where obtained 
from American Regent (Shirley, NY) (equivalent to 4 mg/ml Dex-Phos), 
Faulding (Royal Leamington Spa, UK) (again equivalent to 4 mg/ml Dex-Phos) 
and Organon Laboratories Ltd (Cambridge, UK) (equivalent to 4.6 mg/ml of 
Dex-Phos). Topical lidocaine HCl 4% (Xylocaine Topical 4%) was obtained 
from AstraZeneca (London, UK). Sodium chloride, potassium chloride, calcium 
chloride, Na2HPO4, KH2PO4, mannitol, phosphoric acid (85%) and 
methanesulfonic acid (99%) were from Acros (Geel, Belgium). Potassium 
citrate, methanol (HPLC grade), acetonitrile (far UV HPLC grade), ethyl acetate 
and hydrochloric acid 37% (w/w) were provided by Fisher Scientific 
(Loughborough, UK). NaOH 50% (ion chromatograpy eluent grade) was from 
Fluka (Buchs, Switzerland). Ag wire (> 99.99% purity) and AgCl (99.999%) were 
purchased from Sigma-Aldrich Co. (Gillingham, UK). All regents were at least 
analytical grade and all aqueous solutions were prepared using high purity 
deionized water (18.2 MΩ⋅cm, Barnstead Nanopure DiamondTM, Dubuque, IA). 
The concentration of Dex-Na2-Phos solutions are expressed in term of the Dex-
Phos concentration. For example, a 0.4% Dex-Phos solution contains 4.4 mg/ml 
of Dex-Na2-Phos. 
 
2.2. Skin preparation 
Porcine ears were obtained from a local piggery. Ears were cleaned under 
running cold water and the skin was dermatomed to a nominal thickness of 750 
µm (ZimmerTM Electric Dermatome, Dover, OH).  The pieces of tissue obtained 
(∼9 cm2) were wrapped individually in ParafilmTM and stored for no more than 
three months at -20°C until use. 
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2.3. Preparation of Dex-Phos solution at pH 4 
In one experiment, a solution of Dex-Phos prepared in deionized water at pH 4 
was used. To avoid the inclusion of extraneous anions inevitable when a strong 
acid is used to lower the pH of a Dex-Na2-Phos solution prepared in water 
(typical pH = 7.5), an equimolar mixture of the diacid (dexamethasone-
dihydrogen-phosphate – Dex-H2-Phos) and its conjugate base (Dex-Na2-Phos) 
was dissolved in water to obtain a final concentration of 0.4% of Dex-Phos. 
Dex-H2-Phos was prepared from the disodium salt by adding one part of 37% 
w/w HCl to 3 parts of a solution of 25 mM Dex-Na2-Phos in water. The insoluble 
dihydrogen acid precipitated and was recovered by liquid extraction using ethyl 
acetate. The ethyl acetate was evaporated, leaving a powder of Dex-H2-Phos 
which contained only trace amounts of extraneous ions when assayed by ion 
chromatography. 
 
2.4. Iontophoresis 
In vitro iontophoresis experiments were performed in side-by-side diffusion cells 
(transport area = 0.78 cm2). The skin was clamped between the two half cells, 
with the stratum corneum side facing the donor (drug-containing solution) 
chamber. In all experiments the subdermal compartment was filled with 
phosphate-buffered saline (PBS - 170 mM sodium, 1.4 mM potassium, 137 mM 
chloride and 18 mM phosphate) at pH 7.4. Both chambers held 3.5 ml of 
solution and were magnetically stirred. 30 minutes prior to iontophoresis, the 
cathodal chamber was filled with 3.5 ml of deionized water and the anodal 
chamber with 3.5 ml PBS in order to check for leaks. Both chambers were then 
emptied and refilled with the appropriate donor and receptor solutions before 
the experiment was started. In all experiments, a 0.3 mA constant current 
intensity (current density = 0.38 mA/cm2) was applied for 6 hours via Ag/AgCl 
electrodes connected to a power source (Yokogawa 7651 Programmable DC 
source, Woodburn Green, UK). All experiments were performed at room 
temperature with a minimum of four replicates, using the skin from at least two 
different pigs. To measure the delivery of Dex-Phos, 1 ml of the subdermal 
compartment was collected and replaced by the same volume of PBS every 
hour for the first two hours and every half-hour thereafter. A 24-hour control 
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experiment, with no electrical current applied, was also performed using Dex-
Phos 0.4% in water as donor solution. 
 
Effect of delivery electrode polarity 
First, the effect of the polarity of delivery electrode was verified for two 
formulations containing sufficient Cl- to satisfy the electrochemistry at the 
anode: (i) Dex-Phos 0.4% in 0.9% NaCl, and (ii) a mixture containing one part 
of injectable Dex-Phos (Faulding) for two parts of lidocaine HCl.  
 
Effect of donor composition 
The Dex-Phos delivery from the cathode was measured for a variety of donor 
solutions described in Table 1. The effect of the concentration of the drug in 
absence of background electrolyte was verified for concentrations ranging from 
0.2 to 0.8%. In one experiment, to ensure that the concentration of the Cl- 
released by the Ag/AgCl electrode remained an order of magnitude lower than 
that of the drug in the donor solution (Dex-Phos 0.4% in H2O), the latter was 
continuously perfused (15 ml/h), using a peristaltic pump, during the 
iontophoretic delivery. 
 
Effect of electroosmosis 
Two strategies to reduce electroosmosis against the delivery of Dex-Phos were 
then explored. The first involved pre-treatment of the skin with Ca2+ prior to the 
delivery of Dex-Phos. Calcium ions were delivered from the anode for two hours 
from a 100 mM CaCl2 solution. The content of both chambers was then 
removed and the chambers and electrodes were rinsed with deionized water. 
Following this pre-treatment, the drug was delivered from the cathode as before 
from a donor solution now containing 0.4% Dex-Phos in water. The second 
approach involved delivery of 0.4 % Dex-Phos from a donor solution at pH 4.  
 In these two iontophoretic conditions and those described in Table 2, 
electroosmotic flow was assessed using mannitol (at 10 mM) as a marker. The 
flux of mannitol was evaluated in both anode-to-cathode and cathode-to-anode 
directions. In addition to sampling of the receptor chamber, 0.3 ml of the donor 
solution was also collected hourly. The passive diffusion of mannitol across the 
skin was also measured as a control. 
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Contribution of competing ions 
Finally, the donor solution samples obtained in the study with mannitol, in the 
four cases described in Table 4, were assayed for the major competing counter-
ions sodium, potassium and calcium. The concentration of the co-ion citrate in 
the receptor was also measured when Dex-Phos was formulated with this 
anion. From these values, the contributions of the main competing ions to the 
total current were determined. 
 
2.5. Sample Analysis 
The concentrations of Dex-Phos and Dex in the receptor chamber were 
assayed by high-performance liquid chromatography (ASI-100 automated 
sample injector, P680 pump, TCC-100 thermostated column compartment, 
PDA-100 diode array detector, Chromeleon software, Dionex, Sunnyvale, CA) 
under isocratic conditions. A mobile phase consisting of 30:70 (v:v) 
acetonitrile:phosphate buffer (0.15 M, pH 2) was pumped (0.75 ml/min) through 
a Lichrospher® 100 RP-18 (4 x 125 mm) reverse-phase column (HiChrom, 
Reading, UK) fitted with its guard column and thermostated at 25°C. 
Dexamethasone and dexamethasone phosphate concentrations were quantified 
via their UV absorbance at 240 nm using their respective calibration curves 
obtained from a minimum of five standard solutions (made from 500 ppm stock 
solutions in methanol appropriately diluted in PBS pH 7.4) covering the entire 
range of experimental concentrations. The retention times for Dex-Phos and 
Dex were ∼3.5 and ∼10.5 minutes, respectively; the detection limit for both was 
0.02 µg/ml for a 25 µl injection and detection was linear up to 150 µg/ml (CV > 
0.998). 
Ion chromatography with suppressed conductivity detection (AS50 
autosampler and thermal compartment, GP50 gradient pump, ED50 
electrochemical detector, Dionex, Sunnyvale, CA) was used to measure the 
concentrations of sodium, potassium, calcium and citrate. For the quantification 
of cations, the 20 mM methanesulfonic acid eluent was pumped under isocratic 
conditions (1 ml/min) through an IonPacTM CS12A column (Dionex, 250 x 4 mm) 
thermostated at 30°C and a CSRS ULTRA II suppressor (Dionex, 4 mm) set at 
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a current of 62 mA. Concentrations of Na+, K+ and Ca2+ were measured against 
calibration curves obtained from standard solutions (at least five different 
concentrations) of their respective chloride salt. For the quantification of citrate 
anions in the receptor compartment, the 35 mM NaOH mobile phase was 
pumped under isocratic conditions (1 ml/min) through an IonPacTM AS16 
column (Dionex, 250 x 4 mm) thermostated at 30°C and the ASRS ULTRA II 
suppressor (Dionex, 4 mm) set at a current of 90 mA. At least five potassium 
citrate solutions were used as standards. 
Analysis of mannitol was performed using ion chromatography coupled 
with pulsed amperometric detection (Dionex, Sunnyvale, CA). The mobile 
phase (380 mM NaOH) was pumped (0.4 ml/min) through a CarboPac MA1 
(250 x 4 mm, Dionex) column maintained at a temperature of 20°C. Again, the 
calibration curve was obtained from at least five standards of mannitol in PBS. 
 
2.6. Data analysis and statistics 
Linear regressions and statistics were performed using Graph Pad Prism V.4.00 
(Graph Pad Software Inc., San Diego, CA). Statistical differences within multiple 
data sets was assessed by one-way ANOVA, followed by a Tukey’s multiple 
comparison test. The level of statistical significance was fixed at p < 0.05. The 
fluxes were obtained from the slope of the cumulative amount delivered as a 
function of time for each replicate and are expressed as (mean ± SD). The 
reported Dex-Phos flux is the sum of the Dex-Phos and Dex fluxes into the 
receptor phase to account for the partial dephosphorylation of the prodrug that 
occurred during transdermal passage or in the receptor compartment. Transport 
numbers were calculated using these fluxes and equation 1. The valence used 
for Dex-Phos in the calculations was 2 unless otherwise stated.  
 
3. Results 
 
3.1. Passive diffusion control 
The passive diffusion flux of Dex-Phos from a 0.4% solution in pure water after 
6 hours was below the detection limit and only reached 0.13 ± 0.11 nmol/h at 24 
hours. Considering that all iontophoresis experiments lasted 6 hours, the 
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contribution of passive diffusion could be assumed to be negligible compared to 
electrotransport. 
 
3.2. Anodic vs cathodic delivery 
As Dex-Phos is negatively charged (z ∼ -2 at physiological pH), delivery from 
the cathode (with electromigration as the main driving force) was expected to be 
more efficient than that from the anode (electroosmosis being the only available 
driving force) [11]. Yet, many studies in the literature have used the anode to 
deliver Dex-Phos [17, 22, 30]. We therefore compared directly Dex-Phos 
delivery from the anode with that from the cathode. Two donor solutions, which 
contained sufficient Cl- to assure good functioning of the Ag/AgCl electrode 
during anodic delivery, were tested: (i) 0.4% drug in normal saline, and (ii) a 
mixture of commercially available citrate-buffered injectable Dex-Phos (0.4% 
w/v, Faulding) and lidocaine HCl (4% w/v). In the former case, cathodal and 
anodal fluxes were 14 (± 4) and 0.3 (± 0.2) nmol/h, respectively; for the latter, 
the corresponding transport rates were 2.1 (± 0.6) nmol/h from the cathode and 
below the level of detection from the anode. 
 
3.3. Effect of donor composition on cathodic delivery 
The next logical step was to optimize delivery from the cathode. In the case of 
the negatively charged Dex-Phos, the efficiency of iontophoretic delivery will be 
reduced by the presence of competing anions in the donor solution [11]. Dex-
Phos flux was therefore measured from different formulations, many of which 
had been used in clinical studies, containing a more or less constant 
concentration of the drug together with a range of background electrolytes. The 
Dex-Phos solutions tested, the drug’s flux and the corresponding transport 
numbers are reported in Table 1. The pH of all solutions tested, except the 
mixture of Dex-Phos and lidocaine, was between 7.2 and 7.9 meaning that 
>85% of the drug carried a charge of -2. For the Dex-Phos/lidocaine 
formulation, the pH was 6.8 and only ∼70% of the drug had a charge of -2. 
However, because in all cases the majority of the drug was doubly charged, the 
value for z in equation 1, which was used to determine the transport number 
from the flux, was assumed equal to 2.  
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Table 1:  Effect of the donor solution composition on Dex-Phos fluxes and the 
derived transport numbers during cathodal iontophoresis. 
Donor solution Competing anions 
Dex-Phos 
Flux 
[nmol/h] 
100*Transport 
number 
Inj. Dex-Phos 0.4% (Faulding) : 
Lidocaine 4% (Astra) (1:2) 
Cl
-
 (∼100 mM)
a 
Citrate
3-
 (∼13 mM)
b 
2.1 ± 0.6 0.04 ± 0.01 
Inj. Dex-Phos 0.4% (American 
Regent) 
Citrate
3-
 (∼40 mM)
b
 8.8 ± 3.9 0.16 ± 0.07 
Inj. Dex-Phos 0.4% (Faulding) Citrate
3-
 (∼40 mM)
b
 7.5 ± 2.9 0.13 ± 0.05 
Dex-Phos 0.4% in potassium 
citrate 
Citrate
3-
 (40 mM) 10 ± 5 0.18 ± 0.08 
Dex-Phos 0.4% in 0.9% NaCl Cl
-
 (154 mM) 14 ± 4 0.25 ± 0.07 
Inj. Dex-Phos 0.5% (Organon) 
None (glycerol for 
isotonicity) 
81 ± 39 1.4 ± 0.7 
Dex-Phos 0.4% in H2O None 69 ± 24 1.2 ± 0.4 
a
Deduced from the molar concentration of lidocaine HCl in the final solution. 
b
Determined by direct measurement with ion chromatography. 
 
It is clear that the absence of background electrolyte (Dex-Phos in pure 
water and the injectable Dex-Phos formulation from Organon containing a 
neutral molecule, glycerol, for isotonicity) greatly improved drug delivery. These 
two solutions resulted in fluxes that were not significantly different. 
The donor solution in 40 mM potassium citrate resulted in a Dex-Phos 
flux not significantly different than those from the commercially available 
Faulding and American Regent injectable solutions, which contain sodium 
citrate for isotonicity. When Dex-Phos was formulated with 0.9% (154 mM) NaCl 
rather than 40 mM sodium citrate, the drug flux was slightly increased (P < 
0.05), but remained much smaller than that in the absence of background 
electrolyte. 
Improving Dex-Phos delivery by varying the drug concentration in the 
donor solution in the absence of background electrolyte was then explored. In 
the case of cations, when no background electrolyte is present, the 
electromigration flux is rather independent of the drug concentration in the 
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donor [10, 11, 31]. For anions, however, when Ag/AgCl electrodes are used, 
there is Cl- release from the electrode and the potential for competition to evolve 
over time [32]. Nevertheless, as shown in Figure 1, when the Dex-Phos 
concentration was varied by 4 fold (0.2 to 0.8% w/v), there was no significant 
difference in the drug flux measured after 6 hours of iontophoresis, and these 
values did not differ from that obtained when the donor solution was 
continuously perfused at the high rate of 15 ml/h to ensure that the Cl- 
concentration never attained 1/10th of that of Dex-Phos.  
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Figure 1: Dex-Phos iontophoretic flux as a function of concentration in deionized 
water. In the 0.4% PD experiment, the donor solution was continuously 
perfused with 0.4 % w/v Dex-Phos. 
 
3.4. Effect of electroosmosis 
To evaluate the effect of electroosmosis on the delivery of Dex-Phos, the flux of 
mannitol in the anode-to-cathode direction and its equivalent solvent flow was 
measured for four delivery conditions summarized in Table 2. The mannitol 
fluxes were also measured in the cathode-to-anode direction and were not 
significantly different than the negligible passive diffusion of the neutral marker 
(1.0 ± 0.6 nmol/h). Electroosmosis occurred against Dex-Phos delivery from the 
cathode. Solvent flow was maximal when no background electrolyte was 
present in the donor (Dex-Phos 0.4% in H2O), the condition so far identified as 
‘optimal’ for Dex-Phos delivery. Electroosmotic flow was significantly higher 
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when the background electrolyte was potassium citrate as compared to sodium 
chloride (p < 0.05). The presence of Dex-Phos in the anode, as opposed to the 
cathode, when normal saline acted as background electrolyte, did not 
significantly affect the level of electroosmotic flow.  
 
Table 2: Mannitol flux in the anode-to-cathode direction and the corresponding 
solvent flow for the experimental Dex-Phos delivery conditions tested. 
Dex-Phos 
delivery 
electrode 
Donor solution 
Mannitol flux 
[nmol/h] 
Solvent flow 
[µl/h] 
Cathode Dex-Phos 0.4% in H2O  52 ± 10 5.2 ± 1.0 
Cathode Dex-Phos 0.4% in 40 mM 
potassium citrate 
40 ± 6 4.0 ± 0.6 
Cathode Dex-Phos 0.4% in 0.9% NaCl 24 ± 4 2.4 ± 0.4 
Anode Dex-Phos 0.4% in 0.9% NaCl 32 ± 9 3.2 ± 0.9 
  
Two strategies were then explored to reduce (or reverse) the skin’s 
negative charge, to decrease therefore the electroosmotic flow, and thereby 
enhance the delivery of the drug. First, Ca2+ cations (from a 100 mM CaCl2 
solution) were delivered into the skin from the anode for two hours; the donor 
compartment and electrodes were than washed with deionized water, before 
0.4% Dex-Phos in H2O was iontophoresed from the cathode across the Ca
2+ 
loaded membrane. The rationale behind this approach was that Ca2+ would 
shield the fixed negative charges inside the skin and therefore reduce 
electroosmosis when the electrical field was re-applied [16]. Second, the Dex-
Phos 0.4% in H2O solution was prepared at pH 4 using a mixture of the diacid 
(Dex-H2-Phos) and the disodium salt (Dex-Na2-Phos). The idea, of course, was 
again to reduce the negative charge on the skin, the isoelectric point of which 
has been shown to be between 4 and 5 [33]. 
Table 3 summarizes the results obtained. Pre-treatment of skin by Ca2+ 
iontophoresis had no significant effect on Dex-Phos delivery, nor on solvent flow 
as measured by the electroosmotic transport of mannitol. At pH 4, on the other 
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hand, mannitol delivery was clearly reduced, and convective solvent flow 
decreased, but this had no impact on the electrotransport of Dex-Phos. 
 
Table 3. Cathodal Dex-Phos flux, and anodal mannitol flux and the deduced 
electroosmotic flow when two strategies to reduce the skin’s negative charge 
were examined. 
Formulation Dex-Phos flux 
[nmol/h] 
Mannitol flux 
[nmol/h] 
Solvent flow 
[µl/h] 
Dex-Phos 0.4% in H2O (control) 69 ± 24 52 ± 10 5.2 ± 1.0 
Dex-Phos 0.4% in H2O post-Ca
2+
 43 ± 13 45 ± 5 4.5 ± 0.5 
Dex-Phos 0.4% in H2O at pH 4 65 ± 39 32 ± 6 3.2 ± 0.6 
 
3.5. Transport numbers of main ionic species 
Finally, the transport numbers of the main ionic species present in the different 
experimental conditions studied were measured (Table 4). It was clear that 
sodium was the major charge carrier across the skin contributing >70% in all 
cases. Only when the pH was reduced to 4 was the Na+ transport lowered (p < 
0.05) Calcium flux was significantly greater when CaCl2 was iontophoresed 
before Dex-Phos suggesting that the pre-treatment did increase the presence of 
this cation in the skin (the subdermal compartment contained no external 
source of Ca2+). Lastly, although all donor solutions eliminated Cl-, the Ag/AgCl 
electrochemistry resulted in the progressive release of this anion into the donor 
solution such that a significant contribution to the movement of charge could be 
deduced for this anion.  
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Table 4. Transport numbers (%) of main ionic species during iontophoretic 
delivery of Dex-Phos from different donor solutions. 
Donor 
Ion 
Dex-Phos 0.4% 
in H2O 
Dex-Phos 0.4% 
in H2O, pH4 
Dex-Phos 0.4% 
in H2O post 
Ca
2+ 
Dex-Phos 0.4% in 
40mM potassium 
citrate 
Dex-Phos 1.2 ± 0.4 0.6 ± 0.4 (z = 1) 0.8 ± 0.2 0.18 ± 0.08 
Na
+
 81 ± 7 72 ± 4 86 ± 5 87 ± 2 
K
+
 1.7 ± 0.2 1.4 ± 0.3 1.4 ± 0.2 N.D.
b 
Ca
2+ 
0.11 ± 0.04 0.17 ± 0.04 0.6 ± 0.3 N.D.
b 
Citrate
3- 
-
 
-
 
-
 
3.5 ± 0.3 
(a)
Cl
- 
17
 
26
 
11
 
9
 
a
The Cl
-
 transport number was deduced from {100 – (the sum of all measured transport 
numbers)}. 
b
Not determined 
 
4. Discussion 
 
4.1. Electroosmosis 
Dex-Phos delivery from the cathode proceeded against electroosmotic flow. 
The latter increased when the background electrolyte was removed from the 
drug solution in good agreement with previous reports [13, 15]. 
When Ca2+ was ‘pre-delivered’ into the skin, no impact on the 
subsequent electrotransport of mannitol was observed; an earlier report had 
indicated that electroosmosis was reduced during Ca2+ iontophoresis [16]. 
Lowering the pH of the Dex-Phos donor solution to 4 reduced the 
electroosmotic flow in the anode-to-cathode direction as previously observed 
[15, 33]. Consistent with the reduction of electroosmotic flow, the transport 
number of Na+ was significantly smaller as well, reflecting a change in skin’s 
permselectivity. However, the lower pH in the donor solution failed to improve 
drug delivery, suggesting that the altered electroosmotic flow has a negligible 
effect on the electrotransport of the drug. 
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Dex-Phos delivery from the anode was really inefficient and should 
therefore be avoided in the clinic. This conclusion contradicts an early study, in 
which the drug was iontophoresed in vivo, in a monkey, from the anode and 
resulted in measurable levels in deep underlying structures [30]. While the exact 
reasons for this discrepancy are still unclear, two comments on the latter study 
can be made in that respect: (i) a relatively important drug concentration (>2 
µg/g) in subdermal structures (depth >3 mm) was observed after a short 
application of the drug (20 minutes) in absence of current, which raises the 
question whether the skin barrier in this animal model was compromised; and 
(ii) the current density used (0.94 mA/cm2) is nearly twice the maximum 
tolerable level in man (0.5 mA/cm2) [34], and could have altered the skin barrier. 
 
4.2. Ionic competition 
Not all commercially available Dex-Phos solutions are equivalent for 
iontophoresis. The ideal donor solution contains no background electrolyte to 
compete with the drug to carry charge across the skin. Trends similar to those 
observed in this study had been observed, but to a lesser extent due to a much 
higher passive diffusion contribution, when Dex-Phos was iontophoresed across 
an artificial membrane [35]. The Dex-Phos/lidocaine formulation resulted in a 
Dex-Phos flux much less than those from all other formulations, due to the high 
levels of chloride and citrate present. Although lidocaine hydrochloride 
increases the buffer capacity of the donor solution [9], this is not necessary 
when Ag/AgCl electrodes are used because problems associated with pH 
changes are avoided [32]. In fact, in the experiments reported here, the pH of 
the donor solution never varied by more than 0.2 pH unit over the 6 hours of 
iontophoresis.  
Even in optimal delivery conditions, the transport number of Dex-Phos 
was relatively small with values just over 0.01. This is most probably due to the 
rather poor mobility of the drug inside the membrane resulting from its relatively 
large molecular weight. Similarly, the transport numbers of cations was found to 
fall-off rapidly with molecular weight, with values approaching zero at 400-500 
Da [36]. The principal ionic species carrying electrical current during delivery of 
Dex-Phos from water was the subdermal counter-ion Na+. Even when citrate 
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was present, the transport number of sodium was >80%. This value is in good 
agreement with the transport number of sodium previously observed when the 
competing counter-ion was gluconate, an anion with a molecular weight very 
similar to that of citrate [37]. Interestingly, the release of Cl- from the Ag/AgCl 
cathode during iontophoresis of Dex-Phos from water did not impact 
significantly on drug transport over the period of experiment. Given the amount 
of Cl- produced (∼67 µmol corresponding to a concentration of ∼19 mM), it is 
surprising (and, for the moment, not fully understood) that the Dex-Phos flux did 
not decrease somewhat after 6 hours of current passage. From a practical 
standpoint, however, this is a positive result as it means that an iontophoretic 
delivery device for Dex-Phos would not require complex characteristics, such as 
an ion-exchange membrane to sequester Cl- [32]. 
 
4.3. Other practical issues 
The steady-state flux of Dex-Phos from water (∼70 nmol/h at a current of 0.3 
mA, or ∼2 µg/mA⋅min) translates to the delivery of about 0.16 mg from a typical 
current ‘dose’ of 80 mA⋅min. While this is rather less than that administered via 
injection (1 ml of a 0.4% w/v solution contains 4 mg), it is significantly greater 
than that resulting from iontophoresis of the Dex-Phos formulations containing 
citrate (∼0.02 mg) and lidocaine (again, ∼0.02 mg), as reported previously [9].  
In vivo, the current ‘dose’ is typically delivered over 20 minutes and it 
seems unlikely that a steady-state flux is achieved in this time-span (in the 
experiments reported here (data not shown), a lag-time of about 30-60 minutes 
was observed). The kinetics of transport and uptake in vivo are typically more 
rapid than those seen in vitro due to the presence of a fully functional 
microcirculation which can ‘clear’ drug to the underlying tissue and, ultimately, 
the systemic circulation. Further, it is known that in vivo uptake and absorption 
can be significantly influenced by, for example, local vasoconstriction [38].  
Obviously, the simple in vitro model used in this study cannot perfectly 
replicate the much more complex in vivo situation in man. Porcine skin is 
however a good model for human skin [33, 39] and it is expected that the trends 
observed here should still apply in vivo. Ultimately, well designed in vivo studies 
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will be necessary to demonstrate the efficiency of iontophoresis to deliver 
clinically relevant corticosteroid doses in soft tissues, and the results presented 
here should be of particular importance for their design. 
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Abstract 
 
Purpose: To study the competition effect of chloride released from a Ag/AgCl 
cathode on the iontophoretic delivery of dexamethasone phosphate (Dex-Phos).  
Methods: The effect of Cl- in the donor solution was studied during 
iontophoretic delivery of Dex-Phos in side-by-side diffusion cells (0.78 cm2) 
across pig skin. A 0.3 mA constant current was applied via Ag/AgCl electrodes. 
The amount of Dex-Phos and dexamethasone (Dex) was also quantified in the 
stratum corneum (SC), using tape stripping, after iontophoresis and compared 
to a passive diffusion control. The profiles of Dex-Phos and Dex, as a function 
of the position in the SC, were deduced.   
Results: The delivery of Dex-Phos from pure water was unaffected by the 
accumulation of Cl- released by the donor cathode when the drug’s 
concentration was 0.2 to 0.8% w/v. At 0.04%, however, Cl- competition was 
significant and the drug flux was significantly reduced. Formulation of the drug 
in the presence of Cl- resulted in a non-linear dependence of flux on the molar 
fraction of the drug. Tape stripping experiments confirmed the enhanced 
delivery of Dex-Phos by iontophoresis relative to passive diffusion, with Dex-
Phos concentration greater inside the barrier post-iontophoresis than that in the 
donor. On the other hand, the total amount of drug in the SC after iontophoresis 
was considerably smaller than that crossing the skin per hour.  
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Conclusion: The iontophoretic delivery of Dex-Phos from the cathode is 
relatively robust to the inclusion of Cl- in the donor solution. An increase of the 
drug’s concentration in the SC relative to that in the donor post-iontophoresis 
could possibly explain this phenomenon.  
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1. Introduction 
 
Iontophoresis is a technique used to enhance the transdermal passage of 
charged and polar molecules by the application of a small electrical current 
(<0.5 mA/cm2) [1, 2]. Its symmetrical nature means that both drug delivery and 
clinical monitoring applications are possible [1-3]. The two principal 
mechanisms of transdermal iontophoretic transport are electromigration and 
electroosmosis. Electroosmosis refers to the net solvent flow taking place in the 
anode-to-cathode direction during the application of the electrical current  and 
has its origin in the fact that the skin possesses a net negative charge at 
physiological pH [1, 4]. It is the dominant transport mechanism for neutral, polar 
molecules and ions of relatively large molecular weight [1, 2]. Electromigration, 
on the other hand, is the result of the direct interaction of the electrical field with 
the ions present in the formulation and inside the skin. The iontophoretic flux 
(Jd) of a drug “d” transported by electromigration is directly proportional to the 
intensity of the current (I) applied in agreement with Faraday’s law: 
)1.(eq
zF
It
J
d
d
d
⋅
⋅
=  
where td is the transport number of the drug, zd its valence and F is Faraday’s 
constant [5].  
 The drug’s transport number is the fraction of the electrical current 
applied which is transported across the skin by the drug. The drug competes 
with all other ions present in the system to carry the charge and it follows that to 
optimize electromigration the amount of all other ions should be minimized. 
Ideally, co-ions are absent from the formulation, such that only the endogenous 
counter-ions can compete with the drug, the transport number of which is then 
maximized [6, 7]. When competing co-ions are present, the transport number of 
the drug usually depends upon its molar fraction rather than its absolute 
concentration [5, 8, 9]. 
 Electrodes are critical components of an iontophoretic system as they 
transfer the electrical current supplied by the external circuit into ion migration 
across the skin [10]. Electrodes should meet a variety of performance, 
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compatibility and physical requirements and importantly, they should not 
substantially alter the delivery conditions, meaning that they should not contain 
or release competing ions of the same charge of the drug being delivered [10, 
11]. Ag/AgCl electrodes are commonly used for iontophoretic delivery as they 
are biocompatible and their electrochemistry is driven at a sufficiently low 
potential insuring that unwanted secondary reactions are unlikely. The reactions 
occurring at the anode and the cathode are respectively: 
)2.()( )()()( aeqeAgClClAgAnode SaqM
−− +→+  
)2.()( )()()( beqClAgeAgClCathode aqMS
−− +→+  
Importantly, compared to electrodes made of inert materials (platinum, stainless 
steel and glassy carbon for example), water is not hydrolyzed and pH shifts are 
avoided. Ag/AgCl electrodes are well adapted for the delivery of cationic drugs 
available as chloride salts provided there is a sufficient quantity of chloride in 
the donor to satisfy the electrochemistry at the anode. However, when 
negatively charged drugs are iontophoresed from the cathode, chloride ions 
released by the electrode will compete to transport the current and reduce the 
efficiency of delivery [12-15]. Strategies to circumvent this phenomenon have 
been described in the patent literature [16-18].  
Previously, we observed that the iontophoretic delivery of 
dexamethasone phosphate (Dex-Phos) from the cathode was minimally 
affected by the release of Cl- when the drug was present in the donor solution at 
concentrations between 0.2 and 0.8% w/v in water [Chapter 2]. The objective of 
this study was therefore to better understand the effects of chloride anions 
released from the Ag/AgCl cathode on the delivery of Dex-Phos. To this end, 
the iontophoresis of Dex-Phos was investigated systematically as a function of 
the amount of Cl- present. In addition, tape stripping experiments were 
performed post-iontophoresis to assess the accumulation of the drug in the 
membrane. 
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2. Materials and methods 
 
2.1. Materials 
Dexamethasone (Dex) (>98%) and dexamethasone sodium phosphate (Dex-
Na2-Phos) (>98%) were purchased from Sigma-Aldrich Co. (Gillingham, UK). 
Sodium chloride, Na2HPO4, KH2PO4 and phosphoric acid (85%) were from 
Acros (Geel, Belgium). Potassium citrate, methanol (HPLC grade), acetonitrile 
(far UV HPLC grade) were from Fisher Scientific (Loughborough, UK). NaOH 
50% (ion chromatography eluent grade) was from Fluka (Buchs, Switzerland). 
Ag wire (> 99.99% purity) and AgCl (99.999%) were purchased from Sigma-
Aldrich Co. (Gillingham, UK). All regents were at least analytical grade unless 
stated otherwise and all aqueous solutions were prepared using high purity 
deionized water (18.2 MΩ⋅cm, Barnstead Nanopure DiamondTM, Dubuque, IA). 
The concentration of Dex-Na2-Phos solutions are expressed in term of the Dex-
Phos concentration. For example, a 0.4% Dex-Phos solution contains 4.4 mg/ml 
of Dex-Na2-Phos. 
 
2.2. Skin preparation 
Porcine ears were obtained from a local piggery. Ears were cleaned under 
running cold water and the skin was dermatomed to a nominal thickness of 750 
µm (ZimmerTM Electric Dermatome, Dover, OH).  The pieces of tissue obtained 
(∼9 cm2) were wrapped individually in ParafilmTM and stored for no more than 
three months at -20°C until use. 
 
2.3. Iontophoresis 
Iontophoresis experiments were performed in vitro in side-by-side diffusion cells 
(transport area = 0.78 cm2) with the stratum corneum side facing the donor 
(drug containing solution) chamber. In all experiments the subdermal 
compartment was filled with phosphate-buffered saline (PBS - 170 mM sodium, 
1.4 mM potassium, 137 mM chloride and 18 mM phosphate) at pH 7.4. Both 
chambers held 3.5 ml of solution and were magnetically stirred.  In all 
experiments, a 0.3 mA constant current (0.38 mA/cm2) was applied for 6 hours 
via Ag/AgCl electrodes connected to a power source (Yokogawa 7651 
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Programmable DC source, Woodburn Green, UK). All experiments were 
performed at room temperature with a minimum of five replicates, using skin 
from at least two different pigs. Every hour for the first two hours and every half-
hour for the remaining 4 hours of the experiment, 1 ml of the receptor 
compartment was collected and replaced by the same volume of PBS.  
Two series of solutions were tested. In the first set, the donor solution 
consisted of Dex-Phos solutions with a concentration of 0.04% w/v (0.85 mM), 
0.2% (4.25 mM), 0.4% (8.5 mM) or 0.8% (17 mM) in pure water. When the 
donor solution was 0.4% Dex-Phos in water, in addition to sampling of the 
receptor chamber, 0.3 ml of the donor solution was also collected every hour 
and assayed for chloride. In one specific experiment, the donor solution (Dex-
Phos 0.4% in H2O) was continuously perfused (15 ml/h) through a 1.5 ml donor 
compartment, using a peristaltic pump, during iontophoresis. This ensured that 
the concentration of Cl- never attained 1/10th of the drug’s concentration. In the 
second set of experiments, the donor solutions consisted in 0.4% Dex-Phos 
containing 0.06% w/v (10.3 mM), 0.3% (51 mM), 0.6% (103 mM) or 0.9% (154 
mM) NaCl as background electrolyte. 
 
In three experiments, for which the donor solution was Dex-Phos 0.4% in water, 
the amount of drug in the stratum corneum (SC) was assessed by tape stripping 
following (a) passive diffusion for 3h (n = 4), (b) iontophoresis for 30 minutes (n 
= 5), and (c) iontophoresis for 3 hours (n = 7). 
At the end of the experiment, any solution remaining on the skin surface 
was removed using absorbent paper. The skin was then pinned to a dissecting 
board and a polypropylene foil template with a circular aperture (8 mm 
diameter) was positioned over the treated area. The SC was then removed by 
repeated adhesive tape-stripping (Scotch Book Tape, 3M, St. Paul, MN). 
Between 15 and 28 tapes were required to completely ablate the barrier.  Each 
tape was weighed before and after stripping on a 0.1-µg precision balance 
(Satorius SE2-F, Epsom, UK) to determine the mass and thickness of the SC 
layer removed [19, 20]. Dex and Dex-Phos were completely extracted from the 
tapes by overnight shaking with 1 ml of 30:70 acetonitrile: pH 2 phosphate 
buffer. Validation of the extraction procedure involved spiking tape-stripped 
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samples of untreated skin with a known amount of Dex and/or Dex-Phos; 
recovery was (98 ± 2)% (n = 6). 
 
2.5. Sample Analysis 
The concentrations of Dex-Phos and Dex in the receptor chamber and tape 
extracts were assayed by high-performance liquid chromatography (ASI-100 
automated sample injector, P680 pump, TCC-100 thermostated column 
compartment, PDA-100 diode array detector, Dionex, Sunnyvale, CA) under 
isocratic conditions. A mobile phase consisting of 30:70 (v:v) 
acetonitrile:phosphate buffer (0.15 M, pH 2) was pumped (0.75 ml/min) through 
a Lichrospher® 100 RP-18 (4 x 125 mm) reverse-phase column (HiChrom, 
Reading, UK) fitted with its guard column and thermostated at 25°C. Dex-Phos 
and Dex concentrations were quantified via their UV absorbance at 240 nm 
using their respective linear calibration curves (CV > 0.998) obtained from a 
minimum of five standard solutions (made from 500 ppm stock solutions in 
methanol appropriately diluted in PBS pH 7.4) covering the entire range of 
experimental concentrations. The retention times for Dex-Phos and Dex were 
∼3.5 and ∼10.5 minutes respectively; the detection limit for both was 0.02 µg/ml 
for a 25 µl sample injection (used for analysis in receptor compartment) and 
0.01 µg/ml for a 50 µl sample injection (used for the analysis of tape extracts). 
Ion chromatography (AS50 autosampler and thermal compartment, 
GP50 gradient pump, ED50 electrochemical detector, Chromeleon software, 
Dionex, Sunnyvale, CA) was used to measure the concentrations of chloride. 
The 35 mM NaOH mobile phase was pumped under isocratic conditions (1 
ml/min) through an IonPacTM AS16 column (Dionex, 250 x 4 mm) thermostated 
at 30°C and the ASRS ULTRA II suppressor (Dionex, 4 mm) set at a current of 
90 mA. Here, at least five sodium chloride solutions were used as standards.  
 
2.6. Data analysis and statistics 
Linear regressions, Lowess curves and statistics were performed using Graph 
Pad Prism V.4.00 (Graph Pad Software Inc., San Diego, CA, USA). Statistical 
differences within multiple data sets was assessed by one-way ANOVA, 
followed by a Tukey’s multiple comparison test. The level of statistical 
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significance was fixed at p < 0.05. The fluxes were obtained from the slope of 
the cumulative amount delivered as a function of time for each replicate and are 
expressed as (mean ± SD). The reported Dex-Phos flux is the sum of the Dex-
Phos and Dex fluxes into the receptor phase to account for the partial 
dephosphorylation of the prodrug that occurred during transdermal passage or 
in the receptor phase. Transport numbers were calculated using these fluxes 
and equation 1. The valence used for Dex-Phos in the calculations was 2 in all 
cases since the pH of the donor solution was >7.2, meaning that at least 85% of 
the Dex-Phos in solution was in its dianionic form.   
 
3. Results and discussion 
 
3.1. Effect of Cl- 
Cl- ions are released from the Ag/AgCl electrode into the cathode compartment 
at a constant rate determined by the electrical current flowing in the circuit (eq. 
2b). Hence, the concentration of the competing co-ion will gradually increase in 
the donor solution even when it initially only contained Dex-Phos in water. 
Figure 1 compares the theoretical evolution of the Cl- concentration in the 3.5 ml 
donor solution, as a function of time, for a current of 0.3 mA, assuming that all 
the chloride formed remains in the electrode compartment, with the 
experimentally measured values when the Dex-Phos concentration was 0.4%. 
The figure also shows the Cl- concentrations predicted (dashed line) when 20% 
of the charge is carried by these ions liberated at the cathode. The measured 
values suggest that when Dex-Phos is present at a reasonably high 
concentration in water, the contribution of Cl- to the transport of current is 
relatively modest and is less than 20% as it had been previously deduced from 
the measurement of the transport of the counter-ions [Chapter 2]. 
Earlier results showed that the Dex-Phos fluxes from 0.2%, 0.4% and 
0.8% solutions in water were statistically indistinguishable, despite the fact that 
the times and current doses at which the Cl- concentration reached an 
equivalent level to that of Dex-Phos were quite different. Respectively, these 
can be read from Figure 1: for 0.2% Dex-Phos, Cl- reached the same 
concentration at ∼80 minutes (current dose of about 24 mA⋅min); for 0.4% at 
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160 minutes (48 mA⋅min); for 0.8% at 320 minutes (96 mA⋅min). The same was 
true when the 0.4% Dex-Phos in water was perfused continuously to maintain 
the level of Cl- at 1/10th of this concentration (Figure 2). Only for 0.04% is the 
Dex-Phos flux markedly lower (see Table 1 and Figure 2); in this case Cl- 
matches the Dex-Phos level after 16 minutes (4.8 mA⋅min). 
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Figure 1. Theoretical evolution of Cl- concentration in the cathode compartment 
either when all the ions remain in the donor (solid line) or when 20% are 
subsequently ‘delivered’ across the skin (dashed line). Experimentally 
measured values when the donor solution was initially 0.4% Dex-Phos in water 
(mean ± SD, n = 11) are shown for comparison. Also shown, are the different 
Dex-Phos donor concentrations in water (dotted lines). 
 
The impact of Cl- in the drug formulation was systematically studied and 
the combined results of the new experiments reported here together with those 
from before are summarized in Figure 2 and Table 1. Clearly, the transport of 
the drug is progressively hampered by an increase in the presence of the 
competing halide.  
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Figure 2. Dex-Phos fluxes from a donor solution containing 0.4% of the drug in 
various concentrations of saline, compared to those obtained when the drug 
was dissolved in water alone. 
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Table 1.  Dex-Phos fluxes and transport numbers under various conditions. The 
initial molar fractions of the drug in the donor solutions and their evolution with 
the duration of iontophoresis (t) are also shown. 
Dex-Phos molar fraction 
Experimental 
condition 
Dex-
Phos 
flux 
[nmol/h]  
100*Transport 
number 
t = 0 t = 1h t = 3h t = 6h 
Dex-Phos 0.4% in 
0.9% NaCl  
14 ± 4 0.25 ± 0.07 0.05 0.05 0.05 0.05 
Dex-Phos 0.4% in 
0.6% NaCl 
19 ± 9 0.34 ± 0.16 0.08 0.07 0.07 0.07 
Dex-Phos 0.4% in 
0.3% NaCl 
37 ± 10 0.66 ± 0.18 0.14 0.13 0.12 0.11 
Dex-Phos 0.4% in 
0.06% NaCl 
49 ± 22 0.88 ± 0.39 0.45 0.39 0.30 0.22 
Dex-Phos 0.4% in 
H2O Perfused 
73 ± 25 1.3 ± 0.4 1 > 0.9 > 0.9 > 0.9 
Dex-Phos 0.8% in 
H2O 
71 ± 26 1.3 ± 0.4 1 0.84 0.64 0.47 
Dex-Phos 0.4% in 
H2O 
69 ± 24 1.2 ± 0.4 1 0.73 0.47 0.31 
Dex-Phos 0.2% in 
H2O 
65 ± 24 1.2 ± 0.4 1 0.57 0.31 0.18 
Dex-Phos 0.04% 
in H2O 
27 ± 10 0.48 ± 0.18 1 0.21 0.08 0.04 
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Table 1 also includes the theoretically calculated molar fractions of Dex-
Phos as a function of the time of iontophoresis assuming that all Cl- released 
from the cathode remained in the donor solution. It is apparent that, whenever 
the drug’s molar fraction was less than 50% after 1 hour of current passage, the 
Dex-Phos flux was compromised. In some cases, it is worth noting, the molar 
fraction of drug dropped precipitately during the 6 hours of iontophoresis; for 
example, from 1 to 0.18 and to 0.04, respectively, for 0.2% and 0.04% Dex-
Phos in water. Nevertheless, it is intriguing to note that, despite the decreasing 
Dex-Phos molar fraction, the drug’s iontophoretic flux over the 6-hours duration 
of the experiment first increased over the initial period of current passage before 
remaining relatively constant. This phenomenon is illustrated in Figure 3 for the 
two donor solutions mentioned above. In other words, the anticipated falling-off 
of the flux with increasing time (as has been observed for other anions, such as 
amino acids and peptides  [12, 13], piroxicam [14] and diclofenac [15] under 
similar conditions) was not observed. 
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Figure 3. Measured Dex-Phos fluxes as a function of time of iontophoresis 
(square symbols, mean ± SD) compared to the calculated change in the molar 
fraction of the drug in the donor solution (dotted line) (upper panel: 0.2%  Dex-
Phos in water; lower panel 0.04% Dex-Phos in water). 
 
The transport numbers reported for Dex-Phos in Table 1 do not vary 
linearly with the initial molar fraction of Dex-Phos in the donor solution (Figure 
4). In this respect, the results diverge from those reported for small cations 
(Na+, K+, Li+ and NH4
+), and for drugs like lidocaine [8], but parallel those seen 
for quinine and propanolol, two relatively lipophilic cations believed to interact 
significantly with the fixed charge on the skin and to change its permselective 
properties [7]. The results reported here raise the question, therefore, as to 
whether Dex-Phos is perhaps altering the membrane in some way and/or 
accumulating in the tissue. 
In attempting to predict the effect of co-ion competition, Phipps and 
Gyory derived an expression for the transport number of a drug across a 
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homogeneous uncharged membrane as a function of its molar fraction in the 
donor solution [5]: 
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where t0d and t
0
a are the transport numbers of the drug and the co-anion (Cl
-) 
when they are the only species present (the single anion situation), B is a 
proportionality constant that relates the ratio of the anion concentrations in the 
membrane to that in the donor solution, Z is the valence ratio of the anions and 
X their molar fraction ratio in the donor solution. In practice, this approach has 
found little practical use because there is no validated method to predict the 
value of the parameter B [8]. In theory, when B = 1, the concentration ratio of 
the co-anion and the drug is conserved inside the membrane; a value of B <1 
suggests a higher concentration of the drug in the membrane relative to that of 
the co-anion when compared to the donor solution. The data from the 
experiments described here were fitted to the model assuming t0a = 0.4, the 
reported transport number of Cl- in the single ion situation [6] . The B value 
resulting in the fit was 0.3 (Figure 4) suggesting that the apparent concentration 
of the drug relative to Cl- inside the skin is more important relative to that in the 
donor solution. 
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Figure 4. Transport numbers of Dex-Phos as a function of its initial molar 
fraction in the donor solution compared to predictions of the Phipps and Gyory 
model [5]. 
 
Chapter 3 
 107 
3.2. Tape-stripping 
Tape-stripping experiments were performed to test directly whether Dex-Phos 
accumulated in the stratum corneum (SC) during iontophoretic delivery from a 
donor solution containing Dex-Phos 0.4% in water. Both Dex-Phos and the 
dephosphorylated, uncharged Dex were quantified. The results are in Table 2. 
When no current was applied (passive control), the amount of drug present in 
the SC was an order of magnitude less than that achieved post-iontophoresis. 
The duration of current passage influenced the amount of drug (Dex-Phos + 
Dex) uptake into the SC, with about 70% more being found in the SC after 3 
hours compared to 30 minutes. The higher level of Dex recovered accounted for 
nearly all of this difference. However, the absolute drug level in the SC, even 
with iontophoresis, was small compared to the measured flux (∼69 nmol/h) 
implying that “accumulation” was not a significant factor.  
 
Table 2. Dex-Phos, Dex and {Dex-Phos + Dex} uptake into the SC after 3 hours 
of passive diffusion and 30 minutes and 3 hours of iontophoresis. 
 Iontophoresis 
3 hours 
Iontophoresis 
30 minutes 
Passive diffusion 
3 hours
 
Dex-Phos in SC [nmol] 4.9 ± 2.0 4.6 ± 0.9 0.41 ± 0.17 
Dex in SC [nmol] 5.0 ± 1.6 1.4 ± 0.2 0.28 ± 0.06 
Dex-Phos + Dex [nmol] 9.9 ± 3.3 6.0 ± 1.1 0.69 ± 0.24 
 
As the tape-stripping experiment involved individual analysis of drug on 
all the strips, and quantification of the amount of SC removed (achieved 
gravimetrically as previously described [19]), it was possible to derive 
concentration profiles of Dex-Phos and Dex across the SC after passive 
diffusion and following either 30 minutes or 3 hours of iontophoresis (Figure 5). 
When no current was applied, the profiles decayed rapidly from the skin 
surface, intercepting the concentration axis at a level similar to that of Dex-Phos 
in the donor solution (8.5 mM). With iontophoresis, on the other hand, while the 
surface level of the drug was similar, its concentration (and that of Dex as well) 
then increased over the first one-third or so of the SC, before falling off towards 
the inner boundary of the barrier (although not always returning to zero). Dex-
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Phos levels were obviously higher than Dex at 30 minutes but had become 
quite similar (as well as of greater absolute magnitude) by 3 hours of current 
passage.  
The pattern observed in Figure 5 has been predicted theoretically from 
the Nernst-Plank equation (with the electroneutrality assumption) [21, 22], and 
shows that iontophoresis can enhance a drug’s concentration in the membrane 
relative to that in the delivery formulation. Whether the increased level of Dex-
Phos can account for the negligible impact of Cl- released from the cathode in 
some of the experiments reported here cannot be unambiguously deduced. 
Certainly, it could be argued that an elevated presence of anions inside the 
already negatively-charged membrane would be more likely to raise the 
transport number of Na+ (moving from the receiver solution into the cathode 
chamber) and disadvantage the migration of Cl-, at least over the relatively short 
duration of these experiments. 
 
Chapter 3 
 109 
Dex-Phos 3h Pass diff
0 25 50 75 100
0
2
4
6
8
10
30
40
50
60
SC position (%)
D
e
x
-P
h
o
s
 c
o
n
c
. 
[ µµ µµ
m
o
l/
c
m
3
]
Dex-Phos 3h Ionto
0 25 50 75 100
0
10
20
30
40
50
60
SC position (%)
D
e
x
-P
h
o
s
 c
o
n
c
. 
[ µµ µµ
m
o
l/
c
m
3
]
Dex-Phos 30min Ionto
0 25 50 75 100
0
10
20
30
40
50
60
SC position (%)
D
e
x
-P
h
o
s
 c
o
n
c
. 
[ µµ µµ
m
o
l/
c
m
3
]
Dex 3h Pass diff
0 25 50 75 100
0
2
4
6
8
10
30
40
50
60
SC position (%)
D
e
x
 c
o
n
c
. 
[ µµ µµ
m
o
l/
c
m
3
]
Dex 30min Ionto
0 25 50 75 100
0
10
20
30
40
50
60
SC position (%)
D
e
x
-P
h
o
s
 c
o
n
c
. 
[ µµ µµ
m
o
l/
c
m
3
]
Dex 3h Ionto
0 25 50 75 100
0
10
20
30
40
50
60
SC position (%)
D
e
x
-P
h
o
s
 c
o
n
c
. 
[ µµ µµ
m
o
l/
c
m
3
]
a)
b)
c)
 
Figure 5. Dex-Phos (left panel) and Dex (right panel) concentration profiles as a 
function of relative position in the stratum cornum for a) 3h of passive diffusion 
(n = 4), b) 30 min of iontophoresis (n = 5) and c) 3h of iontophoresis (n = 7) of a 
solution of 0.4% Dex-Phos in H2O. Each piece of skin is represented by a 
different symbol and the full line tracks the trend of the data without following a 
specific model (Lowess curve). 
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4. Conclusions 
 
In summary, the results presented here demonstrate that the delivery of Dex-
Phos from a Ag/AgCl cathode is relatively robust to the presence of Cl- in the 
donor solution. From a practical standpoint, the results suggest that optimal 
delivery of the drug should be obtained if the cathode compartment contains 
sufficient Dex-Phos to ensure that its molar fraction remains >50% for the first 
∼20 mA⋅min of the dose. The exact reasons for this phenomenon are still 
unclear, but quantification of the drug in the SC by tape-tripping revealed that it 
was not due to an important absolute accumulation of the drug in this barrier. 
The concentration profile of the Dex-Phos inside the SC could, on the other 
hand, bring some new insight to this problem.  
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Abstract 
 
Purpose: The skin’s natural moisturizing factor (NMF) comprises a complex 
mixture of chemicals including most of the naturally-occurring amino acids 
(AAs). The quantity and distribution of these compounds are relevant to the 
maintenance of the barrier’s hydration and general health. The goal of this 
research, therefore, was to characterize the AAs in the stratum corneum (SC) 
using tape-stripping and reverse iontophoresis. 
Methods: Experiments were performed in vitro using porcine skin, a good 
model for the human membrane. Repetitive tape-stripping, solvent extraction of 
the layers removed and subsequent analysis by ion chromatography permitted 
the amounts and distribution (as a function of position or depth in the SC) of 13 
AAs to be determined. These data were compared with the relatively non-
invasive extraction of the same compounds by passive diffusion and by the use 
of reverse iontophoresis. 
Results: The AAs were relatively homogeneously distributed across the SC and 
broadly divided into three groups (high, medium, low) in terms of total amount 
present. Extraction via passive diffusion or reverse iontophoresis was facile and 
initially rapid. As the time of extraction increased, superior quantities were 
recovered at the cathode (primarily carried by the electroosmotic flow) relative 
to those at the anode, or measured passively. 
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Conclusion: Overall, both tape-stripping and reverse iontophoresis provided 
information about the amount of AAs in the SC; the former enables a full 
distribution profile to be deduced, while the latter can characterize and quantify 
non-destructively the levels present in the horny layer.  
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1. Introduction 
 
The passive loss of water across human skin is impressively regulated by the 
stratum corneum (SC) [1, 2]. Key to the control of skin hydration is natural 
moisturizing factor (NMF), a complex mixture of low molecular weight 
humectants. More precisely, NMF is composed primarily of free amino acids 
(AAs) which are derived from filaggrin [3]. Originally, profilaggrin, the precursor 
of filaggrin, is expressed in the keratinocytes of the granular layer [4]. As these 
cells differentiate into corneocytes in the SC, profilaggrin undergoes proteolysis 
to filaggrin. The latter is ultimately degraded into free AAs, some of which are 
further transformed into pyrrolidone carboxylic acid, urocanic acid, citrulline and 
urea [5, 6]. The constituents of NMF are very hygroscopic and can retain a large 
amount of water even at relatively low humidity. In effect, the skin responds to 
environmental changes in relative humidity by constantly rectifying the level of 
NMF. For example, at low relative humidity, profilaggrin expression has been 
reported to increase, presumably to enhance skin hydration [7]. It follows that 
the correct control of NMF is vital to maintain homeostasis, and also to provide 
the skin its natural elasticity through the plasticizing effect of water.  
When NMF is compromised, the skin becomes dry and scaly and 
transepidermal water loss increases significantly. Equally, ichthyosis vulgaris 
and psoriasis vulgaris are skin disorders characterised by alteration of 
profilaggrin and filaggrin expression, and involve clear changes in the quality of 
barrier function [8, 9]. Correct and early diagnosis of filaggrin-related disorders 
is not straightforward, and it is interesting to ask whether the monitoring of AAs 
in the SC might be helpful in this regard [10]. Similarly, from a simply cosmetic 
viewpoint, a non-invasive tool with which to evaluate skin hydration and the 
overall ‘health’ of the barrier would be valuable.  
Iontophoresis enhances the transfer of molecules through the skin via 
the application of a low electrical current (<0.5 mA/cm2) [11]. Two transport 
mechanisms are operative: electromigration and electroosmosis [12]. Because 
iontophoresis is a symmetric process, it can be used to enhance delivery into 
the skin and also to extract substances from within and below the barrier to the 
skin surface, as exemplified by the GlucoWatch® Biographer for non-invasive 
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glucose monitoring in diabetics [13]. It is logical to hypothesise, therefore, that 
the components of NMF might also be sampled using reverse iontophoresis. 
This study examines this idea in vitro and compares the results obtained with 
the levels of AAs measured in the SC by extraction and analysis of repetitive 
tape-stripping of the barrier. 
 
2. Materials and methods 
 
2.1. Materials 
Sodium chloride, Na2HPO4, KH2PO4 and phosphoric acid (85% w/w) were 
purchased from Acros (Geel, Belgium). Sodium azide, Ag wire (>99.99% purity) 
and AgCl (99.99%), a standard amino acids solution (17 primary amino acids in 
0.1 N HCl), L-glutamine, L-asparagine, L-tryptophan and D-glucose were from 
Sigma-Aldrich Co. (Gillingham, UK). NaOH 50% (ion chromatography eluent 
grade) was obtained from Fluka (Buchs, Switzerland). Anhydrous sodium 
acetate (electrochemical grade) was purchased from Dionex (Sunnyvale, CA), 
and glacial acetic acid (HPLC grade) from Fisher Scientific (Loughborough, 
UK). Deionized water (18.2 MΩ⋅cm) was used for all aqueous solutions 
(Barnstead Nanopure DiamondTM, Dubuque, IA). 
 
2.2 Skin 
Pig skin was gently washed under running cold water and dermatomed to a 
nominal 750 µm thickness (ZimmerTM Electric Dermatome, Dover, OH) post-
sacrifice at a local abattoir.  The pieces of tissue obtained (∼50 cm2) were 
wrapped individually in ParafilmTM and stored for no more than three months at 
−20°C until use. All experiments were repeated 6 times using skin from 2 
different pigs and different body sites (ear and abdomen). A single piece of skin 
was cut into 3 smaller pieces: one used for reverse iontophoresis, the second 
for passive diffusion, and the third for tape-stripping.  
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2.3. Reverse iontophoresis 
Reverse iontophoresis was performed in vertical cells, previously described 
[14], with a single subdermal compartment and an upper chamber divided into 
cathode and anode compartments. Skin was carefully clamped in place with the 
surface facing the electrode chambers. The latter were filled with 20 mM NaCl 
in 10 mM phosphate buffer at pH 7.4. The subdermal compartment contained 
phosphate-buffered saline (137 mM NaCl and 18 mM phosphate) at pH 7.4, 
which was continuously stirred throughout the experiment. Once the cell had 
been prepared, a constant current of 0.3 mA (0.38 mA/cm2) was applied to 
Ag/AgCl electrodes from a power-supply (Yokogawa 7651 Programmable DC 
source, Woodburn Green, UK). The total duration of current passage was 6 
hours. At 0.25, 0.5, 1, 2, 3, 4, 5, and 6 hours, the current was stopped, and the 
cathodal and anodal solutions were removed for analysis. The two chambers 
were then replenished with fresh buffer and the current was restarted. 
 
2.4. Passive diffusion 
Identical experiments to those involving reverse iontophoresis were performed 
except that no current was applied and that Franz cells (2 cm2 surface area) 
were used. 
 
2.5. Tape stripping 
Layers of SC were progressively removed by consecutively applying and 
removing 20 adhesive tapes (Scotch Book Tape, 3M, St. Paul, MN). To ensure 
that SC was removed from the same location, a 2 cm diameter template was 
used. Each tape (2.5 x 2.5 cm) was weighed before and after stripping on a 0.1-
µg precision balance (Sartorius SE2-F, Epsom, UK), and the thickness of SC on 
each tape was then determined from its mass, the area stripped, and the known 
density of the tissue (1 g/cm3) [15, 16]. Finally, each tape was extracted by 
shaking overnight in 1 ml of an aqueous solution of sodium azide (20 mg/l). 
 
2.6. Sample analysis 
All sample solutions (from the electrode chambers, passive diffusion 
experiments, and the tape-strips) were passed through nylon syringe filters prior 
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to analysis (0.45 µm, Nalgene, Thorn Business Park, UK) by ion 
chromatography with integrated pulsed-amperometric detection (IC-IPAD). This 
approach was preferred to high-performance liquid chromatography as sample 
derivatization was unnecessary and good sensitivity, accuracy and 
reproducibility for primary and secondary amino acids was demonstrated [17, 
18]. The IC-IPAD system comprised three modules: a GP50 gradient pump, an 
AS50 autosampler, and an ED50 electrochemical detector (Dionex, Sunnyvale, 
CA). AAA-certifiedTM disposable gold working electrodes (Dionex) were used for 
amino acid detection, and data acquisition was performed with Chromeleon 
software (Dionex). The improved gradient method for the separation of amino 
acids and carbohydrates was followed [19]. Briefly, a complex gradient of 4 
solutions (10 mM NaOH, 250 mM NaOH, 1 mM sodium acetate in 10 mM 
NaOH, and 100 mM acetic acid) was pumped at a constant flow rate of 0.25 
ml/min, and separation was performed on an anion exchange column 
(AminoPac PA10, 2 x 250 mm analytical column and 2 x 50 mm guard column, 
Dionex) kept at 33°C. The run time for one sample was 92 minutes (including 
column washing and equilibration for subsequent sample) and included an 8 
minute isocratic period at 10 mM NaOH at the beginning of each run. A complex 
potential waveform (AAA-directTM waveform, Dionex) versus a combination 
pH/Ag/AgCl reference electrode was applied at the detector to measure current 
at the surface of the electrode.  
 
2.7. Data analysis and statistics 
The extraction fluxes were determined for each sampling interval. The term 
‘cathodal fluxes’ refers to the extractions collected from cathodal compartments. 
Data manipulation, linear regressions and statistics were performed using 
Graph Pad Prism V.4.00 (Graph Pad Software Inc., CA). When data were 
compared, the level of statistical significance was fixed at p < 0.05. Unless 
stated otherwise, all values are expressed as mean ± standard deviation (SD). 
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3. Results and discussion 
 
3.1. Analysis of AAs by IC-IPAD 
It was possible to detect and quantify 13 AAs accurately: glycine (Gly), alanine 
(Ala), valine (Val), leucine (Leu), isoleucine (Ile), phenylalanine (Phe), 
tryptophan (Trp), proline (Pro), serine (Ser), threonine (Thr), tyrosine (Tyr), 
asparagine (Asn) and histidine (His).  
 
3.2. Distribution of AAs across the SC determined by tape-stripping 
The average concentrations and the total amounts of the 13 AAs determined 
from the SC tape-stripping experiments are collected in Table 1. The results can 
be divided into three clear groups: (1) AAs present at high levels (ranging from 
23 ± 6 to 40 ± 11 mmol/kg): Ser, Gly, Ala and His; (2) those at moderate 
concentrations (ranging from 7.7 ± 1.8 to 10 ± 3 mmol/kg): Thr, Pro and Leu; 
and (3) the rest which were the least abundant (ranging from 0.6 ± 0.1 to 3.5 ± 
0.7 mmol/kg): Val, Ile, Tyr, Phe, Asn and Trp. Representative distribution 
profiles of an illustrative AA from each group are shown in Figure 1. All of the 
substances measured were homogenously distributed across the SC, with no 
significant difference between the levels found at the outer and inner surfaces of 
the barrier. 
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Figure 1. Concentration profiles of Ser, Pro, and Phe across the SC illustrating 
the behaviours of the three groups of AAs (high, medium and low 
concentrations) present in the barrier. Each symbol corresponds to a different 
piece of skin. 
 
3.3. Passive and reverse iontophoretic extraction of AAs from the SC 
The quantities of AAs extracted passively and during reverse iontophoresis 
were measured as a function of time. The total amounts recovered in the 
absence of current and found in the cathode and anode compartments, for each 
AA are summarized in Table 1. The rates of extraction (i.e., the instantaneous 
Chapter 4 
 123 
fluxes) for the same three illustrative analytes are in Figure 2. The pattern of 
behaviours observed was the same regardless of the absolute level of AA in the 
SC. Initial fluxes were high but then settled to lower values at longer times. At 
15 minutes, no differences (except for histidine – see below) between the 
quantities extracted iontophoretically (cathode and anode) or passively were 
found. With increasing time, however, for all AAs, extraction to the cathode 
eventually and significantly exceeded that at the anode and removed passively. 
 Under the conditions of the reverse iontophoretic experiments 
performed (pH 7.4), the AAs studied would have been essentially (>94%) 
zwitterionic. Preferential extraction to the cathode via electroosmosis was 
anticipated, therefore, and was clearly seen when the amounts recovered at 6 
hours in the cathode and anode chambers were compared (Table 1). Histidine 
is a weakly basic AA (pKa of side chain = 6.0 [20]) and could be partially present 
in the cationic form inside the SC, at least at the beginning of the experiment, 
due to the slightly acidic nature of the membrane [21]; the more exaggerated 
enhancement of extraction at the cathode for the AA is, therefore, most 
probably due to an increased contribution from electromigration. Indeed, for this 
AA, the 6-hour ratio of cathodal to anodal extraction was, on average, nearly 4 
whereas, for all other species, the ratio never exceeded 2. 
 Passive extraction of AAs from the SC was quite efficient (and no 
different from that to the anode when current was applied (with the exception of 
His)) suggesting that the compounds were able to diffuse readily from the SC 
when the surface was contacted with an aqueous solution. The ‘release’ 
process followed t1/2 kinetics quite closely for the whole duration of the 
experiment.  
The origin of the AAs extracted in these experiments remains unclear. As 
mentioned earlier, free AAs, which form part of the NMF, are believed to result 
from the degradation of filaggrin in the cytosol of corneocytes. The immediate 
and high extraction of AAs during passive diffusion would imply that these 
molecules have diffused through the cornified envelope, the corneocyte lipid 
envelope and finally the extracellular lipid matrix relatively quickly. This is in 
contradiction with the generally accepted idea that the predominant route of 
transport through the SC is via the intercellular spaces [22]. The results suggest 
therefore that at least some AAs of the NMF must be present in these regions. It 
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has been proposed that NMF compounds could remain in the extracellular lipid 
matrix, but no specific reference to AAs has been made [23]. Clearly, more work 
is necessary to elucidate the origin of the water extractable AAs. 
 
Table 1. Quantities of AAs in skin determined by tape-stripping, passive 
extraction and reverse iontophoresis (mean ± SD; n = 6). 
AA extracted: 
AA 
[AA] in SC 
from tape-
stripping 
(mmol/kg) 
AA removed 
from SC by 
tape stripping 
(nmol/cm
2
) 
at cathode 
(nmol/cm
2
) 
at anode 
(nmol/cm
2
) 
by passive 
diffusion 
(nmol/cm
2
) 
Ser 
Gly 
Ala 
His 
40 ± 11 
25 ± 6 
24 ± 8 
23 ± 6 
37 ± 9 
23 ± 6 
22 ± 4 
21 ± 4 
68 ± 15 
53 ± 16 
39 ± 8 
37 ± 5 
45 ± 12 
38 ± 14 
25 ± 8 
10 ± 4 
47 ± 12 
34 ± 7 
26 ± 6 
23 ± 6 
Thr 
Pro 
Leu 
10 ± 3 
7.9 ± 2.3 
7.7 ± 1.8 
10 ± 2 
7.3 ± 1.5 
7.3 ± 2.1 
16 ± 4 
14 ± 3 
12 ± 3 
10 ± 3 
8.5 ± 2.1 
7.2 ± 2.6 
10 ± 3 
8.5 ± 2.7 
9.4 ± 2.8 
Val 
Ile 
Tyr 
Phe 
Asn 
Trp 
3.5 ± 0.7 
3.2 ± 0.6 
3.4 ± 0.5 
2.2 ± 0.4 
1.9 ± 0.5 
0.6 ± 0.1 
3.4 ± 1.0 
3.0 ± 0.8 
3.2 ± 0.6 
2.1 ± 0.5 
1.8 ± 0.6 
0.5 ± 0.2 
7.3 ± 2.2 
5.8 ± 1.7 
4.0 ± 1.2 
3.1 ± 1.3 
2.9 ± 1.2 
0.6 ± 0.3 
3.6 ± 1.2 
3.4 ± 1.0 
2.5 ± 0.6 
1.9 ± 0.4 
1.8 ± 0.8 
0.3 ± 0.1 
4.7 ± 1.2 
4.5 ± 1.5 
3.0 ± 0.9 
2.3 ± 0.8 
2.4 ± 1.0 
0.4 ± 0.2 
Glucose 1.7 ± 1.4 1.4 ± 0.7 3.6 ± 3.0 1.4 ± 0.8 1.0 ± 0.8 
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Figure 2. Passive and reverse iontophoretic (cathode and anode) extraction 
fluxes as a function of time of Ser, Pro and Phe illustrating the behaviours of the 
three groups of AAs (high, medium and low concentrations) present in the 
barrier. 
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Perhaps not surprisingly, the total amounts of AAs extracted passively 
correlated well with the quantities recovered from the tape-stripping 
experiments (Figure 3). With increasing time of extraction, the slope of the 
regression with the passive data approached a value of 1 suggesting that the 
non-invasive extraction had depleted the SC reservoir of AAs. Cathodal 
extraction proved to be more efficient in extracting AAs from the skin (Table 1), 
suggesting that reverse iontophoresis may be able to sample sites deeper than 
the SC. This possibility becomes more evident when the extraction fluxes from 
3 to 6 hours are compared (Table 2). It is observed, for 11 out of 13 AAs, that 
the ratio of average cathodal to passive fluxes significantly exceeded unity. 
Further, when the cumulative amounts extracted as a function of time are 
compared, and are also considered relative to the mean amounts (±SD) of the 
quantities recovered from the tape-stripping experiments, the enhanced 
efficiency of reverse iontophoresis to the cathode is apparent (Figure 4). The 
extent to which this finding might be exploited further is addressed in a 
subsequent paper [Chapter 5]. 
Parenthetically, Figure 5 illustrates the cumulative amounts of His 
extracted by reverse iontophoresis to the cathode and by passive diffusion. In 
contrast to Figure 4, the almost immediate differentiation between with and 
without current is striking for the reason already discussed and the ability of 
iontophoresis to continue to pull the AA from the tissue is evident.  
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Figure 3. Correlation between the amounts of AAs extracted passively, and by 
reverse iontophoresis to the cathode, after 15 minutes (triangles), 1 hour 
(circles), and 6 hours (crosses), with the quantities removed in the SC tape-
stripping experiments. Linear regressions through the data are shown. 
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Table 2. Comparison of average cathodal extraction fluxes and passive 
diffusion between 3 and 6 hours (mean ± SD, n = 6). 
AA 
Flux to cathode 
[nmol/(h⋅cm
2
)] 
Passive flux 
[nmol/(h⋅cm
2
)] 
Ratio of cathodal 
to passive fluxes 
Ser 
Gly 
Ala 
His 
4.1 ± 1.2 
3.7 ± 1.2 
2.7 ± 0.6 
1.8 ± 0.4 
3.4 ± 1.0 
2.3 ± 0.6 
1.7 ± 0.5 
1.8 ± 0.5 
1.2 
1.6 
1.6 
1.0 
Thr 
Pro 
Leu 
1.1 ± 0.3 
0.9 ± 0.2 
1.1 ± 0.3 
0.8 ± 0.2 
0.6 ± 0.2 
0.8 ± 0.3 
1.4 
1.5 
1.4 
Val 
Ile 
Tyr 
Phe 
Asn 
Trp 
0.6 ± 0.3 
0.5 ± 0.2 
0.4 ± 0.1 
0.3 ± 0.1 
0.2 ± 0.1 
0.05 ± 0.03 
0.4 ± 0.1 
0.4 ± 0.1 
0.3 ± 0.1 
0.2 ± 0.1 
0.2 ± 0.1 
0.03 ± 0.01 
1.5 
1.3 
1.3 
1.5 
1.0 
1.7 
Glucose 0.4 ± 0.3 0.06 ± 0.05 6.7 
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Figure 4. Cumulative extraction of Ser, Pro and Phe as a function of time by 
reverse-iontophoresis at the cathode (filled squares) and by passive diffusion 
(open circles). The quantities of the AAs present in the SC determined by tape-
stripping (mean = solid line; ±SD = dashed lines) are shown for comparison. 
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Figure 5. Cumulative extraction of histidine as a function of time by reverse-
iontophoresis at the cathode (filled squares) and by passive diffusion (open 
circles). The quantity of the AA present in the SC determined by tape-stripping 
(mean = solid line; ±SD = dashed lines) is shown for comparison. 
 
Finally, it is also appropriate to comment on the data obtained for glucose 
in these experiments. The presence of glucose in the SC has been 
demonstrated [24], and the need to deplete this reservoir for the application of 
non-invasive monitoring of blood sugar by reverse iontophoresis has been 
recognized in the development of the GlucoWatch Biographer. From the 
results in Table 1 and 2, the store of glucose in the SC is confirmed and the 
efficiency of iontophoresis to then pull the analyte from the deeper tissues is 
very obvious: the cathodal flux from 3 to 6 hours surpassed the corresponding 
passive transport rate by nearly 7-fold. 
 
4. Conclusions 
 
This investigation shows that AA sampling from the skin can be accomplished 
by tape-stripping, by passive extraction and by reverse iontophoresis. Tools to 
examine quantitatively the key components of NMF, and hence the SC’s 
hydration status, are suggested therefore. The advantage of tape-stripping is 
that it samples uniquely the SC and can produce a full concentration profile of 
the AAs across the barrier. The procedure, on the other hand is relatively 
invasive. Passive extraction is a benign procedure and also reveals the 
quantities of the analytes in the SC (but without the distribution profiles); 
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however, 6 hours are needed to pull out all the AAs which are present in the 
SC. Reverse iontophoresis to the cathode is more efficient and can shorten the 
time needed to fully sample the SC to only ∼3 hours for zwitterionic AAs, even 
less for only partially charged species like His (see Figures 4 and 5, 
respectively). Furthermore, reverse iontophoresis can also “interrogate” deeper 
into the skin, and this represents an opportunity worthy of further exploration.  
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Abstract 
 
Purpose: To apply reverse iontophoresis as a minimally-invasive tool to 
determine amino acid (AA) content in the stratum corneum (SC) and  
subdermally.  
Methods: In vitro experiments were performed in which electrode 
compartments, initially containing a simple buffer were separated by excised 
porcine skin from a subdermal chamber containing a mixture of 14 amino acids 
(at concentrations of 0.1, 0.25 and 0.5 mM) and glucose (at 1, 2.5 and 5 mM) in 
a buffered electrolyte at pH 7.4. Iontophoresis at 0.3 mA (0.38 mA/cm2) was 
applied and the extraction of the analytes to the anode and cathode was 
measured as a function of time. 
Results: As expected, extraction to the cathode for the essentially neutral 
analytes involved was more efficient. Initial samples obtained during the first 
hour or two of iontophoresis primarily extracted the amino acids from the SC. 
The fluxes observed in the latter half of the 6-hour experiment, on the other 
hand, correlated well with the corresponding subdermal concentrations. 
Conclusion: Once the ‘reservoir’ of amino acids in the SC has been depleted, 
reverse iontophoresis can be used to monitor the subdermal concentrations of 
the analytes. The procedure appears to be most useful for compounds which 
are present at lower quantities in the SC. 
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1. Introduction 
 
Amino acids (AAs) are the constituents of myriad proteins responsible for a 
diverse array of vital functions essential to life [1]. Genetic defects affecting the 
metabolism of AAs, such as phenylketonuria, can result in severe problems if 
undetected and/or left untreated. In neonates, therefore, the levels of AAs are 
often measured in a blood sample to screen for such hereditary disorders [1, 2]. 
Free AAs are also involved in important metabolic processes. For example, 
tryptophan and glutamate are precursors of the neurotransmitters serotonin (5-
HT) and γ-aminobutyrate (GABA), respectively. Moreover, changes in AA blood 
levels have been linked to fatigue in athletes [3, 4] and post-operative patients 
[5]. It follows that there is potential to explore the development of a minimally-
invasive (i.e., needle-free) method to monitor free AA levels in blood. 
Reverse iontophoresis is such an approach that enhances the extraction 
of (charged and polar) substances through the skin by the application of a small 
electrical current (< 0.5 mA/cm2) [6]. The method has been successfully 
employed in the GlucoWatch Biographer [7] to continuously monitor blood 
glucose.  
The flux of a solute extracted by reverse iontophoresis (Js) is the sum of 
the contributions of passive diffusion (JP), electromigration (JEM) and 
electroosmosis (JEO):  
)1.(eqJJJJ EOEMPs ++=  
Electromigration results from the direct interaction between a charged solute 
and the electrical field. Electroosmosis arises from the fact that the skin is 
negatively charged under normal physiological conditions; application of an 
electrical field therefore induces a net solvent (water) flow in the anode-to-
cathode direction [8]. The solute flux of electroosmotic origin (JEO) is 
proportional, at least to a first approximation, to the solute’s subdermal 
concentration (Cs): 
)2.(eqCJ s
EO
s ⋅=υ  
where υ is the solvent volume flow [9]. The third, passive contribution (JP) is 
typically small relative to JEM and JEO. 
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The application of reverse iontophoresis to the skin provokes molecular 
transport towards the cathode by all three mechanisms. In the case of 
zwitterionic amino acids and glucose, the first molecules to reach the skin 
surface originate from the outermost layer of the membrane, the stratum 
corneum (SC). AAs form an important part (>50%) of the SC’s natural 
moisturizing factor (NMF) [10-12] and the initial extraction of this source of 
analytes is highly significant, whether an iontophoretic current is applied or not 
[Chapter 4]. Nevertheless, previous in vitro experiments have shown that, with 
increasing time of current passage, the SC “reservoir” of the AAs is depleted 
and that subsequent extraction is ‘pulling’ molecules from deeper within the skin 
[Chapter 4]. It follows that the technique has the potential to sample AAs (just 
as it has with glucose) which are in equilibrium with systemic levels.  
The goal of this work, therefore, was to validate this hypothesis and to 
verify that the extraction rates of AAs as iontophoresis proceeds are correlated 
with their subdermal concentrations. Glucose extraction was used as a positive 
control. At the same time, the experiments performed served to differentiate the 
SC and subdermal sources of the extracted AAs and provided guidance, 
therefore, on the manner in which the technique might be used to probe these 
different compartments.  
 
2. Materials and methods 
 
2.1. Chemicals 
Sodium chloride, sodium phosphate (dibasic), potassium phosphate 
(monobasic) and phosphoric acid (85%) were from Acros (Geel, Belgium). 
Sodium hydroxide (50%, ion chromatography eluent grade) was from Fluka 
(Buchs, Switzerland). Sodium azide, D-glucose, silver wire (> 99.99% purity) 
and silver chloride (99.999%) were purchased from Sigma-Aldrich Co. 
(Gillingham, UK). The 20 primary AAs in powder form and the AA standard 
solution (containing 17 primary amino acids in 0.1 N HCl) were from Sigma 
(Gillingham, UK). Sodium acetate (anhydrous, electrochemical grade) was from 
Dionex (Sunnyvale, CA) and glacial acetic acid (HPLC grade) from Fisher 
Scientific (Loughborough, UK). All chemicals were at least of reagent grade 
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unless stated otherwise and all aqueous solutions were prepared using high-
purity deionized water (18.2 MΩ⋅cm, Barnstead Nanopure DiamondTM, 
Dubuque, IA). 
 
2.2. Skin preparation 
Pig skin was gently washed under running cold water post-sacrifice at a local 
abattoir. The skin was then dermatomed to a nominal thickness of 750 µm 
(ZimmerTM Electric Dermatome, Dover, OH). The tissue samples obtained (∼9 
cm2) were wrapped individually in ParafilmTM and stored for no more than three 
months at -20°C until use.  
 
2.3. Reverse iontophoresis 
Experiments were performed in vertical cells, described elsewhere [13], having 
the two electrode chambers on epidermal side of the skin. The area of skin 
exposed in each chamber was 0.8 cm2. The subdermal compartment volume 
was ∼7 ml. A constant current (Yokogawa 7651 Programmable DC source, 
Woodburn Green, UK) of 0.3 mA (0.38 mA/cm2) was applied via Ag/AgCl 
electrodes. The extraction solution was 20 mM NaCl in 10 mM phosphate buffer 
at pH 7.4. 
The magnetically stirred subdermal compartment contained a solution of 
the 20 primary AAs at concentrations of 0.1, 0.25 or 0.5 mM and glucose at 1, 2 
or 5 mM in either (a) phosphate-buffered saline (PBS, 137 mM NaCl and 18 mM 
phosphate) at pH 7.4, or (b) phosphate buffer (PB) alone at the same pH. The 
anodal and cathodal chambers were filled with 0.8 ml of the extraction solution 
and current was applied for 6 hours in total. Every hour, the entire contents of 
the electrode compartments were removed for analysis and replenished with 
fresh solution. Samples were filtered with 0.45 µm nylon syringe filters 
(Nalgene, Thorn Business Park, UK) and stored at -20°C. 
 
2.4. Analytical method 
Extraction samples were analyzed for amino acids and glucose using ion 
chromatography coupled with integrated pulsed-amperometric detection (IC-
IPAD) as previously described [Chapter 4] (AminoPac PA10 column set, AS50 
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autosampler and thermal compartment, GP50 gradient pump, ED50 
electrochemical detector, Chromeleon software (Dionex, Sunnyvale, CA)). The 
improved gradient method for the separation of amino acids and carbohydrates 
was followed [14-18]. The run time for one sample was 92 minutes (including 
column washing and equilibration for the subsequent sample) and included an 
8-minute isocratic period with 10 mM NaOH at the beginning of each run. 
Integrated pulsed amperometric detection at the surface of a AAA-certifiedTM 
disposable gold working electrode (Dionex) was performed by the application of 
the AAA-directTM waveform versus a combination pH/Ag/AgCl reference 
electrode. 
 
2.5. Data analysis and statistics 
Extraction fluxes were determined for each sampling interval. The equivalent 
volume flow (υ) was calculated from the flux and the subdermal concentration 
using equation 2. Data manipulation, linear regressions and statistics were 
performed using Graph Pad Prism V.4.00 (Graph Pad Software Inc., San Diego, 
CA). Linear regressions were tested for significance by ANOVA. When data 
were compared, the level of statistical significance was fixed at p < 0.05. Unless 
stated otherwise, all values are expressed as mean ± standard deviation (SD) 
of six replicates obtained using skin (from the abdomen or ears) from two pigs. 
 
3. Results and discussion 
 
3.1. Reverse iontophoresis 
Of the 20 primary AAs and glucose, 15 molecules were successfully quantified: 
glucose, asparagine (Asn), alanine (Ala), threonine (Thr), glycine (Gly), valine 
(Val), seronine (Ser), proline (Pro), isoleucine (Ile), leucine (Leu), methionine 
(Met), histidine (His), phenylalanine (Phe), tyrosine (Tyr) and tryptophan (Trp). 
Arginine, glutamine and cysteine coeluted with other substances and could not 
be assessed, while lysine, aspartate and glutamate were detected with 
insufficient precision to be quantified. All compounds measured, therefore, were 
essentially neutral (zwitterionic in the case of the AAs) at pH 7.4 and 
transported to the skin surface by electroosmosis and passive diffusion. 
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 The behaviour observed, in terms of the rate and extent of extraction, 
was the same for both background electrolytes used in the subdermal 
compartment. The saline-free buffer allowed for a higher electroosmotic flow as 
anticipated when the ionic strength was reduced [8, 19]. 
 The extraction fluxes of three representative AAs (Ser, Pro and Phe, 
illustrating examples of those present in the SC at high, medium and low levels 
[Chapter 4]), as a function of time and of subdermal concentration, are shown in 
Figure 1. For all AAs measured, and for glucose, extraction to the cathode was 
significantly higher than that to the anode (paired t-test, p < 0.05), in accord with 
a cation-permselective membrane. 
 For the AAs, which are most abundant in the SC (Ser, Gly, Ala, His), 
the extracted fluxes were not very sensitive to the subdermal levels, suggesting 
that the ‘reservoir’ of these compounds, requires a significant period to be fully 
depleted (as indicated in an earlier study in which no AAs were added to the 
subdermal solution) [Chapter 4]. The extraction was initially very high and then 
decayed over time, consistent with classic release behaviour from a membrane 
initially loaded with solute [20]. 
In contrast, the AAs least present in the SC (Phe, Trp, Met, Asn, Tyr, Ile, 
Val) as well as glucose, revealed a clear relationship between extraction flux 
and subdermal concentration over the entire duration of the extraction. In this 
case, the relatively small SC ‘reservoir’ of these compounds is quickly depleted 
and reverse iontophoresis samples the subdermal space. At the highest AA 
concentrations, there is no obvious drop-off in the extraction flux with increasing 
time of current passage, implying that even at the earliest times, the contribution 
of the SC source of AAs is negligible relative to that originating from the 
subdermal space. 
Logically, the behaviour of the AAs present in the SC at intermediate 
levels (Pro, Thr, Leu) fall between the two extremes just described, with the 
extraction fluxes becoming more obviously sensitive to the subdermal levels at 
higher concentrations and longer times of current passage. 
For all AAs, replacement of PBS with PB in the subdermal chamber 
enhanced the fluxes observed by roughly a factor of four except for the earliest 
periods of extraction of the AAs most abundant in the SC. 
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Figure 1. Iontophoretic extraction fluxes at the cathode and anode as a function 
of time and subdermal concentrations of Ser, Pro and Phe, when the subdermal 
electrolyte was PBS at pH 7.4. 
 
3.2. Apparent electroosmotic solvent flow 
For all AAs, at the three subdermal concentrations tested and for both PBS and 
PB background electrolytes, the extraction fluxes to the anode during the 3-6 
hour period of current passage were relatively constant. When these values 
were normalized by the corresponding subdermal concentration, an apparent 
electroosmotic flow was determined in accord with equation 2. The results for 
the PBS experiments are collected in Figure 2 (those obtained with PB as 
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background electrolyte are substantially similar except that the apparent 
convective flows are about 4-fold higher); also shown for comparison are the 
amounts of AAs determined in the SC by tape-striping [Chapter 4]. The 
normalized fluxes were evaluated relative to those measured for glucose, the 
electroosmotic extraction of which after 3 hours of iontophoresis is known to 
originate uniquely from the subdermal compartment (the skin depot having been 
completely cleared by this time). 
 Clearly, the AAs, which are most abundant in the SC, demonstrated 
normalized fluxes which were significantly higher than those for glucose, 
signalling that these extractions included an important contribution from the SC 
‘reservoir’. These relative contributions became smaller as the subdermal 
concentrations increased. For the least present AAs in the SC, on the other 
hand, their normalized fluxes were comparable to that of glucose, indicating that 
their extraction was originating exclusively from the subdermal space. 
 From a practical standpoint, the results imply that while reverse 
iontophoretic monitoring of systemic AA levels may be possible in theory, there 
are clearly some important limitations. First, for the most abundant AAs in the 
SC, the time necessary to deplete this depot is more than 6 hours and the 
probability, therefore, that useful information can be obtained from the 
subdermal compartment is negligible. Second, for AAs which are present at low 
levels in the SC, although the approach looks more promising (in that it is 
possible to show a correlation between extraction flux and the subdermal 
concentration), the actual in vivo concentration ranges of these species in the 
systemic compartment is often less than 0.1 mM. There is an issue of assay 
sensitivity as a result, as well as a concern that even the low SC levels of these 
AAs may overwhelm the contribution to the extracted flux from the systemic 
source. The greatest potential value of the approach concerns AAs, which are 
at low concentrations in the SC and in the plasma, but which show large 
positive deviations in the latter compartment when a pathology exists. For 
example, in phenylketonuria, plasma concentrations can exceed 1 mM [21], a 
dramatic increase over the normal range of 35-80 µM [22]. A monitoring system 
in children afflicted with this metabolic disease may represent, therefore, a 
practically useful device. 
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Figure 2. Panels A, B, C – AA and glucose cathodal extraction fluxes (during 
the 3-6 hour period) normalized by the subdermal concentration (mean ± SD) in 
PBS background electrolyte. Values significantly different from that for glucose 
(Anova followed by a Dunnett’s test) are indicated with asterisks (** p < 0.01, * p 
< 0.05). Panel D displays the previously measured amounts of the AAs in the 
SC (mean ± SD) form tape-stripping experiments [Chapter 4]. Amount of Met in 
SC was below quantification limit. 
 
3.3. Separating SC and subdermal sources of AAs 
Figure 3 shows that the AAs extracted to the cathode in the first hour of 
iontophoresis correlated very well with the corresponding amounts measured in 
the SC in a previously reported tape-stripping experiment (see Panel D of 
Figure 2) [Chapter 4]. Regardless of the subdermal concentration of the AAs, 
almost all the individual data points fell within the 95% confidence interval of the 
regression obtained (slope = 0.88 ± 0.05) when no AAs were introduced into the 
solution beneath the skin. This means that the ratio of the amounts extracted by 
reverse iontophoresis to those measured in the tape-stripping did not deviate 
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appreciably from unity and demonstrates that the initial period of current 
passage is sampling, to all intents and purposes, only the SC. The contrast to 
glucose, in that case, is striking. When the subdermal concentrations of glucose 
are set at 1, 2.5 and 5 mM, respectively, the amounts extracted at the cathode 
in the first hour are ∼4, 6 and 12 times greater than the quantity recovered from 
the SC by tape-stripping. 
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Figure 3. AAs extracted at the cathode in the first hour of reverse iontophoresis 
when their subdermal concentration was 0.1, 0.25 or 0.5 mM plotted as a 
function of the corresponding levels in the SC determined by tape-stripping 
[Chapter 4]. The solid and dashed lines show the regression obtained 
previously (± 95% confidence interval) when no AAs were added to the 
subdermal solution. Note that the values for Met are not included as the amount 
in the SC was not determined for this AA. 
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The evolution of the extraction process as a function of time for different 
examples of the AAs studied is illustrated in Figure 4. As already explained, the 
first hour of iontophoresis samples primarily the SC and is insensitive to the 
subdermal level. In the case of an AA which is abundantly present in the SC, 
such as Ser, and even Pro, 6 hours of current passage are insufficient to 
unambiguously demonstrate that the SC ‘depot’ has been fully depleted. On the 
other hand, for AAs which are less concentrated in the SC, like phenylalanine 
and tryptophan, reverse iontophoresis effectively ‘clears’ the SC reservoir within 
a couple of hours of current passage and the extraction is then very sensitive to 
the presence (or not) of the AA in the subdermal compartment.   
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Figure 4. Cumulative extraction of 4 AAs by reverse iontophoresis as a function 
of time when initially present in the subdermal compartment at either 0 (open 
squares) or 0.5 mM (filled squares). The solid and dashed lines represent, 
respectively, the mean amount, and the ±SD, of the AAs recovered in the SC by 
tape-stripping [Chapter 4]. 
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4. Conclusions 
 
The results reported in this paper confirm that a relatively short period of 
reverse iontophoresis (∼1 hour) is an effective, minimally-invasive method with 
which to determine the levels of many AAs within the skin. When the period of 
current passage is prolonged, the levels of AAs collected at the cathode are 
correlated with their subdermal concentrations for those compounds having 
relatively small SC reservoirs (e.g., phenylalanine). Fluctuations in the systemic 
concentrations of such AAs, as a result, for example, of a metabolic disorder, 
may therefore be usefully monitored by reverse iontophoresis.  
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Abstract 
 
Purpose: To examine the application of stratum corneum (SC) tape-stripping 
and reverse iontophoresis as minimally invasive tools for the analysis of amino 
acids (AAs) within the skin, and subdermally, in man.  
Methods: AAs in the SC were determined following repetitive tape-stripping, 
extraction and analysis. At distinct skin sites, reverse iontophoresis and passive 
diffusion were also employed to extract AAs to the skin surface over a 4-hour 
period; a subsequent tape-stripping procedure evaluated the residual presence 
of these substances in the skin’s outermost layer. Plasma concentrations were 
also measured for comparison with the levels extracted. In all samples 
obtained, glucose concentrations were evaluated as a positive control.  
Results: SC concentrations of 13 essentially zwitterionic AAs were 
approximately two orders of magnitude higher than their respective plasma 
levels.  Passive and reverse iontophoretic extraction for 4 hours did not deplete 
the SC depot of AAs, a fact reinforced by post-extraction tape-stripping, which 
revealed that AAs remained in the SC at this time. In contrast, glucose was 
much less abundant in the SC and was fully and relatively quickly extracted by 
reverse iontophoresis. 
Conclusion: Reverse iontophoresis is not practical for the routine monitoring of 
AA plasma concentrations (as it is, in contrast, for glucose, the skin reservoir of 
which is much smaller). On the contrary, the data obtained in this way are highly 
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correlated with the levels measured in the SC by tape-stripping. It is 
questionable, however, if the improvement in extraction efficiency of the method 
is sufficient to justify its used compared to the more simple passive diffusion. 
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1. Introduction 
 
Amino acids (AAs) are substances essential for life [1], and imbalances in their 
systemic levels, due to genetic defects or metabolic problems, may have 
serious consequences [1, 2].  The importance of AAs is further reinforced by 
their role as neurotransmitter precursors, and as markers of central fatigue and 
stress [2-5]. In addition, within the skin, AAs make up a significant part of the 
so-called “natural moisturising factor” (NMF), originating (primarily) from the 
breakdown of filaggrin, and responsible for the maintenance of hydration in the 
outermost barrier layer of the membrane, the stratum corneum (SC) [6-8]. 
Changes in NMF levels are correlated with abnormally dry and scaly skin [8-11], 
and considerable dermatological and cosmetic effort is directed at resolving this 
condition. 
 It follows that there is a rationale for the development of tools with which 
to monitor the presence of AAs both systemically and in the skin. In previous 
investigations [Chapters 4 and 5], the applications of reverse iontophoresis and 
SC tape-stripping have been examined in vitro for the interrogation of AA levels 
in the subdermal ‘compartment’ beneath the skin and in the SC.  Reverse 
iontophoresis uses a small electrical current to enhance molecular transport 
across a membrane [12], and is a technique employed in a recently developed, 
minimally-invasive glucose monitoring device, the GlucoWatch® Biographer 
[13]. For glucose, and for the zwitterionic AAs, which are the subjects of this 
study, imposition of an electric field results in their extraction to the skin surface 
by passive diffusion and by electroosmosis [14]. The former mechanism 
dominates at early times, as the ‘reservoir’ of the analytes in the SC is emptied. 
Thereafter, convective solvent flow to the cathode begins to make a 
progressively more important contribution (especially for those substances 
which are least abundant in the SC) [15-17]. Tape-stripping is a simple 
procedure by which the SC can be progressively and completely removed; 
extraction and analysis of the contents of the strips allows an unequivocal 
estimation of the levels of AAs in the membrane and provides details on their 
spatial distribution [Chapter 4]. The amounts present have been correlated with 
those extracted from the skin by passive diffusion and by reverse iontophoresis, 
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and have permitted delineation of the SC and subdermal origins of the analytes 
[Chapter 5]. 
 The objective of the experiments presented here was to extend the 
earlier in vitro studies (which were conducted using porcine skin) to 
measurements in vivo in human volunteers. Specific goals were to determine 
whether levels of AAs in the SC were correlated with amounts extracted by 
relatively short periods of either passive diffusion or reverse iontophoresis, and 
to examine whether the latter techniques can ultimately be used to sample 
subdermal (i.e., systemic) concentrations. Concurrent analyses of glucose [18, 
19] were also undertaken as a positive control. 
 
2. Materials and methods  
 
2.1. Chemicals 
Sodium chloride, Na2HPO4, KH2PO4 and phosphoric acid (85%) were from 
Acros (Geel, Belgium). NaOH 50% (ion chromatography eluent grade) was 
obtained from Fluka (Buchs, Switzerland). Sodium azide, D-glucose, Ag wire 
(>99.99% purity) and AgCl (99.999%) were purchased from Sigma-Aldrich Co. 
(Gillingham, UK).  An amino acid standard solution (containing 17 primary 
amino acids in 0.1 N HCl), L-glutamine, L-asparagine, and L-tryptophan were 
from Sigma (Gillingham, UK). Sodium acetate (anhydrous, electrochemical 
grade) was acquired from Dionex (Sunnyvale, CA), and glacial acetic acid 
(HPLC grade) was from Fisher Scientific (Loughborough, UK). All chemicals 
were at least reagent grade unless stated otherwise and all aqueous solutions 
were prepared using high purity deionized water (18.2 MΩ⋅cm, Barnstead 
Nanopure DiamondTM, Dubuque, IA). 
 
2.2. Human subjects 
Four healthy volunteers (2 males, 2 females, aged between 20 and 30 years) 
with no history of skin disease participated in the study, which was approved by 
the Bath Local Research Ethics Committee, and provided written consent. 
Experiments were performed in the morning on the ventral forearm on two 
separate occasions at least four weeks apart. The volunteers fasted overnight 
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and were allowed only water until the experiments were completed. The ventral 
forearm surface was first cleaned gently with an isopropyl alcohol swab. Then, 
in the first component of the study, samples for AA and glucose analysis were 
obtained by reverse iontophoresis and tape-stripping (at an adjacent site). In the 
second part, sampling involved passive diffusion and tape-stripping (again, at 
an adjacent site). On both occasions, capillary blood samples were obtained 
from the finger-tips during and/or at the end of the extraction periods. 
 
2.3. Reverse iontophoresis extraction 
Two glass cells (internal diameter of 1.6 cm, extraction surface 2 cm2) 
separated by ∼7 cm were fixed to the ventral forearm of the subjects with 
silicone grease and medical grade tape (Curafix H, Lohmann & Rauscher, 
Rengsdorf, Germany). Both cells were filled with 1.6 ml of 20 mM NaCl in 10 
mM phosphate buffer at pH 7.4.  A direct current of 0.6 mA (i.e., 0.3 mA/cm2) 
was applied from a Phoresor II Auto (Iomed, Salt Lake City, UT) via Ag/AgCl 
electrodes. The entire contents of the anode and cathode chambers were 
collected and replaced by an equal volume of extraction solution at 15 and 30 
minutes and then every half-hour thereafter for a total extraction time of 4 hours. 
The collected samples were passed through a sterile syringe filter (Millex-GV, 
0.22 µm, 13 mm diameter, Millipore, Watford, UK) and stored in the freezer at -
20°C until analysis. 
 
2.4. Passive diffusion extraction 
One glass cell (extraction surface = 2 cm2) was adhered to the skin as before 
and was filled with 1.6 ml of the same extraction solution used in the reverse 
iontophoresis experiment. Identical sample collection, filtration and storage 
procedures were followed.  
 
2.5. Tape-stripping 
Tape-stripping was performed at skin sites adjacent to the reverse 
iontophoresis and passive extraction sites. The SC was progressively removed 
by the repeated application and removal of adhesive tape-strips (Scotch Book 
Tape, 3M, St. Paul, MN). A polypropylene foil template with a central hole was 
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first fixed to the skin with self-adhesive medical tape (Micropore, 3M, St. Paul, 
MN) to ensure that all tape-strips were taken from exactly the same site. The 
tapes (2.5 x 2.5 cm) were applied with pressure from a weighted roller and then 
removed.  Up to 25 strips were taken, but the SC was never completely 
removed. Instead, transepidermal water loss (TEWL) measurements were 
taken (AquaFlux V4.7, Biox Systems Ltd., London, UK) before and during the 
stripping procedure, which was stopped when TEWL reached ~4-fold the 
baseline value, at which point approximately 75% of the SC had been removed 
[20].  Each tape was weighed before and after stripping on a 0.1-µg precision 
balance (Sartorius SE2-F, Epsom, UK) to determine the mass (and hence the 
thickness [21]) of the SC layer removed. AAs and glucose present in SC on the 
tape-strips were subsequently extracted with an aqueous solution of sodium 
azide (20 mg/l). The first and second tapes were extracted individually into 1 ml, 
while the remaining tapes were extracted in groups of three into 3 ml of solution. 
The extracts were filtered (0.45 µm, Nalgene, Thorn Business Park, UK) and 
stored at -20°C until analysis.  
 
2.6. Capillary blood samples 
Capillary blood samples were obtained from the finger-tips of the volunteers 
after 2, 3 and 4 hours of iontophoresis and after 4 hours of passive diffusion. 
The finger-tip was disinfected with an isopropyl alcohol swab prior to pricking 
with a BD GenieTM Lancet (Becton Dickinson, Oxford, UK) (1.5 mm width and 
1.5 mm depth).  The first drop of blood was analyzed for blood glucose (Accu-
Chek Compact Plus, Roche); subsequently, 200-400 µL of blood was collected 
in heparin-coated tubes (BD MicrotainerTM LH).  Plasma was separated by 
centrifugation (Boeco U-32, Hamburg, Germany) at 2000x g for 3 minutes, and 
then diluted 5-fold in a solution containing 20 mM NaCl, 10mM phosphate buffer 
at pH 7.4, and 20 mg/l sodium azide before deproteination by ultrafiltration 
(Centrifree Micropartition Devices, Millipore, Watford, UK) at 1000x g for 35 
minutes. The resulting sample was further diluted by 4-fold and stored at -20°C 
until analysis. 
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2.7. Sample Analysis 
Except for glucose in plasma, all samples were analyzed for amino acids and 
glucose using ion chromatography coupled with integrated pulsed-
amperometric detection (IC-IPAD) as previously described (Dionex, Sunnyvale, 
CA) [22] (see Chapters 4 and 5). 
 
2.8. Data analysis and statistics 
AA and glucose concentrations in the SC were expressed in terms of amount 
per mass of tissue, and their profiles across the barrier were deduced from the 
tape-stripping data as previously described [23]. Extraction fluxes were 
calculated by dividing the amounts removed during a sampling interval by the 
duration of that collection period.  Data manipulation and statistics were 
performed using Graph Pad Prism V.4.00 (Graph Pad Software Inc., San Diego, 
CA).  When datasets were compared, the level of statistical significance was 
fixed at p < 0.05.  All results were expressed as mean ± standard deviation 
(SD). 
 
3. Results and discussion  
 
Thirteen essentially zwitterionic AAs and glucose were successfully quantified. 
Other AAs were detected but could not be quantified (aspartic and glutamic 
acids, lysine, methionine) while the chromatographic peaks of arginine, cystine, 
citrulline and glutamine either co-eluted or could not be sufficiently separated to 
allow their quantification.   
 
3.1. Tape-stripping 
The levels of AAs and glucose in human SC in vivo determined by tape-
stripping are in Table 1 and are compared with the results previously reported 
for pig SC ex vivo [Chapter 4]. Significantly greater amounts (up to 10-fold) of 
the AAs were found in the human barrier; in contrast, the levels of glucose in 
human and pig SC were not significantly different. 
Figure 1 illustrates the concentration profiles of the AAs as a function of 
position in the SC for serine (in abundant presence), proline (moderately 
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abundant) and phenylalanine (a lesser presence); the glucose profile is also 
shown for comparison. The pattern of the AAs distribution is consistant, being 
negligible at the skin surface (believed to be due to regular washing [8, 24]) 
before increasing to relatively constant levels; the glucose profile, on the other 
hand, shows no obvious trend. 
 
Table 1. Amounts and concentrations of AAs and glucose (mean ± SD) in 
human (n = 8) and pig (n = 6) SC. 
Human Pig 
Compound 
[nmol/cm
2
] [mmol/kg] [nmol/cm
2
] [mmol/kg] 
Concentration 
ratio 
human/pig 
Ser 370 ± 80 386 ± 53 37 ± 9 40 ± 11 9.7 
Gly 250 ± 53 260 ± 33 23 ± 6 25 ± 6 10.4 
Ala 184 ± 39 194 ± 45 22 ± 4 24 ± 8 8.1 
His 101 ± 34 104 ± 28 21 ± 4 23 ± 6 4.5 
Thr 84 ± 19 88 ± 15 10 ± 2 10 ± 3 8.8 
Pro 42 ± 11 44 ± 12 7.3 ± 1.5 7.9 ± 2.3 5.6 
Leu 20 ± 4 21 ± 2 7.3 ± 2.1 7.7 ± 1.8 2.7 
Val 30 ± 7 31 ± 6 3.4 ± 1.0 3.5 ± 0.7 8.9 
Ile 13 ± 5 13 ± 4 3.0 ± 0.8 3.2 ± 0.6 4.1 
Tyr 21 ± 5 21 ± 3 3.2 ± 0.6 3.4 ± 0.5 6.2 
Phe 8.5 ± 3.5 8.7 ± 2.3 2.1 ± 0.5 2.2 ± 0.4 4.0 
Asn 14 ± 5 15 ± 4 1.8 ± 0.6 1.9 ± 0.5 7.9 
Trp 8.8 ± 2.0 9.2 ± 0.9 0.5 ± 0.2 0.6 ± 0.1 15.3 
Glucose 1.2 ± 0.3 1.3 ± 0.4 1.4 ± 0.7 1.7 ± 1.4 0.8 
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Figure 1. Concentration profiles of serine, proline, phenylalanine and glucose as 
a function of position in the SC in 4 human volunteers (subject 1, open and 
closed squares; subject 2, open and closed circles; subject 3, open and closed 
triangles; subject 4, open and closed diamonds). 
 
3.2. Systemic concentrations 
The pooled values of the systemic levels of the AAs (plasma) and glucose 
(blood) of the three measurements made during reverse iontophoresis are 
reported in Table 2. The concentrations measured at the end of the passive 
extraction experiment were similar. The results, for the most part, fall within the 
normal ranges [1, 25, 26]. Only tryptophan is consistently lower than usual, 
probably because of its known, strong binding to plasma proteins [27] which 
were removed by ultrafiltration during sample preparation.  
It is noteworthy that the AA concentrations in plasma fall in the range of 
10-350 µM, whereas those in the SC are much higher (5-400 mM, assuming a 
SC density of ∼1 g/ml). The SC/plasma ratio ranges from 150 for valine to 
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>1000 for serine and glycine. Conversely, the concentrations of glucose in the 
SC and in the blood were of the same order of magnitude. 
 
Table 2. AA plasma levels and blood glucose concentrations (µM) in 4 
volunteers (mean ± SD; n = 3 for subjects 1, 3, 4; n = 2 for subject 2). 
Molecule Subject 1 Subject 2 Subject 3 Subject 4 
Normal 
range
a
 
Ser 219 ± 22 265 ± 4 160 ± 7 274 ± 26 90-290 
Gly 206 ± 11 187 ± 6 184 ± 3 230 ± 14 100-330 
Ala 306 ± 8 251 ± 2 168 ± 3 184 ± 2 150-450 
His 121 ± 4 110 ± 2 79 ± 2 92 ± 3 30-150 
Thr 114 ± 4 163 ± 6 82 ± 1 91 ± 3 70-220 
Pro 242 ± 6 148 ± 6 99 ± 6 138 ± 9 85-290 
Leu 119 ± 3 97 ± 1 95 ± 1 118 ± 4 65-220 
Val 235 ± 11 157 ± 6 181 ± 9 235 ± 2 90-300 
Ile 93 ± 4 81 ± 2 80 ± 2 99 ± 4 26-100 
Tyr 60 ± 8 42 ± 1 32 ± 1 43 ± 3 30-120 
Phe 66 ± 3 54 ± 5 40 ± 2 53 ± 2 35-100 
Asn 55 ± 2 56 ± 2 48 ± 3 48 ± 2 35-80 
Trp 20 ± 1 15.5 ± 0.5 15.3 ± 0.3 11.2 ± 0.2 30-80 
Glucose 5000 ± 200 4200 ± 120 4150 ± 50 4270 ± 50 3600-6100 
a
From reference [25] except for Asn [26] and glucose [1]. 
 
3.3. Extraction by reverse iontophoresis and passive diffusion 
Iontophoresis was well tolerated by all subjects. As observed before [12, 15, 18, 
19, 28], only minor tingling sensations, more noticeable at the anode, were 
reported during the first 30 minutes of the experiment. The iontophoretic sites 
were slightly erythematous after the experiment, a situation that resolved within 
24 hours after termination of current. 
Iontophoretic extraction fluxes at the cathode and anode were compared 
to those resulting from passive diffusion. Figure 2 illustrates the results for 
serine, proline, phenylalanine and glucose. For all AAs, initial fluxes were high, 
then fell rapidly over the first 60 minutes before becoming relatively constant 
during the last 2 hours of the experiment. In general, reverse iontophoresis to 
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the cathode was significantly higher than that to the anode and greater than 
passive diffusion (repeated measures ANOVA followed by Tukey’s post-test); 
exept for glucose and isoleucine, passive extaction was not significantly 
different from reverse iontophoresis to the anode. When a nonparametric 
Friedman test was performed followed by Dunn’s post-test instead, the cathode 
was again found more efficient than the anode for all molecules except 
isoleucine and glucose, and more efficient than passive diffusion for all 
molecules except histidine and tyrosine. In the last 2 hours of extraction, the 
trend in AAs fluxes and that of glucose was cathodal > passive > anodal, 
although not all differences were significant. The higher extraction rate to the 
cathode is consistent with the anticipated direction of the convective solvent 
(electroosmotic) flow [14]. Except for glucose, however, the improvement of 
extraction efficiency at the cathode compared to passive diffusion was rather 
small. 
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Figure 2. Reverse iontophoretic (to the cathode and to the anode) and passive 
diffusion extraction fluxes of three AAs and glucose in vivo in human volunteers 
as a function of time.  
 
3.4. Origin of the substances extracted 
Figure 3 compares graphically the amounts of serine, histidine and glucose 
extracted from the skin over 4 hours by passive diffusion and by reverse 
iontophoresis at the cathode. Also shown on these graphs are the average 
amounts of these same substances (± SD) measured at adjacent SC sites by 
tape-stripping. Table 3 collects the corresponding data for all the compounds 
assayed in this study. 
For all zwitterionic AAs (as illustrated by serine in Figure 3), reverse 
iontophoresis extraction at the cathode, which exceeded that at the anode and 
that extracted passively, failed to empty the SC ‘depot’. Only for histidine, which 
may have been present to a greater extent in its cationic form [Chapter 4], was 
the amount extracted iontophoretically not significantly different from that in the 
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SC as measured by tape-stripping. In other words, for all AAs, the non-invasive 
sampling procedure only interrogated the SC and did not provide any 
information about the levels beneath this skin layer. For glucose, in contrast, the 
SC reservoir was already depleted by 2-3 hours of current passage, at which 
point subdermal sampling was taking place [15]. The cumulative amount of 
glucose extracted iontophoretically at the end of the experiment was increasing 
linearly with time as expected. On the other hand, the profiles for the AAs 
showed initially higher fluxes which then dropped off at longer times. Indeed, 
the behaviour closely followed a square root of time dependence ( r2 > 98) 
(Figure 4), characteristic of the classic “burst” effect from an initially full reservoir 
being depleted of solute [15], a further indication that electroosmosis 
contributed only slightly to the extraction of AAs from the SC. 
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Figure 3. Cumulative amounts (mean ± SD, n = 4) of serine, histidine and 
glucose extracted passively (open circles) and by reverse iontophoresis (filled 
squares) as a function of time. The solid and dashed lines represent the mean 
and the ±SD, respectively, of the substances measured in the SC by tape 
stripping. 
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Table 3. Amounts of AAs and glucose in the SC determined by tape-stripping 
compared to the quantities extracted in 4 hours by reverse iontophoresis and by 
passive diffusion. 
Molecule 
SC 
[nmol/cm
2
] 
Iontophoresis 
- cathode 
[nmol/cm
2
] 
Iontophoresis 
- anode 
[nmol/cm
2
] 
Passive 
diffusion 
[nmol/cm
2
] 
Ser 370 ± 80 204 ± 43 114 ± 17 107 ± 37 
Gly 250 ± 53 138 ± 33 69 ± 8 82 ± 27 
Ala 184 ± 39 99 ± 25 50 ± 7 59 ± 19 
His 101 ± 34 84 ± 38 14 ± 6 25 ± 15 
Thr 84 ± 19 38 ± 10 21 ± 3 24 ± 8 
Pro 42 ± 11 16 ± 4 9.4 ± 1.9 11 ± 4 
Leu 20 ± 4 11 ± 2 5.5 ± 1.8 4.5 ± 0.8 
Val 30 ± 7 14 ± 3 8.2 ± 1.0 7.8 ± 3.1 
Ile 13 ± 5 7.5 ± 1.5 4.6 ± 1.1 3.0 ± 0.8 
Tyr 21 ± 5 7.1 ± 1.5 4.5 ± 0.7 5.4 ± 1.8 
Phe 8.5 ± 3.5 3.3 ± 1.0 2.1 ± 0.7 2.1 ± 1.0 
Asn 14 ± 5 4.5 ± 1.5 3.2 ± 0.8 2.6 ± 1.3 
Trp 8.8 ± 2.0 3.1 ± 0.6 2.3 ± 0.4 2.0 ± 0.6 
Glucose 1.2 ± 0.3 2.7 ± 1.8 0.8 ± 0.3 0.2 ± 0.1 
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Figure 4. Cumulative amounts (mean ± SD, n = 4) of serine extracted passively 
(open circles) and by reverse iontophoresis (filled squares) as a function of the 
square root of time. Linear regressions through the data are shown. 
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The amounts of AAs extracted by reverse iontophoresis and passive 
diffusion during the first hour of the experiment were highly correlated (r2 > 0.79) 
with the amounts recovered from the SC by tape-stripping (Figure 5, upper 
panels). The slopes of the regressions were 0.23 (± 0.02) for iontophoresis 
compared to 0.14 (± 0.01) for passive transport, showing that the imposition of 
current had improved the extraction efficiency slightly by about 50%. However, 
the fact that the gradients were much less than unity demonstrated that the SC 
reservoir of the analytes was far from depleted in one hour. When extraction 
fluxes during the final two hours of the experiment were plotted against the 
amounts in the SC, a strong correlation (r2 > 0.9) was again observed (Figure 4, 
lower graphs); once more, reverse iontophoresis extraction showed a modest 
improvement in extraction compared to passive diffusion with a ratio of the 
slopes of the lines in the lower graphs of Figure 4 being ∼1.45. It is 
questionable, therefore, whether this relatively small improvement in extraction 
justifies the use of a more complex device over passive diffusion. 
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Figure 5. Correlations between the quantities of AAs extracted by reverse 
iontophoresis at the cathode (left panels) and by passive diffusion (right panels) 
after 1h of transport (upper graphs) and the corresponding extraction fluxes 
during the final two hours of the experiment (lower graphs), with the amounts 
measured in the SC by tape-stripping. The four symbols corresponds to the 
different subjects studied; error bars represent SDs for n = 4, and lines of linear 
regression have been drawn through the data. 
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To further emphasise, in vivo in man, that the non-invasive extraction 
procedure during a 4-hour experiment was not able to sample the subdermal 
‘compartment’, Figure 6 displays the ratio of the AAs reverse iontophoresis 
extraction fluxes (2-4 hour average) to the measured plasma concentrations. If 
the technique was indeed interrogating the tissue beneath the SC, these ratios 
should correspond to the electroosmotic flow induced across the skin by the 
applied electric field (i.e., υ = JAA/CAA) and should be approximately equal. In 
fact, the values are highly divergent, ranging from 8 (±2) µL⋅hr-1⋅cm-2 for leucine 
to 146 (± 36) µL⋅hr-1⋅cm-2 for serine. It follows that the SC reservoir of AAs in 
vivo in humans is significantly greater than that observed in porcine skin in vitro, 
and that the opportunity to sample systemic AA levels using reverse 
iontophoresis will be limited either to experiments of rather long duration, or to 
situations in which metabolic diseases (e.g., phenylketonuria) cause a 
substantial increase in blood levels over those found normally. 
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Figure 6. Reverse iontophoresis extraction fluxes of AAs to the cathode during 
the last 2 hours of the experiment normalized by the corresponding plasma 
concentrations (mean ± SD; n = 4) 
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Finally, when the SC was tape-stripped at the end of the 4-hour passive 
extraction experiment, it was possible to perform a “mass balance” and show 
that for each AA the amount extracted in 4 hours added to that which remained 
equalled (more or less) the quantity measured previously in the SC which had 
not been subjected to extraction (Table 4). Unfortunately, because of the 4-hour 
hydration period, the removal of the SC was a much less uniform process and it 
was difficult, therefore, to generate reproducible concentration profiles to 
compare with those observed pre-extraction (Figure 1). 
 
Table 4. AA mass balance in SC (mean ± SD; n = 4). 
Molecule 
Unextracted SC  
[nmol/cm
2
] 
Extracted by 
passive 
diffusion 
[nmol/cm
2
] 
Extracted from SC 
post-passive 
diffusion 
[nmol/cm
2
] 
Ser 338 ± 51 107 ± 32 211 ± 106 
Gly 256 ± 54 82 ± 24 161 ± 83 
Ala 194 ± 36 59 ± 16 113 ± 55 
His 104 ± 32 25 ± 13 61 ± 33 
Thr 84 ± 20 24 ± 7 55 ± 28 
Pro 47 ± 12 11 ± 4 29 ± 16 
Leu 18 ± 2 4.5 ± 0.7 8.4 ± 3.1 
Val 30 ± 8 7.8 ± 2.7 19 ± 11 
Ile 9 ± 2 3.0 ± 0.7 5.6 ± 2.2 
Tyr 21 ± 5 5.4 ± 1.6 14 ± 7 
Phe 9 ± 4 2.1 ± 0.8 5.2 ± 3.0 
Asn 13 ± 5 2.6 ± 1.2 7.7 ± 5.3 
Trp 9 ± 2 2.0 ± 0.5 5.3 ± 2.9 
Glucose 1.4 ± 0.1 0.24 ± 0.08 1.1 ± 0.1 
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4. Conclusions 
 
AAs are abundantly present in human SC in vivo. Although depleted near the 
skin surface by normal daily washing routines, their concentrations are relatively 
constant across the rest of the SC. A 4-hour period of extraction either with 
iontophoresis, or simply passively, only removes part of the SC reservoir of AAs 
and does not allow interrogation of subdermal levels (as is possible with reverse 
iontophoresis for glucose, on the other hand). AA amounts extracted passively 
or with current are highly correlated with the quantities in the SC measured by 
an invasive tape-stripping procedure. It follows that minimally-invasive tools are 
available, therefore, with which to probe various analytes which are relevant to 
maintenance of the skin’s hydration state in vivo. While iontophoresis has the 
additional advantage of being able to extract the AAs at a slightly higher (∼50%) 
efficiency relative to passive diffusion, it is questionable if the increased 
complexity of the device for the former method justifies its use over the latter. 
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Conclusion and perspectives 
 
In this thesis, the use of transdermal iontophoresis in sports medicine was 
investigated. More specifically, the objectives were to: (1) optimize the local 
delivery of the corticosteroid dexamethasone phosphate (Dex-Phos) by 
iontophoresis for the treatment of musculoskeletal inflammation, and (2) 
evaluate reverse iontophoresis as a mean to extract systemic amino acids 
(AAs), possible markers of fatigue in athletes. 
 
1. Iontophoretic delivery of Dex-Phos 
Iontophoresis represents an interesting alternative to the needle for the local 
delivery of corticosteroids, such as Dex-Phos, to treat injury-related 
inflammation of soft tissues. The optimal conditions for the electrotransport of 
Dex-Phos have, however, not been clearly identified yet. The iontophoretic 
delivery of Dex-Phos was therefore studied, in vitro using pig skin as a model, in 
order to evaluate the effects of competing ions and electroosmosis, and identify 
the optimal conditions for its delivery. 
 The negatively charged Dex-Phos was best delivered by 
electromigration from the cathode in absence of background electrolyte in the 
drug solution. In this situation, the Dex-Phos transport occurs against the 
electroosmotic solvent flow, which was found to have negligible effect on the 
efficiency of the drug the delivery. Iontophoresis of Dex-Phos is limited 
principally by the small mobility of the drug inside the membrane and the 
competition with counter-ions (mainly Na+) present subdermally. As expected, 
the presence of competing co-ions, such as chloride or citrate, in the drug 
solution results in decreased Dex-Phos delivery.  
In that respect, the effect of the accumulation of Cl-, released by the 
Ag/AgCl cathode in the drug solution during current passage, was studied in 
detail. The Dex-Phos delivery was relatively robust to the release of Cl- from the 
cathode in the donor solution, and remained optimal as long as the molar 
fraction of the drug in the first hour of current passage remained >50%. Tape-
stripping experiments, performed after Dex-Phos iontophoresis, confirmed that 
the amount of the drug present in the stratum corneum (SC) was more 
abundant than that obtained after passive diffusion. The absolute amount of the 
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drug found in the membrane after iontophoresis could not explain the limited 
effect of Cl- release by the cathode. It is possible, however, that the increased 
Dex-Phos concentration measured in the membrane compared to that in the 
donor solution, could bring insight to this phenomenon.  
 The results obtained in these in vitro studies will ultimately have to be 
verified in vivo. Clinical studies using the optimal delivery conditions should be 
conducted in order to demonstrate that the method is effective for the treatment 
of musculoskeletal injuries. Ideally, the drug’s concentration in the (targeted) 
structures underlying the delivery electrode after iontophoresis should also be 
assessed to verify that sufficient drug is present to obtain a clinical effect. Such 
a quantitative study in human subjects could, however, be problematic as 
invasive methods (e.g., biopsy, microdialysis) would be required. One possible 
approach would be to deliver iontophoretically Dex-Phos, pre-surgery, in 
volunteers requiring a surgical repair of injured tissues. The tissues could then 
be sampled during the intervention and assayed for Dex-Phos.  
 
2. Reverse iontophoresis of AAs 
The AAs glutamine, tryptophan, isoleucine, leucine and valine are possible 
markers of overtraining in athletes. It was hypothesised that reverse 
iontophoresis could be used to monitor these molecules minimally-invasively. 
As the monitoring of AAs could find many other applications in medicine, the 
targeted molecules were extended to the 14 primary AAs that could be 
quantified by the analytical method used. The iontophoretic extraction of AAs 
from the skin was first evaluated in vitro, using pig skin as a model. The findings 
were then verified in a group of human subjects. Extraction of glucose was also 
measured as a positive control in both situations. 
As expected, the extraction of essentially zwitterionic AAs from the skin 
was more efficient from the cathode, than from the anode or by passive 
diffusion. The iontophoretic extraction of the AAs was highly influenced by their 
presence in the outermost layer of the skin, the stratum corneum (SC). The AAs 
are indeed present in high quantity in the SC as they are major constituents of 
natural moisturizing factor (NMF), important to keep the skin hydrated. In pig 
skin, extraction by passive diffusion sampled only the AAs present in the SC. 
This was evidenced by the excellent agreement found between the amounts 
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extracted passively in 6 hours and those recovered in the tape-strips used to 
sample the SC. Iontophoretic extraction at the cathode permitted a quicker (∼3 
hours) extraction of the AAs ‘reservoir’. Furthermore, the amounts of AAs 
extracted iontophoretically in a short extraction period (1 hour) were not 
influenced significantly by their sudermal concentration and correlated with their 
abundance in the SC. This demonstrated that iontophoresis could be used to 
assess the SC content in AAs, which could be useful for applications in 
dermatology and cosmetology. Once this ‘reservoir’ was emptied, the 
subdermal compartment could be sampled, suggesting that iontophoresis could 
also be used to monitor systemic levels of AAs.  
The experiments in human volunteers revealed, however, that a 4-hour 
iontophoretic extraction period was insufficient to deplete the AAs ‘reservoir’. 
The AAs were indeed much more abundant in human SC than in pig, meaning 
that a longer extraction period is required to deplete the SC ‘depot’. It follows 
that the method can be used, in vivo in man, to evaluate the abundance of 
zwitterionic AAs in the SC, but is unpractical for the clinical monitoring of 
systemic levels. Since all the AAs identified as potential biological markers of 
fatigue in athletes are zwitterions, reverse iontophoresis is therefore not a viable 
option for their clinical monitoring. Reverse iontophoresis of neutral analytes 
remains, however, an interesting avenue for clinical monitoring when the 
molecule of interest, such as glucose for example, has a similar or higher 
systemic concentration than that found in the SC. 
Finally, comparing the amount of a compound extracted by iontophoresis 
to that present in the SC determined by tape-stripping was an effective method 
to evaluate the ability of iontophoresis to pull molecules from beyond the SC 
reservoir. It would be interesting to apply this method to other compounds, such 
as the negatively charged lactate for example, another potential marker of 
fatigue in athletes, whose extraction in vivo was not clearly related to the blood 
levels. 
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ANNEX I. Analytical method for the detection of amino 
acids and glucose 
 
Amino acids and glucose were analyzed using ion chromatography combined 
with integrated pulsed amperometric detection (IC-IPAD). The ‘improved’ 
gradient method for the AAA-DirectTM separation of amino acids and 
carbohydrates in complex samples was used (Application Update 152, Dionex). 
As the separation is performed with an anion exchange column at high pH, 
amino acids and carbohydrates can be separated in the same run. The 
electrochemical detection has some advantages compared to other detection 
methods available for the quantification of amino acids. Compared to 
spectroscopic detection methods (i.e. UV absorption or fluorescence) no 
derivatization of the molecules is required and the method is more sensitive.  
The electrochemical detection has a similar sensitivity to mass spectroscopy 
and is much less sensitive to the presence of ions in the matrix of the samples 
to analyze. Indeed, the sensitivity of mass spectroscopy deceases dramatically 
when sodium is present in the solution of amino acids to analyze (Nagy et al., 
2003, Rapid Commun Mass Specrom, 17, 983). As the extraction solution used 
for iontophoresis contained 20 mM NaCl, IC-IPAD seemed as the most 
convenient method to analyze amino acids (and glucose) as no sample 
preparation was necessary before analysis. 
  
Equipment: 
- gradient pump GP-50 
- autosampler with column oven AS-50 
- electrochemical detector ED-50 
- Chromeleon software 
- combination pH/Ag/AgCl reference electrode 
- AAA-CertifiedTM disposable Au working electrode 
- AminoPac PA10 analytical column + AminoPac PA10 guard column 
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Conditions: 
Temperature:  33°C (to improve separation between Ser and Pro) 
Flow rate:  0.25 mL/min 
Injection volume: 25 µL (the volume of sample required is 100 µL) 
Eluent:   (A) 10 mM NaOH (2 litres) 
   (B) 250 mM NaOH (2 litres) 
   (C) 1 M sodium acetate + 25 mM NaOH (1 litre) 
   (D) 100 mM acetic acid (1litre) 
All solutions were prepared from deionised water (18.2 MΩ⋅cm). The 
solutions were degassed with helium (He) for 10 minutes and kept under 
He pressure afterwards to avoid contamination from air. The sodium 
acetate was of electrochemical grade and bought from Dionex. 50% 
NaOH (electrochemical grade) was used to avoid inclusion of 
carbonates. 
 
Table 1. AAA-Direct waveform applied for the detection at the gold surface 
Time (s) Potential vs pH reference (V) Integration 
0.00 +0.13 Off 
0.04 +0.13 Off 
0.05 +0.13 Off 
0.21 +0.33 On 
0.22 +0.55 On 
0.46 +0.55 On 
0.47 +0.33 On 
0.56 +0.33 On 
0.57 -1.67 Off 
0.58 -1.67 Off 
0.59 +0.93 Off 
0.60 +0.13 Off 
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Table 2. Gradient method 
Solution Time 
(minutes) 
Curve type 
%A %B %C %D 
0.0 5 100.0 0.0 0.0 0.0 
8.0 5 100.0 0.0 0.0 0.0 
14.0 8 66.7 33.3 0.0 0.0 
17.0 5 66.7 33.3 0.0 0.0 
24.0 8 1.0 89.0 10.0 0.0 
27.0 5 1.0 89.0 10.0 0.0 
30.0 8 0.0 80.0 20.0 0.0 
32.0 5 0.0 80.0 20.0 0.0 
34.0 8 40.0 30.0 30.0 0.0 
36.0 5 40.0 30.0 30.0 0.0 
38.0 8 30.0 30.0 40.0 0.0 
40.0 5 30.0 30.0 40.0 0.0 
42.0 8 20.0 30.0 50.0 0.0 
44.0 5 20.0 30.0 50.0 0.0 
46.0 8 10.0 30.0 60.0 0.0 
48.0 5 10.0 30.0 60.0 0.0 
50.0 8 0.0 30.0 70.0 0.0 
62.0 5 0.0 30.0 70.0 0.0 
62.1 8 0.0 0.0 0.0 100.0 
64.1 5 0.0 0.0 0.0 100.0 
64.2 8 20.0 80.0 0.0 0.0 
66.2 5 20.0 80.0 0.0 0.0 
66.3 5 100.0 0.0 0.0 0.0 
92.0 5 100.0 0.0 0.0 0.0 
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Results 
As previously mentioned, it is possible to separate amino acids and 
carbohydrates with the IC-IPAD method. As glucose is known to be present in 
samples obtained by reverse iontophoresis (e.g., the GlucoWatch), it was 
important to make sure that this compound would not interfere with the 
detection of the amino acids. An initial concentration of 10 mM NaOH at the 
beginning of the gradient permits a quick elution of glucose (and most of other 
carbohydrates) compared to all primary amino acids except arginine and lysine 
(Application Note 150, Dionex). The inconvenient of this low initial NaOH 
concentration is a loss in sensitivity for some amino acids (mainly lysine, 
glutamine and asparagine), and was one of the reasons why lysine could not be 
quantified (Table 3).  
Glutamine, a potential biomarker of fatigue in athletes, was found to co-
elute with citrulline (Table 3) with the gradient method used (Table 2). Several 
variations of the gradient (e.g. vary the initial isocratic period, vary the curve 
type of initial gradient) were tried in order to increase the resolution between 
these two molecules, but none improved their separation. It was therefore 
decided to concentrate our efforts on the separation of the other amino acids 
with potential interest in sports medicine (tryptophan, isoleucine, leucine and 
valine) and those constituting natural moisturizing factor (NMF). 
Using the recommended column temperature of 30°C resulted in a poor 
separation of serine and proline. Different temperatures (25-35°C) were 
therefore tested to optimize the separation of these two abundant compounds in 
NMF and a temperature of 33°C was chosen for that purpose. 
Figure 1 is an example of chromatogram obtained with the conditions 
used. The following molecules were analysed in unknown samples: glucose, 
asparagine, alanine, threonine, glycine, valine, serine, proline, isoleucine, 
leucine, methionine, histidine, phenylalanine, tyrosine, tryptophan. In Table 3, 
the amino acids that could not be quantified are presented with the reasons for 
their exclusion. Finally, the linearity range, precision and repeatability for each 
amino acid quantified are summarized in Table 4. 
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Figure 1. Example of chromatogram obtained for a standard solution containing 
5 µM of each of the 20 primary amino acids and glucose. 
 
Table 3. Molecules not analyzed in samples and reason for exclusion. 
Molecule Reason for exclusion 
Arginine Co-elution with urea + other unidentified molecules 
Lysine Poor sensitivity + co-elution with unidentified molecules 
Glutamine Co-elution with citrulline 
Aspartate Poor sensitivity 
Glutamate Poor sensitivity 
Cysteine Co-elution with cystine and other unidentified molecules 
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Table 4. Linearity range (r > 0.99), precision (at 1µM) and repeatability (at 1µM) 
of the method for the molecules analyzed using the above mentioned 
conditions. 
Molecule Linearity range 
(µM) 
Precision (n = 4) 
(%) 
Repeatability (n = 4) 
(%) 
Glucose 0.05 - 50 97 1 
Asparagine 0.1 – 5.0 113 6 
Alanine 0.5 – 25 112 6 
Threonine 0.25 - 25 97 4 
Glycine 0.25 - 25 101 6 
Valine 0.25 - 25 92 7 
Serine 0.1 – 50 99 2 
Proline 0.1 – 10 95 5 
Isoleucine 0.1 – 10 95 4 
Leucine 0.1 – 10 96 8 
Methionine 0.25 – 10 94 5 
Histidine 0.1 – 10 101 9 
Phenylalanine 0.1 – 10 101 9 
Tyrosine 0.1 - 10 97 7 
Tryptophan 0.05 - 10 89 6 
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ANNEX II. Complements to Chapter 4 
 
 
1. Concentration profiles of AAs and glucose in pig SC 
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1. Concentration profiles of amino acids and glucose in pig SC 
(continued) 
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2. Fluxes at the cathode, anode and passive diffusion for amino acids and glucose as a function of time 
Extraction fluxes ± SD  (n = 6) at [nmol/(h⋅cm
2
)] Molecule Compartment 
0.25 h 0.5 h 1 h 2 h 3 h 4 h 5 h 6 h 
Cathode 76.5 ± 23.4 38.3 ± 12.1 17.9 ± 3.5 10.2 ± 2.0 7.5 ± 2.0 5.0 ± 1.3 4.0 ± 1.0 3.3 ± 0.8 
Anode 57.9 ± 19.0 21.0 ± 5.4 11.0 ± 3.2 7.0 ± 2.6 4.7 ± 1.9 3.5 ± 1.1 2.8 ± 0.9 1.8 ± 0.5 Serine 
Passive 56.5 ± 20.1 18.0 ± 6.8 10.1 ± 2.8 7.4 ± 1.5 5.5 ± 1.1 4.1 ± 1.0 3.3 ± 0.9 2.8 ± 0.8 
Cathode 57.9 ± 16.1 30.5 ± 12.8 13.0 ± 2.7 7.5 ± 2.7 5.6 ± 1.7 4.1 ± 1.1 3.6 ± 1.2 3.3 ± 1.3 
Anode 49.7 ± 17.4 18.7 ± 5.6 9.6 ± 4.5 5.2 ± 2.3 3.9 ± 1.9 3.1 ± 1.0 2.3 ± 0.8 1.7 ± 0.5 Glycine 
Passive 42.5 ± 9.7 15.1 ± 4.4 7.7 ± 1.8 5.1 ± 0.7 3.6 ± 0.6 2.7 ± 0.5 2.2 ± 0.5 1.9 ± 0.5 
Cathode 40.2 ± 9.2 21.8 ± 7.2 10.4 ± 2.3 5.9 ± 1.0 4.3 ± 0.9 3.0 ± 0.6 2.6 ± 0.6 2.4 ± 0.7 
Anode 34.2 ± 13.4 12.4 ± 4.7 6.2 ± 2.2 3.5 ± 1.2 2.3 ± 1.0 1.8 ± 0.4 1.6 ± 0.3 1.0 ± 0.3 Alanine 
Passive 32.0 ± 11.0 11.5 ± 3.6 6.4 ± 1.1 4.0 ± 0.6 2.9 ± 0.6 2.3 ± 0.5 1.6 ± 0.4 1.3 ± 0.3 
Cathode 42.2 ± 11.2 24.2 ± 4.6 10.8 ± 2.5 5.6 ± 1.0 3.6 ± 0.3 2.3 ± 0.1 1.8 ± 0.1 1.4 ± 0.1 
Anode 19.1 ± 7.7 5.0 ± 1.8 2.1 ± 0.8 1.1 ± 0.4 0.7 ± 0.3 0.4 ± 0.3 0.3 ± 0.2 0.2 ± 0.1 Histidine 
Passive 25.6 ± 9.9 8.6 ± 3.7 5.1 ± 1.7 3.8 ± 0.8 2.9 ± 0.7 2.2 ± 0.5 1.7 ± 0.5 1.4 ± 0.4 
Cathode 15.7 ± 5.3 8.4 ± 3.3 4.2 ± 1.0 2.6 ± 0.4 1.9 ± 0.6 1.3 ± 0.3 1.0 ± 0.3 0.9 ± 0.2 
Anode 12.3 ± 4.8 4.3 ± 1.4 2.4 ± 0.8 1.5 ± 0.6 1.0 ± 0.6 0.8 ± 0.3 0.6 ± 0.2 0.3 ± 0.1 Threonine 
Passive 11.9 ± 5.2 4.0 ± 1.9 2.2 ± 0.6 1.7 ± 0.4 1.2 ± 0.3 1.0 ± 0.2 0.7 ± 0.2 0.6 ± 0.2 
Cathode 14.4 ± 4.2 7.7 ± 2.5 3.8 ± 1.3 2.2 ± 0.6 1.6 ± 0.2 1.1 ± 0.2 0.9 ± 0.2 0.7 ± 0.1 
Anode 11.7 ± 3.9 4.1 ± 1.1 2.1 ± 0.5 1.3 ± 0.3 0.8 ± 0.2 0.6 ± 0.1 0.5 ± 0.1 0.3 ± 0.1 Proline 
Passive 10.9 ± 4.5 3.4 ± 1.3 2.0 ± 0.6 1.3 ± 0.4 0.9 ± 0.4 0.7 ± 0.1 0.5 ± 0.2 0.4 ± 0.2 
Cathode 10.0 ± 3.4 5.4 ± 1.8 3.2 ± 1.0 1.9 ± 0.5 1.5 ± 0.5 1.3 ± 0.3 1.0 ± 0.3 1.0 ± 0.4 
Anode 8.8 ± 5.4 3.2 ± 0.9 1.6 ± 0.7 1.1 ± 0.4 0.7 ± 0.2 0.7 ± 0.2 0.5 ± 0.1 0.4 ± 0.1 Leucine 
Passive 10.0 ± 4.7 4.2 ± 1.3 2.0 ± 0.6 1.2 ± 0.3 1.1 ± 0.3 0.9 ± 0.2 0.9 ± 0.4 0.7 ± 0.2 
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2. Fluxes at the cathode, anode and passive diffusion for amino acids and glucose as a function of time (continued) 
Extraction fluxes ± SD  (n = 6) at [nmol/(h⋅cm
2
)] Molecule Compartment 
0.25 h 0.5 h 1 h 2 h 3 h 4 h 5 h 6 h 
Cathode 6.8 ± 3.0 3.6 ± 1.4 2.1 ± 0.6 1.1 ± 0.2 0.9 ± 0.3 0.7 ± 0.4 0.5 ± 0.2 0.4 ± 0.2 
Anode 5.1 ± 2.2 1.8 ± 0.9 0.8 ± 0.2 0.5 ± 0.2 0.3 ± 0.1 0.25 ± 0.03 0.23 ± 0.08 0.15 ± 0.04 Valine 
Passive 5.8 ± 2.1 1.7 ± 0.7 1.0 ± 0.3 0.7 ± 0.2 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 
Cathode 5.0 ± 1.7 2.6 ± 0.8 1.5 ± 0.6 0.9 ± 0.3 0.7 ± 0.2 0.7 ± 0.2 0.5 ± 0.1 0.4 ± 0.1 
Anode 4.1 ± 1.8 1.6 ± 0.6 0.7 ± 0.1 0.5 ± 0.2 0.3 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 Isoleucine 
Passive 4.8 ± 2.5 1.8 ± 0.5 0.9 ± 0.3 0.6 ± 0.2 0.5 ± 0.2 0.5 ± 0.1 0.4 ± 0.2 0.4 ± 0,1 
Cathode 3.1 ± 1.5 1.7 ± 0.7 0.9 ± 0.3 0.7 ± 0.2 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 
Anode 2.7 ± 1.2 1.1 ± 0.3 0.6 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.1 ± 0.1 Tyrosine 
Passive 3.0 ± 1.4 1.0 ± 0.4 0.6 ± 0.2 0.5 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.1 ± 0.1 
Cathode 2.6 ± 1.4 1.4 ± 0.6 0.7 ± 0.3 0.5 ± 0.2 0.4 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 
Anode 2.3 ± 0.9 0.8 ± 0.2 0.4 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 0.17 ± 0.04 0.15 ± 0.05 0.09 ± 0.04 Phenylalanine 
Passive 2.6 ± 1.2 0.8 ± 0.3 0.5 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.24 ± 0.04 0.2 ± 0.1 0.18 ± 0.04 
Cathode 2.8 ± 1.5 1.5 ± 0.5 0.7 ± 0.3 0.5 ± 0.2 0.3 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 
Anode 2.3 ± 1.3 0.7 ± 0.4 0.4 ± 0.2 0.2 ± 0.1 0.2 ± 0.1 0.1 ± 0.1 0.09 ± 0.04 0.06 ± 0.05 Asparagine 
Passive 2.9 ± 1.5 0.9 ± 0.5 0.5 ± 0.2 0.4 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.1 ± 0.1 
Cathode 0.5 ± 0.3 0.2 ± 0.1 0.2 ± 0.1 0.09 ± 0.05 0.08 ± 0.03 0.06 ± 0.03 0.05 ± 0.03 0.05 ± 0.03 
Anode 0.4 ± 0.2 0.2 ± 0.1 0.06 ± 0.03 0.03 ± 0.02 0.03 ± 0.02 0.02 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 Tryptophan 
Passive 0.5 ± 0.2 0.2 ± 0.1 0.08 ± 0.04 0.07 ± 0.03 0.06 ± 0.02 0.04 ± 0.02 0.04 ± 0.02 0.03 ± 0.02 
Cathode 2.5 ± 2.0 1.5 ± 1.3 0.9 ± 0.9 0.6 ± 0.5 0.5 ± 0.4 0.4 ± 0.3 0.4 ± 0.3 0.4 ± 0.3 
Anode 2.4 ± 1.5 0.5 ± 0.3 0.2 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.2 ± 0.2 Glucose 
Passive 1.8 ± 1.1 0.4 ± 0.3 0.2 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.05 ± 0.04 0.05 ± 0.04 
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3. Cumulative amount of amino acids and glucose (mean ± SD, n = 6) 
extracted as a function of time at the cathode and by passive diffusion. 
The quantities in the SC determined by tape-stripping are shown for 
comparison. 
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3. Cumulative amount of amino acids and glucose (mean ± SD, n = 6) 
extracted as a function of time at the cathode and by passive diffusion. 
The quantities in the SC determined by tape-stripping are shown for 
comparison.  (continued) 
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3. Cumulative amount of amino acids and glucose (mean ± SD, n = 6) 
extracted as a function of time at the cathode and by passive diffusion. 
The quantities in the SC determined by tape-stripping are shown for 
comparison. (continued) 
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ANNEX III. Complements to Chapter 5 
 
1. Iontophoretic extraction fluxes at the cathode and anode as a function 
of time and subdermal concentration of AAs and glucose when the 
subdermal electrolyte was PBS. 
 
Serine fluxes (± SD, n = 6) for experiments in PBS [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 29.1 ± 11.3 24.0 ± 5.7 30.5 ± 11.0 19.6 ± 6.7 27.2 ± 4.6 15.2 ± 3.0 
2 8.6 ± 1.7 6.8 ± 0.7 10.4 ± 8.1 7.2 ± 4.5 10.3 ± 4.2 6.9 ± 2.7 
3 4.7 ± 0.7 3.3 ± 0.4 6.1 ± 4.6 4.2 ± 3.2 7.2 ± 3.7 4.3 ± 2.2 
4 3.3 ± 0.7 2.0 ± 0.3 5.2 ± 4.3 2.9 ± 2.4 5.8 ± 2.4 3.9 ± 2.7 
5 2.7 ± 0.6 1.4 ± 0.2 4.1 ± 2.8 2.3 ± 1.8 5.0 ± 1.6 2.8 ± 1.9 
6 2.1 ± 0.5 1.0 ± 0.2 3.5 ± 2.3 1.9 ± 1.3 4.3 ± 1.5 2.5 ± 1.6 
 
Glycine fluxes (± SD, n = 6) for experiments in PBS [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 24.0 ± 7.9 20.3 ± 3.0 22.6 ± 9.6 16.5 ± 7.0 20.7 ± 4.4 12.4 ± 2.9 
2 6.6 ± 2.0 5.1 ± 0.9 7.7 ± 5.2 5.5 ± 3.8 7.5 ± 2.8 4.8 ± 2.0 
3 3.9 ± 1.0 2.6 ± 1.0 5.4 ± 3.7 3.1 ± 2.6 5.5 ± 1.9 2.9 ± 1.9 
4 3.0 ± 0.8 1.8 ± 0.9 4.8 ± 3.2 2.2 ± 1.6 4.7 ± 1.4 2.6 ± 1.7 
5 2.4 ± 0.8 1.5 ± 1.1 4.1 ± 2.3 2.0 ± 1.4 4.5 ± 0.9 2.0 ± 1.2 
6 2.1 ± 0.7 1.4 ± 1.1 3.9 ± 2.4 1.7 ± 1.1 3.9 ± 1.0 2.1 ± 1.0 
 
Alanine fluxes (± SD, n = 6) for experiments in PBS [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 17.2 ± 5.0 13.5 ± 2.3 17.6 ± 4.9 12.0 ± 3.8 20.3 ± 2.8 10.9 ± 2.4 
2 5.2 ± 0.9 3.8 ± 0.4 6.7 ± 3.6 4.3 ± 2.0 7.3 ± 3.0 4.5 ± 2.2 
3 2.9 ± 0.6 1.9 ± 0.4 4.6 ± 2.8 2.5 ± 1.5 5.3 ± 2.2 2.7 ± 1.7 
4 2.3 ± 0.4 1.3 ± 0.5 4.0 ± 2.4 1.8 ± 0.9 4.5 ± 1.4 2.3 ± 1.5 
5 1.9 ± 0.5 1.0 ± 0.6 3.2 ± 1.8 1.5 ± 0.6 4.1 ± 0.9 1.4 ± 0.7 
6 1.6 ± 0.5 0.9 ± 0.7 3.1 ± 1.7 1.3 ± 0.5 3.5 ± 0.9 1.7 ± 0.7 
 
 
Annex III 
 200 
 
Histidine fluxes (± SD, n = 6) for experiments in PBS [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 18.4 ± 5.0 8.0 ± 2.3 17.7 ± 6.4 5.1 ± 2.0 19.6 ± 3.1 3.3 ± 1.1 
2 5.9 ± 0.8 2.1 ± 0.9 6.4 ± 4.2 1.9 ± 0.7 6.8 ± 2.4 1.0 ± 0.4 
3 3.2 ± 0.5 1.0± 0.3 3.7 ± 1.9 0.9 ± 0.3 4.8 ± 1.7 0.6 ± 0.4 
4 2.1 ± 0.4 0.5 ± 0.2 3.2 ± 2.1 0.5 ± 0.1 4.2 ± 1.4 0.6 ± 0.4 
5 1.8 ± 0.5 0.4 ± 0.2 2.7 ± 0.9 0.4 ± 0.1 3.6 ± 0.8 0.4 ± 0.3 
6 1.5 ± 0.5 0.2 ± 0.1 2.4 ± 1.1 0.3 ± 0.1 3.0 ± 0.6 0.4 ± 0.3 
 
Threonine fluxes (± SD, n = 6) for experiments in PBS [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 7.2 ± 2.7 5.2 ± 0.9 7.1 ± 1.9 4.7 ± 1.8 7.6 ± 1.5 3.3 ± 0.5 
2 2.5 ± 0.6 1.6 ± 0.1 3.2 ± 1.8 1.9 ± 1.1 3.5 ± 0.9 1.5 ± 0.5 
3 1.4 ± 0.3 0.8 ± 0.2 2.1 ± 1.2 1.0 ± 0.8 2.9 ± 0.9 1.0 ± 0.4 
4 1.1 ± 0.2 0.5 ± 0.1 2.0 ± 1.2 0.8 ± 0.5 2.5 ± 0.5 0.9 ± 0.6 
5 0.9 ± 0.2 0.4 ± 0.1 1.6 ± 0.8 0.6 ± 0.3 2.5 ± 0.4 0.7 ± 0.3 
6 0.8 ± 0.2 0.3 ± 0.1 1.5 ± 0.7 0.5 ± 0.2 2.2 ± 0.3 0.7 ± 0.3 
 
Proline fluxes (± SD, n = 6) for experiments in PBS [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 6.9 ± 2.6 5.0 ± 1.4 6.6 ± 1.5 4.2 ± 1.8 7.0 ± 0.6 3.0 ± 0.6 
2 2.3 ± 0.5 1.5 ± 0.2 2.9 ± 1.6 1.5 ± 0.8 3.4 ± 0.9 1.4 ± 0.7 
3 1.4 ± 0.3 0.8 ± 0.2 1.9 ± 0.8 0.8 ± 0.5 2.6 ± 0.7 0.8 ± 0.4 
4 1.0 ± 0.2 0.5 ± 0.2 1.8 ± 1.0 0.5 ± 0.3 2.4 ± 0.5 0.8 ± 0.4 
5 0.9 ± 0.3 0.4 ± 0.2 1.5 ± 0.6 0.5 ± 0.2 2.3 ± 0.2 0.5 ± 0.2 
6 0.8 ± 0.2 0.3 ± 0.2 1.4 ± 0.6 0.4 ± 0.2 2.0 ± 0.4 0.7 ± 0.2 
 
Leucine fluxes (± SD, n = 6) for experiments in PBS [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 5.5 ± 1.7 3.9 ± 1.3 5.2 ± 1.1 3.2 ± 2.0 5.8 ± 1.5 5.1 ± 6.2 
2 2.4 ± 0.7 1.4 ± 0.3 2.7 ± 1.4 1.4 ± 0.8 3.1 ± 0.4 1.6 ± 1.3 
3 1.3 ± 0.3 0.7 ± 0.2 1.8 ± 0.5 0.7 ± 0.4 2.5 ± 0.6 0.9 ± 0.2 
4 1.2 ± 0.4 0.5 ± 0.2 1.7 ± 0.9 0.5 ± 0.2 2.5 ± 0.4 0.9 ± 0.4 
5 1.2 ± 0.5 0.4 ± 0.1 1.8 ± 0.3 0.6 ± 0.2 2.5 ± 0.2 0.7 ± 0.2 
6 1.0 ± 0.4 0.3 ± 0.1 2.0 ± 0.6 0.5 ± 0.2 2.4 ± 0.4 0.7 ± 0.2 
 
 
Annex III 
 201 
Valine fluxes (± SD, n = 6) for experiments in PBS [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 3.2 ± 1.2 2.5 ± 0.4 3.6 ± 1.1 2.1 ± 1.2 4.1 ± 1.3 1.5 ± 0.5 
2 1.5 ± 0.4 0.6 ± 0.1 2.0 ± 1.0 0.9 ± 0.6 2.4 ± 0.4 0.6 ± 0.1 
3 0.9 ± 0.3 0.4 ± 0.1 1.4 ± 0.7 0.5 ± 0.4 2.0 ± 0.4 0.4 ± 0.2 
4 0.6 ± 0.2 0.3 ± 0.2 1.5 ± 0.6 0.4 ± 0.2 1.9 ± 0.2 0.4 ± 0.2 
5 0.6 ± 0.1 0.2 ± 0.1 1.3 ± 0.5 0.4 ± 0.2 2.0 ± 0.1 0.2 ± 0.1 
6 0.5 ± 0.1 0.1 ± 0.2 1.2 ± 0.5 0.4 ± 0.1 1.7 ± 0.2 0.5 ± 0.1 
 
Isoleucine fluxes (± SD, n = 6) for experiments in PBS [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 2.2 ± 0.6 1.4 ± 0.3 2.2 ± 0.4 1.7 ± 1.5 3.3 ± 1.1 1.0 ± 0.3 
2 1.1 ± 0.3 0.4 ± 0.2 1.5 ± 0.6 0.7 ± 0.5 2.1 ± 0.3 0.5 ± 0.1 
3 0.7 ± 0.1 0.3 ± 0.1 1.1 ± 0.3 0.3 ± 0.2 1.9 ± 0.4 0.3 ± 0.1 
4 0.6 ± 0.2 0.21 ± 0.04 1.1 ± 0.3 0.3 ± 0.1 1.9 ± 0.2 0.4 ± 0.1 
5 0.6 ± 0.1 0.2 ± 0.1 1.1 ± 0.1 0.3 ± 0.1 1.9 ± 0.2 0.3 ± 0.1 
6 0.6 ± 0.1 0.2 ± 0.1 1.1 ± 0.2 0.2 ± 0.1 1.7 ± 0.3 0.4 ± 0.1 
 
Tyrosine fluxes (± SD, n = 6) for experiments in PBS [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 1.6 ± 0.5 0.9 ± 0.3 1.8 ± 0.4 1.5 ± 1.3 2.2 ± 0.8 0.9 ± 0.2 
2 1.1 ± 0.2 0.7 ± 0.2 1.4 ± 0.5 0.8 ± 0.6 1.9 ± 0.5 0.5 ± 0.1 
3 0.7 ± 0.1 0.4 ± 0.2 1.1 ± 0.3 0.5 ± 0.3 1.9 ± 0.4 0.4 ± 0.1 
4 0.6 ± 0.1 0.2 ± 0.2 1.1 ± 0.4 0.4 ± 0.2 1.8 ± 0.2 0.4 ± 0.1 
5 0.6 ± 0.1 0.2 ± 0.1 1.1 ± 0.2 0.3 ± 0.2 1.8 ± 0.2 0.3 ± 0.1 
6 0.5 ± 0.1 0.1 ± 0.1 1.1 ± 0.3 0.3 ± 0.2 1.6 ± 0.2 0.3 ± 0.1 
 
Phenylalanine fluxes (± SD, n = 6) for experiments in PBS [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 1.3 ± 0.5 1.0 ± 0.2 1.5 ± 0.4 1.3 ± 1.3 2.2 ± 0.9 0.6 ± 0.2 
2 0.8 ± 0.3 0.3 ± 0.1 1.3 ± 0.5 0.6 ± 0.5 1.9 ± 0.5 0.3 ± 0.1 
3 0.5 ± 0.1 0.18 ± 0.04 1.0 ± 0.3 0.3 ± 0.2 1.8 ± 0.5 0.2 ± 0.1 
4 0.5 ± 0.1 0.15 ± 0.02 1.1 ± 0.4 0.2 ± 0.1 1.8 ± 0.2 0.3 ± 0.1 
5 0.4 ± 0.1 0.13 ± 0.03 1.1 ± 0.2 0.3 ± 0.1 1.7 ± 0.2 0.2 ± 0.1 
6 0.4 ± 0.1 0.10 ± 0.03 1.0 ± 0.3 0.2 ± 0.1 1.6 ± 0.3 0.3 ± 0.1 
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Asparagine fluxes (± SD, n = 6) for experiments in PBS [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 1.5 ± 0.6 0.9 ± 0.1 1.7 ± 0.6 1.4 ± 1.3 2.8 ± 1.1 0.7 ± 0.1 
2 0.7 ± 0.2 0.29 ± 0.05 1.2 ± 0.4 0.6 ± 0.6 1.8 ± 0.3 0.3 ± 0.1 
3 0.5 ± 0.1 0.17 ± 0.04 1.1 ± 0.3 0.3 ± 0.3 1.8 ± 0.3 0.2 ± 0.1 
4 0.4 ± 0.1 0.13 ± 0.06 1.1 ± 0.2 0.2 ± 0.1 1.8 ± 0.1 0.2 ± 0.1 
5 0.4 ± 0.1 0.11 ± 0.03 1.1 ± 0.1 0.2 ± 0.1 1.8 ± 0.2 0.20 ± 0.03 
6 0.4 ± 0.1 0.10 ± 0.03 1.0 ± 0.2 0.2 ± 0.1 1.7 ± 0.2 0.3 ± 0.1 
 
Tryptophan fluxes (± SD, n = 6) for experiments in PBS [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 0.4 ± 0.1 0.21 ± 0.05 0.6 ± 0.1 0.62 ± 1.02 1.2 ± 0.7 0.26 ± 0.13 
2 0.3 ± 0.1 0.12 ± 0.04 0.7 ± 0.1 0.32 ± 0.40 1.3 ± 0.3 0.16 ± 0.06 
3 0.3 ± 0.1 0.08 ± 0.02 0.7 ± 0.1 0.13 ± 0.07 1.4 ± 0.3 0.11 ± 0.03 
4 0.3 ± 0.1 0.05 ± 0.01 0.8 ± 0.1 0.11 ± 0.03 1.5 ± 0.2 0.13 ± 0.04 
5 0.3 ± 0.1 0.05 ± 0.02 0.8 ± 0.1 0.09 ± 0.02 1.5 ± 0.3 0.11 ± 0.03 
6 0.3 ± 0.1 0.04 ± 0.02 0.8 ± 0.1 0.09 ± 0.04 1.4 ± 0.2 0.13 ± 0.05 
 
Methionine fluxes (± SD, n = 6) for experiments in PBS [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 0.6 ± 0.2 0.18 ± 0.16 0.8 ± 0.2 0.21 ± 0.23 1.8 ± 0.8 0.27 ± 0.16 
2 0.4 ± 0.1 0.09 ± 0.02 0.7 ± 0.1 0.14 ± 0.17 1.4 ± 0.3 0.08 ± 0.04 
3 0.3 ± 0.1 0.04 ± 0.02 0.56 ± 0.04 0.07 ± 0.03 1.3 ± 0.3 0.08 ± 0.02 
4 0.2 ± 0.1 0.04 ± 0.04 0.6 ± 0.1 0.07 ± 0.04 1.4 ± 0.3 0.13 ± 0.10 
5 0.2 ± 0.1 0.05 ± 0.01 0.7 ± 0.1 0.09 ± 0.04 1.4 ± 0.3 0.10 ± 0.04 
6 0.2 ± 0.1 0.04 ± 0.03 0.6 ± 0.2 0.05 ± 0.02 1.2 ± 0.3 0.13 ± 0.05 
 
Glucose fluxes (± SD, n = 6) for experiments in PBS [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 5.1 ± 2.4 1.5 ± 1.6 8.3 ± 3.0 8.1 ± 14.3 16.2 ± 7.9 1.6 ± 2.1 
2 4.1 ± 0.8 0.4 ± 0.4 9.1 ± 1.4 3.1 ± 5.2 15.6 ± 3.4 0.5 ± 0.4 
3 3.9 ± 0.4 0.3 ± 0.3 9.0 ± 1.0 1.3 ± 1.4 16.6 ± 2.9 0.5 ± 0.2 
4 3.8 ± 0.2 0.4 ± 0.3 10.0 ± 1.0 0.7 ± 0.5 17.1 ± 2.3 0.6 ± 0.2 
5 3.9 ± 0.5 0.5 ± 0.4 9.8 ± 1.0 0.9 ± 0.7 17.4 ± 2.1 0.8 ± 0.3 
6 3.9 ± 0.3 0.5 ± 0.4 9.9 ± 1.2 1.1 ± 0.7 16.1 ± 1.8 1.5 ± 0.7 
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2. Iontophoretic extraction fluxes at the cathode and anode as a function 
of time and subdermal concentration of AAs and glucose when the 
subdermal electrolyte was PB. 
 
Serine fluxes (± SD, n = 6) for experiments in PB [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 45.1 ± 18.2 34.5 ± 16.0 39.1 ± 6.5 28.5 ± 4.9 47.5 ± 13.6 28.3 ± 12.5 
2 15.0 ± 4.0 12.2 ± 5.2 15.4 ± 2.7 10.3 ± 3.8 20.4 ± 4.4 9.3 ± 3.3 
3 9.6 ± 3.1 6.0 ± 2.6 10.7 ± 2.2 7.0 ± 2.9 14.8 ± 3.5 5.7 ± 2.2 
4 7.4 ± 2.6 3.1 ± 1.3 8.9 ± 1.4 4.3 ± 1.7 12.9 ± 1.7 3.6 ± 2.4 
5 5.6 ± 1.7 1.8 ± 0.7 8.1 ± 1.8 3.1 ± 1.3 11.7 ± 2.5 3.7 ± 1.6 
6 5.3 ± 1.6 1.7 ± 1.1 7.1 ± 1.2 2.0 ± 0.8 12.0 ± 2.5 1.9 ± 1.0 
 
Glycine fluxes (± SD, n = 6) for experiments in PB [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 27.5 ± 7.4 24.0 ± 6.5 20.6 ± 10.3 18.6 ± 5.8 29.5 ± 8.5 18.6 ± 6.8 
2 11.2 ± 3.6 7.3 ± 2.2 8.8 ± 3.1 6.1 ± 3.0 13.6 ± 2.3 5.8 ± 2.7 
3 6.9 ± 2.1 3.5 ± 1.7 6.9 ± 2.9 4.1 ± 2.0 11.4 ± 2.3 3.8 ± 2.3 
4 6.4 ± 2.0 2.0 ± 1.0 6.3 ± 1.6 2.6 ± 1.5 10.1 ± 2.3 2.6 ± 2.3 
5 5.6 ± 2.0 0.9 ± 0.3 5.5 ± 2.1 1.9 ± 1.1 9.4 ± 1.5 2.8 ± 1.0 
6 4.7 ± 0.9 0.9 ± 0.8 5.3 ± 1.5 1.4 ± 0.9 9.4 ± 1.3 1.8 ± 0.9 
 
Alanine fluxes (± SD, n = 6) for experiments in PB [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 19.0 ± 3.6 13.7 ± 3.3 17.2 ± 7.0 14.4 ± 4.4 19.7 ± 5.3 11.4 ± 3.9 
2 8.0 ± 1.8 5.2 ± 1.3 8.3 ± 2.6 4.8 ± 2.4 11.4 ± 2.6 4.0 ± 1.8 
3 5.7 ± 1.1 2.7 ± 0.8 6.7 ± 2.2 3.1 ± 1.5 9.9 ± 1.0 2.6 ± 1.7 
4 4.8 ± 1.3 1.6 ± 0.4 5.7 ± 0.8 1.9 ± 1.0 8.7 ± 0.9 1.7 ± 1.9 
5 4.2 ± 0.8 1.2 ± 0.4 5.6 ± 1.5 1.4 ± 0.5 8.9 ± 0.9 1.6 ± 1.0 
6 4.4 ± 0.7 1.1 ± 0.3 5.0 ± 0.8 1.0 ± 0.5 8.6 ± 1.0 1.2 ± 0.5 
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Histidine fluxes (± SD, n = 6) for experiments in PB [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 18.1 ± 3.7 5.4 ± 2.9 16.9 ± 4.0 4.9 ± 1.5 21.2 ± 6.5 5.6 ± 2.0 
2 7.9 ± 1.8 1.4 ± 0.9 8.9 ± 2.7 1.1 ± 0.2 14.0 ± 3.3 1.6 ± 0.6 
3 5.8 ± 2.2 0.6 ± 0.5 7.6 ± 2.7 0.5 ± 0.2 12.9 ± 2.6 0.8 ± 0.2 
4 4.9 ± 1.9 0.3 ± 0.2 7.1 ± 1.9 0.3 ± 0.1 10.1 ± 1.4 0.4 ± 0.1 
5 4.0 ± 1.1 0.2 ± 0.1 6.2 ± 1.9 0.3 ± 0.1 9.4 ± 1.2 0.5 ± 0.2 
6 4.2 ± 0.9 0.2 ± 0.1 5.4 ± 0.8 0.2 ± 0.1 9.4 ± 0.9 0.2 ± 0.1 
 
Threonine fluxes (± SD, n = 6) for experiments in PB [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 10.8 ± 4.3 7.5 ± 3.7 10.6 ± 2.3 7.0 ± 1.4 13.1 ± 3.1 6.4 ± 2.5 
2 4.5 ± 1.0 2.8 ± 1.4 5.6 ± 0.6 2.6 ± 0.9 8.7 ± 1.5 2.3 ± 0.7 
3 3.3 ± 1.1 1.4 ± 0.6 4.9 ± 1.4 1.9 ± 0.8 8.3 ± 1.6 1.5 ± 0.5 
4 2.9 ± 0.9 0.7 ± 0.3 4.6 ± 0.9 1.2 ± 0.5 7.9 ± 1.0 1.0 ± 0.6 
5 2.5 ± 0.6 0.5 ± 0.2 4.5 ± 1.5 0.8 ± 0.3 8.0 ± 1.1 0.9 ± 0.4 
6 2.5 ± 0.3 0.4 ± 0.2 4.1 ± 1.0 0.6 ± 0.2 8.5 ± 2.0 0.6 ± 0.2 
 
Proline fluxes (± SD, n = 6) for experiments in PB [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 9.8 ± 3.9 5.5 ± 2.4 9.2 ± 2.9 4.6 ± 1.9 12.4 ± 2.8 5.6 ± 2.5 
2 4.0 ± 1.1 1.9 ± 0.9 4.8 ± 1.3 1.6 ± 0.5 8.7 ± 1.6 1.8 ± 0.7 
3 2.9 ± 1.1 0.9 ± 0.4 4.1 ± 1.3 1.1 ± 0.3 7.9 ± 1.7 1.1 ± 0.4 
4 2.6 ± 0.9 0.5 ± 0.2 3.9 ± 1.3 0.6 ± 0.2 7.6 ± 1.1 0.7 ± 0.4 
5 2.1 ± 0.4 0.2 ± 0.1 3.7 ± 1.7 0.5 ± 0.1 6.9 ± 1.0 0.7 ± 0.2 
6 2.1 ± 0.3 0.2 ± 0.1 3.4 ± 1.4 0.3 ± 0.1 8.0 ± 1.4 0.4 ± 0.2 
 
Leucine fluxes (± SD, n = 6) for experiments in PB [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 7.9 ± 4.4 5.3 ± 2.5 12.5 ± 2.5 6.2 ± 1.5 10.0 ± 3.2 5.0 ± 2.3 
2 4.2 ± 1.2 2.2 ± 1.1 5.8 ± 0.9 2.4 ± 0.8 8.2 ± 1.8 2.0 ± 0.4 
3 3.5 ± 1.5 1.3 ± 0.7 4.8 ± 0.8 1.9 ± 1.0 7.6 ± 2.1 1.6 ± 0.4 
4 2.4 ± 0.5 0.7 ± 0.3 4.5 ± 1.0 1.2 ± 0.6 6.7 ± 1.1 0.9 ± 0.3 
5 1.7 ± 0.2 0.5 ± 0.2 3.9 ± 1.3 1.0 ± 0.4 8.0 ± 1.3 1.0 ± 0.5 
6 2.0 ± 0.3 0.5 ± 0.1 3.8 ± 1.4 1.0 ± 0.3 7.6 ± 1.5 0.8 ± 0.2 
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Valine fluxes (± SD, n = 6) for experiments in PB [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 5.5 ± 1.6 3.1 ± 1.4 5.8 ± 1.8 3.1 ± 1.1 7.7 ± 1.7 2.5 ± 0.9 
2 2.9 ± 0.9 0.8 ± 0.5 3.8 ± 0.7 1.0 ± 0.5 6.6 ± 0.9 0.9 ± 0.4 
3 2.1 ± 0.7 0.4 ± 0.3 3.6 ± 1.0 0.8 ± 0.4 6.7 ± 1.2 0.6 ± 0.3 
4 1.9 ± 0.6 0.2 ± 0.2 3.5 ± 0.5 0.5 ± 0.3 6.9 ± 0.9 0.3 ± 0.3 
5 1.7 ± 0.4 0.1 ± 0.1 3.3 ± 1.1 0.3 ± 0.2 6.5 ± 0.5 0.4 ± 0.1 
6 1.5 ± 0.2 0.1 ± 0.1 3.2 ± 0.8 0.2 ± 0.2 7.3 ± 1.2 0.3 ± 0.1 
 
Isoleucine fluxes (± SD, n = 6) for experiments in PB [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 4.5 ± 1.5 2.1 ± 0.9 6.5 ± 1.6 2.8 ± 0.8 6.9 ± 1.8 2.8 ± 1.3 
2 2.6 ± 1.0 0.7 ± 0.3 3.8 ± 0.7 1.1 ± 0.4 6.7 ± 1.3 1.0 ± 0.3 
3 2.1 ± 1.1 0.4 ± 0.3 3.8 ± 1.0 0.9 ± 0.5 6.8 ± 1.1 0.8 ± 0.3 
4 1.8 ± 0.6 0.2 ± 0.1 3.5 ± 0.7 0.6 ± 0.3 6.6 ± 1.0 0.5 ± 0.2 
5 1.5 ± 0.2 0.2 ± 0.1 3.4 ± 1.1 0.4 ± 0.2 6.6 ± 0.8 0.6 ± 0.2 
6 1.7 ± 0.2 0.2 ± 0.1 3.2 ± 1.1 0.3 ± 0.2 6.6 ± 1.3 0.5 ± 0.2 
 
Tyrosine fluxes (± SD, n = 6) for experiments in PB [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 3.1 ± 1.1 2.0 ± 1.1 4.1 ± 1.7 2.2 ± 0.7 5.8 ± 1.6 1.8 ± 0.5 
2 2.0 ± 0.5 0.8 ± 0.3 3.3 ± 1.0 1.1 ± 0.3 5.8 ± 1.3 1.2 ± 0.6 
3 1.9 ± 0.7 0.5 ± 0.3 3.4 ± 1.1 0.8 ± 0.3 6.4 ± 0.9 1.0 ± 0.4 
4 1.8 ± 0.6 0.3 ± 0.1 3.4 ± 1.0 0.5 ± 0.2 6.0 ± 0.6 0.6 ± 0.2 
5 1.6 ± 0.3 0.2 ± 0.1 3.2 ± 1.1 0.4 ± 0.1 6.4 ± 0.6 0.5 ± 0.1 
6 1.7 ± 0.2 0.2 ± 0.1 3.1 ± 1.0 0.3 ± 0.1 6.9 ± 1.0 0.4 ± 0.1 
 
Phenylalanine fluxes (± SD, n = 6) for experiments in PB [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 2.8 ± 1.1 1.6 ± 0.8 3.4 ± 1.3 1.3 ± 0.4 5.3 ± 1.6 1.4 ± 0.6 
2 1.8 ± 0.6 0.6 ± 0.2 2.7 ± 0.8 0.6 ± 0.2 5.8 ± 1.4 0.6 ± 0.2 
3 1.9 ± 1.0 0.4 ± 0.2 2.7 ± 0.9 0.5 ± 0.1 6.3 ± 1.3 0.4 ± 0.1 
4 1.7 ± 0.8 0.2 ± 0.1 2.7 ± 0.7 0.3 ± 0.1 6.0 ± 1.3 0.3 ± 0.1 
5 1.4 ± 0.3 0.2 ± 0.0 2.6 ± 0.9 0.2 ± 0.1 6.4 ± 1.2 0.4 ± 0.1 
6 1.6 ± 0.2 0.2 ± 0.1 2.5 ± 0.8 0.2 ± 0.1 6.9 ± 1.2 0.3 ± 0.1 
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Asparagine fluxes (± SD, n = 6) for experiments in PB [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 2.8 ± 0.7 1.7 ± 0.6 3.7 ± 1.4 1.7 ± 0.5 6.2 ± 2.1 1.4 ± 0.5 
2 1.8 ± 0.3 0.6 ± 0.2 2.4 ± 0.6 0.6 ± 0.2 6.0 ± 1.3 0.5 ± 0.2 
3 1.8 ± 0.5 0.3 ± 0.1 2.8 ± 0.7 0.4 ± 0.2 6.4 ± 1.2 0.4 ± 0.1 
4 1.9 ± 0.6 0.2 ± 0.1 2.8 ± 0.3 0.3 ± 0.1 6.3 ± 1.7 0.3 ± 0.2 
5 1.8 ± 0.3 0.2 ± 0.1 2.9 ± 0.7 0.2 ± 0.1 6.7 ± 1.6 0.4 ± 0.1 
6 1.9 ± 0.3 0.1 ± 0.1 2.8 ± 0.5 0.2 ± 0.1 7.3 ± 1.6 0.4 ± 0.1 
 
Tryptophan fluxes (± SD, n = 6) for experiments in PB [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 1.1 ± 0.5 0.13 ± 0.09 1.7 ± 0.9 0.10 ± 0.03 3.7 ± 1.6 0.20 ± 0.12 
2 1.2 ± 0.4 0.06 ± 0.03 2.3 ± 0.9 0.08 ± 0.04 5.0 ± 1.1 0.10 ± 0.07 
3 1.2 ± 0.4 0.04 ± 0.03 2.5 ± 0.9 0.05 ± 0.03 6.0 ± 0.9 0.07 ± 0.02 
4 1.2 ± 0.4 0.02 ± 0.02 2.7 ± 0.7 0.04 ± 0.02 5.8 ± 0.9 0.06 ± 0.06 
5 1.2 ± 0.3 0.01 ± 0.01 2.7 ± 0.8 0.03 ± 0.01 6.3 ± 0.7 0.03 ± 0.02 
6 1.3 ± 0.2 0.01 ± 0.01 2.8 ± 0.7 0.02 ± 0.01 7.1 ± 1.0 0.02 ± 0.02 
 
Methionine fluxes (± SD, n = 6) for experiments in PB [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 1.4 ± 0.8 0.5 ± 0.2 2.3 ± 0.6 0.3 ± 0.2 3.8 ± 1.6 0.3 ± 0.2 
2 1.3 ± 0.4 0.15 ± 0.08 2.0 ± 0.4 0.12 ± 0.02 5.0 ± 1.2 0.12 ± 0.08 
3 1.2 ± 0.7 0.07 ± 0.06 2.21 ± 0.61 0.09 ± 0.05 5.3 ± 1.6 0.12 ± 0.09 
4 1.0 ± 0.3 0.05 ± 0.02 2.3 ± 0.5 0.05 ± 0.05 5.2 ± 1.6 0.07 ± 0.05 
5 0.9 ± 0.2 0.06 ± 0.03 2.1 ± 0.7 0.03 ± 0.01 5.1 ± 0.7 0.06 ± 0.03 
6 1.0 ± 0.2 0.04 ± 0.02 2.0 ± 0.8 0.05 ± 0.03 5.9 ± 1.0 0.06 ± 0.03 
 
Glucose fluxes (± SD, n = 6) for experiments in PB [nmol/(h⋅cm2)] 
0.1 mM 0.25 mM 0.5 mM Time 
(h) Cathode Anode Cathode Anode Cathode Anode 
1 15.3 ± 9.0 1.6 ± 1.7 24.4 ± 13.6 1.7 ± 1.9 40.4 ± 19.4 0.7 ± 0.4 
2 13.1 ± 4.5 0.4 ± 0.2 25.2 ± 9.4 0.9 ± 1.1 48.1 ± 11.0 0.2 ± 0.1 
3 14.5 ± 4.9 0.2 ± 0.1 29.3 ± 8.7 0.5 ± 0.1 56.1 ± 11.2 0.3 ± 0.2 
4 14.6 ± 4.8 0.2 ± 0.1 31.1 ± 7.1 0.4 ± 0.1 56.1 ± 10.0 0.5 ± 0.3 
5 14.1 ± 3.2 0.18 ± 0.04 31.0 ± 8.2 0.5 ± 0.2 60.4 ± 7.5 1.1 ± 0.5 
6 15.4 ± 2.4 0.24 ± 0.04 30.4 ± 6.2 0.5 ± 0.3 69.0 ± 11.3 0.9 ± 0.5 
 
Annex III 
 207 
3. Extraction fluxes (mean ± SD) at the cathode for the 3-6 hour period as 
a function of subdermal concentration for 14 AAs and glucose when the 
background electrolyte was PBS pH 7.4. Values obtained in absence of 
the analytes are also included [Chapter 4]. 
Extraction fluxes [nmol/(h⋅cm
2
)] for subdermal concentration in PBS 
Molecule 
0 mM 
0.1 mM AAs 
1 mM glucose 
0.25 mM AAs 
2.5mM glucose 
0.5 mM AAs 
5 mM glucose 
Serine 4.1 ± 1.2 2.7 ± 0.8 4.3 ± 3.2 5.1 ± 1.9 
Glycine 3.7 ± 1.2 2.5 ± 0.8 4.3 ± 2.5 4.4 ± 1.1 
Alanine 2.7 ± 0.6 1.9 ± 0.5 3.4 ± 1.9 4.0 ± 1.1 
Histidine 1.8 ± 0.4 1.8 ± 0.5 2.8 ± 1.4 3.6 ± 1.1 
Threonine 1.1 ± 0.3 0.9 ± 0.3 1.7 ± 0.9 2.4 ± 0.4 
Proline 0.9 ± 0.2 0.9 ± 0.2 1.6 ± 0.7 2.3 ± 0.4 
Leucine 1.1 ± 0.3 1.1 ± 0.4 1.9 ± 0.6 2.5 ± 0.4 
Valine 0.6 ± 0.3 0.6 ± 0.1 1.3 ± 0.5 1.9 ± 0.2 
Isoleucine 0.5 ± 0.2 0.6 ± 0.1 1.1 ± 0.2 1.8 ± 0.2 
Tyrosine 0.4 ± 0.1 0.6 ± 0.1 1.1 ± 0.3 1.7 ± 0.2 
Phenylalanine 0.3 ± 0.1 0.5 ± 0.1 1.1 ± 0.3 1.7 ± 0.2 
Asparagine 0.2 ± 0.1 0.4 ± 0.1 1.1 ± 0.2 1.8 ± 0.2 
Tryptophan 0.05 ± 0.03 0.31 ± 0.04 0.8 ± 0.1 1.5 ± 0.2 
Methionine N.A. 0.2 ± 0.1 0.6 ± 0.1 1.3 ± 0.3 
Glucose 0.4 ± 0.3 3.9 ± 0.3 9.9 ± 1.0 16.9 ± 2.0 
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4. Extraction fluxes (mean ± SD) at the cathode for the 3-6 hour period as 
a function of subdermal concentration for 14 AAs and glucose when the 
background electrolyte was PB pH 7.4. 
Extraction fluxes [nmol/(h⋅cm
2
)] for subdermal 
concentration in PB 
Molecule 
0.1 mM AAs 
1 mM glucose 
0.25 mM AAs 
2.5mM glucose 
0.5 mM AAs 
5 mM glucose 
Serine 6.1 ± 2.1 8.0 ± 1.6 12.2 ± 2.2 
Glycine 5.6 ± 1.8 5.7 ± 1.7 9.6 ± 1.7 
Alanine 4.5 ± 0.9 5.4 ± 1.1 8.7 ± 0.9 
Histidine 4.4 ± 1.3 6.2 ± 1.7 9.6 ± 1.2 
Threonine 2.6 ± 0.6 4.4 ± 1.1 8.1 ± 1.4 
Proline 2.3 ± 0.6 3.7 ± 1.4 7.5 ± 1.2 
Leucine 2.1 ± 0.5 4.1 ± 1.2 7.4 ± 1.4 
Valine 1.7 ± 0.4 3.4 ± 0.6 6.9 ± 0.9 
Isoleucine 1.7 ± 0.4 3.4 ± 0.9 6.6 ± 1.0 
Tyrosine 1.7 ± 0.4 3.2 ± 1.0 6.4 ± 0.8 
Phenylalanine 1.6 ± 0.5 2.6 ± 0.7 6.4 ± 1.2 
Asparagine 1.8 ± 0.4 2.8 ± 0.5 6.8 ± 1.6 
Tryptophan 1.2 ± 0.3 2.7 ± 0.7 6.4 ± 1.0 
Methionine 1.0 ± 0.2 2.1 ± 0.6 5.4 ± 1.2 
Glucose 14.7 ± 3.4 30.9 ± 6.8 61.8 ± 10.7 
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5. Linear regressions of the average fluxes of the 3-6 hour extraction 
period at the cathode as a function of subdermal concentration for 14 AAs 
and glucose. The slopes (± SE (r2)), which represent apparent 
electroosmotic flows, when either PBS or PB was the background 
electrolyte are presented. The amount of each compound in the SC as 
determined by tape-stripping [Chapter 4] is also presented. 
 
Molecule Slope PBS 
[µL/(h⋅cm
2
)] 
Slope PB 
[µL/(h⋅cm
2
)] 
Amount in SC 
[nmol/cm
2
] 
Serine 3.1 ± 1.3   (0.08) 15 ± 2   (0.63) 37 ± 9 
Glycine 2.6 ± 1.0   (0.08) 11 ± 2   (0.49) 23 ± 6 
Alanine 3.5 ± 0.8   (0.23) 11 ± 1   (0.77) 22 ± 4 
Histidine 3.8 ± 0.6   (0.37) 13 ± 1   (0.71) 21 ± 4 
Threonine 3.0 ± 0.3   (0.51) 14 ± 1   (0.83) 10 ± 2 
Proline 2.9 ± 0.3   (0.61) 13 ± 1   (0.80) 7.3 ± 1.5 
Leucine 3.0 ± 0.3   (0.61) 13 ± 1   (0.82) 7.3 ± 2.1 
Valine 2.8 ± 0.2   (0.71) 13 ± 1   (0.91) 3.4 ± 1.0 
Isoleucine 2.8 ± 0.1   (0.87) 12 ± 1   (0.87) 3.0 ± 0.8 
Tyrosine 2.9 ± 0.1   (0.89) 12 ± 1   (0.87) 3.2 ± 0.6 
Phenylalanine 3.0 ± 0.1   (0.88) 12 ± 1   (0.83) 2.1 ± 0.5 
Asparagine 3.2 ± 0.1   (0.94) 13 ± 1   (0.80) 1.8 ± 0.6 
Tryptophan 2.9 ± 0.1   (0.95) 13 ± 1   (0.90) 0.5 ± 0.2 
Methionine 2.5 ± 0.1   (0.88) 11 ± 1   (0.85) N.A. 
Glucose 3.3 ± 0.1   (0.96) 12 ± 1   (0.88) 1.4 ± 0.7 
 
The slopes in each group (PBS and PB) are not significantly different one 
another and the pooled slopes are 3.3 and 12 (µL/cm2⋅h)) respectively. 
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6. AA and glucose cathodal extraction fluxes (during the 3-6 hour period) 
normalized by the subdermal concentration (mean ± SD) when the 
background electrolyte is PB. Values significantly different from that for 
glucose (ANOVA followed by Dunnett’s test) are indicated by asterisks 
(**p<0.01, *p<0.05). 
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7. Amount extracted at the cathode in the 1st hour normalized by the mean amount found in the SC for 13 AAs and glucose 
for the different subdermal concentration tested (PBS and PB). 
Subdermal concentration in PBS Subdermal concentration in PB 
Molecule 0.1 mM AAs 
1 mM glucose 
0.25 mM AAs 
2.5 mM glucose 
0.5 mM AAs 
5 mM glucose 
0.1 mM AAs 
1 mM glucose 
0.1 mM AAs 
1 mM glucose 
0.5 mM AAs 
5 mM glucose 
Serine 0.8 ± 0.3 0.8 ± 0.3 0.7 ± 0.1 1.1 ± 0.5 1.0 ± 0.2 1.2 ± 0.3 
Glycine 1.0 ± 0.3 1.0 ± 0.4 0.9 ± 0.2 1.1 ± 0.3 0.8 ± 0.4 1.2 ± 0.3 
Alanine 0.8 ± 0.2 0.8 ± 0.2 0.9 ± 0.1 0.8 ± 0.2 0.7 ± 0.3 0.8 ± 0.2 
Histidine 0.9 ± 0.2 0.9 ± 0.3 0.9 ± 0.1 0.8 ± 0.2 0.7 ± 0.2 0.9 ± 0.3 
Threonine 0.8 ± 0.3 0.8 ± 0.2 0.8 ± 0.2 1.1 ± 0.4 1.0 ± 0.2 1.3 ± 0.3 
Proline 1.0 ± 0.4 0.9 ± 0.2 1.0 ± 0.1 1.2 ± 0.5 1.2 ± 0.4 1.6 ± 0.4 
Leucine 0.8 ± 0.2 0.7 ± 0.1 0.8 ± 0.2 1.0 ± 0.6 1.6 ± 0.3 1.3 ± 0.4 
Valine 1.0 ± 0.3 1.1 ± 0.3 1.2 ± 0.4 1.6 ± 0.5 1.7 ± 0.5 2.2 ± 0.5 
Isoleucine 0.7 ± 0.2 0.7 ± 0.1 1.1 ± 0.4 1.4 ± 0.5 2.0 ± 0.5 2.2 ± 0.6 
Tyrosine 0.5 ± 0.2 0.6 ± 0.1 0.7 ± 0.2 0.9 ± 0.3 1.2 ± 0.5 1.7 ± 0.5 
Phenylalanine 0.6 ± 0.2 0.7 ± 0.2 1.1 ± 0.4 1.3 ± 0.5 1.5 ± 0.6 2.4 ± 0.7 
Asparagine 0.8 ± 0.3 0.9 ± 0.3 1.5 ± 0.6 1.5 ± 0.3 1.9 ± 0.7 3.2 ± 1.1 
Tryptophan 0.7 ± 0.2 1.1 ± 0.2 2.2 ± 1.2 2.0 ± 0.9 3.0 ± 1.6 6.6 ± 2.9 
Glucose 3.6 ± 1.7 6.0 ± 2.1 11.7 ± 5.7 9.1 ± 5.4 14.5 ± 8.1 24.0 ± 11.5 
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8. Cumulative amount extracted at the cathode as a function of time when 
the subdermal compartment was 0.5 mM AAs and 5 mM glucose in PBS 
when no analytes were added in the subdermal compartment (Blank). The 
amounts found in the SC by tape-stripping are also presented [Chapter 4]. 
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8. Cumulative amount extracted at the cathode as a function of time when 
the subdermal compartment was 0.5 mM AAs and 5 mM glucose in PBS 
when no analytes were added in the subdermal compartment (Blank). The 
amounts found in the SC by tape-stripping are also presented [Chapter 4]. 
(continued) 
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8. Cumulative amount extracted at the cathode as a function of time when 
the subdermal compartment was 0.5 mM AAs and 5 mM glucose in PBS 
when no analytes were added in the subdermal compartment (Blank). The 
amounts found in the SC by tape-stripping are also presented [Chapter 4]. 
(continued) 
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ANNEX IV. Complements to Chapter 6 
 
1. Concentration profiles of 13 AAs and glucose in the SC in the four 
subjects measured on two occasions. 
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1. Concentration profiles of 13 AAs and glucose in the SC in the four 
subjects measured on two occasions. (continued) 
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1. Concentration profiles of 13 AAs and glucose in the SC in the four 
subjects measured on two occasions. (continued) 
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2. Plasma levels of 13 AAs and blood glucose in the four subjects studied 
during the passive diffusion experiment. The blood sample was obtained 
after 4 hours of extraction. 
Molecule 
S1  
(µM) 
S2  
(µM) 
S3  
(µM) 
S4 
(µM) 
Usual range 
(µM) 
Serine 175 239 208 237 90-290 
Glycine 192 234 276 205 100-330 
Alanine 321 285 234 154 150-450 
Histidine 115 112 92 121 30-150 
Threonine 85 130 93 141 70-220 
Proline 222 137 139 145 85-290 
Leucine 123 116 82 145 65-220 
Valine 234 190 162 185 90-300 
Isoleucine 91 100 87 81 26-100 
Tyrosine 69 44 40 52 30-120 
Phenylalanine 55 54 45 68 35-100 
Asparagine 36 38 39 28 40-90 
Tryptophan 13 19 11 15 30-80 
Glucose 5000 4400 4600 4700 4000-5500 
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3. Fluxes at the cathode, anode and by passive diffusion for 13 AAs and glucose as a function of time 
Extraction fluxes ± SD  (n = 4) at [nmol/(h⋅cm
2
)] AA or 
Glucose 
Compart-
ment 0.25 h 0.5 h 1 h 1.5 h 2 h 2.5 h 3 h 3.5 h 4 h 
Cathode 139 ± 28 89.1 ± 35.7 68.3 ± 17.5 46.6 ± 18.9 46.3 ± 18.9 35.4 ± 13.4 35.1 ± 7.2 35.0 ± 4.7 26.3 ± 4.9 
Anode 93.7 ± 45.9 62.4 ± 19.1 43.3 ± 5.5 30.7 ± 4.8 25.2 ± 3.4 17.4 ± 4.5 12.3 ± 2.6 11.7 ± 3.7 9.0 ± 2.6 Ser 
Passive 82.5 ± 46.3 40.6 ± 16.1 29.9 ± 11.1 24.9 ± 8.5 21.3 ± 6.5 21.9 ± 6.9 19.9 ± 7.8 16.8 ± 6.3 17.4 ± 6.6 
Cathode 102 ± 24 68.6 ± 26.9 46.6 ± 11.8 32.6 ± 10.8 30.7 ± 12.0 23.2 ± 8.9 20.6 ± 3.4 20.2 ± 2.4 15.5 ± 2.3 
Anode 53.8 ± 15.8 36.1 ±9.9 24.6 ± 3.1 17.7 ± 3.0 16.0 ± 3.1 11.5 ± 3.0 8.8 ± 1.8 8.4 ± 2.4 6.2 ± 2.1 Gly 
Passive 57.4 ± 26.4 31.6 ± 14.7 22.8 ± 8.4 19.7 ± 6.2 18.2 ± 5.4 16.6 ± 4.7 14.3 ± 4.7 13.6 ± 4.9 13.8 ± 4.9 
Cathode 70.8 ± 18.4 46.6 ± 19.1 33.4 ± 10.2 22.6 ± 7.6 21.3 ± 6.6 16.9 ± 6.3 16.5 ± 3.9 16.3 ± 3.5 13.2 ± 4.4 
Anode 40.3 ± 14.5 26.7 ± 6.1 18.1 ± 4.4 13.5 ± 1.4 11.5 ± 1.6 8.1 ± 2.4 5.8 ± 1.6 5.7 ± 2.1 4.3 ± 1.5 Ala 
Passive 44.5 ± 23.6 22.7 ± 9.0 16.3 ± 5.7 14.7 ± 5.5 11.9 ± 3.9 11.7 ± 2.7 10.8 ± 3.0 9.1 ± 2.6 9.3 ± 2.6 
Cathode 81.3 ± 30.8 46.8 ± 29.2 31.1 ± 12.0 19.7 ± 10.9 17.3 ± 11.6 9.9 ± 6.6 9.9 ± 4.3 8.7 ± 2.7 7.0 ± 2.0 
Anode 8.5 ± 4.4 7.2 ± 2.6 5.4 ± 1.8 4.2 ± 2.6 3.3 ± 2.2 2.5 ± 2.0 1.6 ± 1.2 1.8 ± 1.6 1.2 ± 1.2 His 
Passive 20.1 ± 17.1 9.8 ± 6.0 6.7 ± 4.7 5.7 ± 3.5 5.1 ± 2.9 5.0 ± 2.7 4.7 ± 2.3 3.9 ± 1.7 4.2 ± 2.2 
Cathode 23.8 ± 6.5 15.9 ± 7.6 12.0 ± 3.7 8.5 ± 3.3 8.5 ± 3.8 6.9 ± 2.9 7.1 ± 1.2 7.0 ± 0.9 5.6 ± 1.0 
Anode 17.4 ± 8.7 11.3 ± 3.5 8.2 ± 0.9 5.9 ± 1.0 4.9 ± 0.9 3.3 ± 0.9 2.4 ± 0.7 2.3 ± 0.8 1.7 ± 0.6 Thr 
Passive 19.0 ± 10.5 8.9 ± 3.9 6.3 ± 2.5 5.6 ± 2.0 4.6 ± 1.6 4.6 ± 1.3 4.4 ± 1.7 3.8 ± 1.4 4.1 ± 1.6 
Cathode 9.9 ± 3.4 5.9 ± 3.0 5.2 ± 1.8 3.1 ± 1.3 3.6 ± 1.7 3.0 ± 1.1 3.2 ± 0.6 3.2 ± 0.5 2.6 ± 0.4 
Anode 7.5 ± 3.9 5.0 ± 1.9 3.6 ± 0.4 2.5 ± 0.5 2.0 ± 0.4 1.5 ± 0.5 1.1 ± 0.3 1.0 ± 0.5 0.8 ± 0.2 Pro 
Passive 8.9 ± 5.1 3.8 ± 1.9 2.9 ± 1.4 2.4 ± 0.8 2.2 ±0.8 2.4 ±0.9 2.0 ± 0.8 1.7 ± 0.7 1.8 ± 0.8 
Cathode 6.0 ± 0.5 5.3 ± 1.3 3.2 ± 0.7 2.7 ± 0.9 2.1 ± 0.8 1.8 ± 0.8 1.9 ± 0.5 2.1 ± 0.7 1.6 ± 0.2 
Anode 4.8 ± 2.5 2.6 ± 1.4 1.7 ± 0.5 1.3 ± 0.4 1.2 ± 0.3 1.0 ± 0.5 0.8 ± 0.4 0.7 ± 0.3 0.7 ± 0.3 Leu 
Passive 3.2 ± 1.2 2.0 ± 0.6 1.1 ± 0.3 1.0 ± 0.2 0.9 ± 0.2 0.9 ± 0.1 0.9 ± 0.2 0.8 ± 0.1 0.9 ± 0.1 
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3. Fluxes at the cathode, anode and passive diffusion for 13 AAs and glucose as a function of time (continued) 
Extraction fluxes ± SD  (n = 4) at [nmol/(h⋅cm
2
)] AA or 
Glucose 
Compart-
ment 0.25 h 0.5 h 1 h 1.5 h 2 h 2.5 h 3 h 3.5 h 4 h 
Cathode 8.4 ± 1.9 5.7 ± 2.4 4.4 ± 1.2 3.3 ± 1.0 3.3 ± 1.6 2.4 ± 1.0 2.9 ± 0.6 3.0 ± 0.3 2.6 ± 0.8 
Anode 6.9 ± 2.5 4.1 ± 1.4 3.3 ± 0.7 2.2 ± 0.4 1.8 ± 0.3 1.2 ± 0.4 0.8 ± 0.3 0.8 ± 0.3 0.7 ± 0.2 Val 
Passive 6.4 ± 3.7 2.9 ± 1.4 2.0 ± 1.0 1.8 ± 0.8 1.5 ± 0.6 1.7 ± 0.7 1.4 ± 0.4 1.3 ± 0.5 1.3 ± 0.5 
Cathode 4.3 ± 0.9 2.6 ± 1.1 2.3 ± 0.6 1.6 ± 0.7 1.8 ± 0.5 1.5 ± 0.6 1.4 ± 0.3 1.5 ± 0.1 1.2 ± 0.2 
Anode 4.0 ± 2.2 2.3 ± 0.7 1.7 ± 0.5 1.1 ± 0.2 1.0 ± 0.2 0.7 ± 0.2 0.6 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 Ile 
Passive 2.1 ± 0.7 1.4 ± 0.5 0.9 ± 0.4 0.7 ± 0.3 0.7 ± 0.2 0.6 ± 0.2 0.5 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 
Cathode 4.0 ± 0.8 2.4 ± 0.6 2.0 ± 0.3 1.8 ± 0.9 2.0 ± 1.1 1.2 ± 0.4 1.4 ± 0.2 1.4 ± 0.1 1.2 ± 0.2 
Anode 3.3 ± 1.8 2.4 ± 0.8 1.8 ± 0.4 1.3 ± 0.4 0.9 ± 0.2 0.7 ± 0.2 0.5 ± 0.1 0.6 ± 0.2 0.4 ± 0.2 Tyr 
Passive 4.2 ± 2.1 2.1 ± 0.8 1.4 ± 0.6 1.2 ± 0.4 1.1 ± 0.3 1.1 ± 0.4 1.0 ± 0.4 0.9 ± 0.3 0.9 ± 0.3 
Cathode 2.1 ± 0.8 1.0 ± 0.5 1.0 ± 0.3 0.7 ± 0.3 0.9 ± 0.5 0.6 ± 0.3 0.6 ± 0.1 0.7 ± 0.1 0.5 ± 0.1 
Anode 1.6 ± 1.2 1.0 ± 0.5 0.8 ± 0.3 0.5 ± 0.2 0.4 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 Phe 
Passive 1.6 ± 1.2 0.7 ± 0.4 0.5 ± 0.3 0.5 ± 0.3 0.4 ± 0.2 0.5 ± 0.2 0.5 ± 0.2 0.4 ± 0.2 0.4 ± 0.2 
Cathode 3.5 ± 1.4 1.9 ± 0.8 1.5 ± 0.4 1.1 ± 0.3 1.1 ± 0.8 0.7 ± 0.2 0.7 ± 0.3 0.7 ± 0.2 0.5 ± 0.1 
Anode 2.7 ± 1.1 1.9 ± 0.8 1.2 ± 0.4 0.9 ± 0.3 0.7 ± 0.2 0.5 ± 0.1 0.35 ± 0.04 0.29 ± 0.05 0.22 ± 0.02 Asn 
Passive 2.1 ± 1.3 1.1 ± 0.5 0.8 ± 0.4 0.7 ± 0.4 0.5 ± 0.3 0.5 ± 0.3 0.5 ± 0.2 0.4 ± 0.2 0.4 ± 0.2 
Cathode 2.0 ± 0.5 1.3 ± 0.3 1.1 ± 0.2 0.7 ± 0.3 0.8 ± 0.4 0.6 ± 0.2 0.7 ± 0.2 0.7 ± 0.1 0.6 ± 0.1 
Anode 1.6 ± 0.9 1.3 ± 0.5 0.9 ± 0.2 0.7 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 Trp 
Passive 1.5 ± 0.7 0.7 ± 0.3 0.5 ± 0.2 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.2 0.3 ± 0.1 0.3 ± 0.1 
Cathode 1.1 ± 1.1 0.6 ± 0.7 0.6 ± 0.5 0.6 ± 0.6 0.7 ± 0.5 0.6 ± 0.5 0.7 ± 0.2 0.8 ± 0.3 0.6 ± 0.1 
Anode 1.1 ± 1.3 0.2 ± 0.1 0.09 ± 0.04 0.12 ± 0.04 0.12 ± 0.05 0.2 ± 0.1 0.1 ± 0.1 0.2 ± 0.1 0.1 ± 0.1 Glucose 
Passive 0.3 ± 0.1 0.1 ± 0.1 0.05 ± 0.03 0.05 ± 0.03 0.04 ± 0.02 0.05 ± 0.03 0.06 ± 0.01 0.03 ± 0.02 0.03 ± 0.02 
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4. Fluxes of AAs and glucose of the final 2-hour period of extraction at the 
cathode and by passive diffusion normalized by systemic levels and the 
quantities in the SC. 
Molecule 
Cathode/ 
systemic 
[µL/(h⋅cm
2
)] 
Cathode/SC 
[h
-1
] 
Passive diffusion/  
SC 
[h
-1
] 
Ser 146 ± 36 0.08 ± 0.02 0.06 ± 0.02 
Gly 99 ± 26 0.08 ± 0.02 0.06 ± 0.01 
Ala 70 ± 13 0.09 ± 0.02 0.05 ± 0.01 
His 87 ± 31 0.09 ± 0.02 0.04 ± 0.01 
Thr 62 ± 17 0.08 ± 0.02 0.05 ± 0.01 
Pro 17 ± 4 0.08 ± 0.02 0.04 ± 0.01 
Leu 8 ± 2 0.09 ± 0.03 0.05 ± 0.01 
Val 14 ± 4 0.09 ± 0.02 0.05 ± 0.01 
Ile 13 ± 3 0.09 ± 0.03 0.05 ± 0.01 
Tyr 30 ± 7 0.07 ± 0.01 0.05 ± 0.01 
Phe 11 ± 3 0.08 ± 0.02 0.05 ± 0.01 
Asn 13 ± 5 0.04 ± 0.01 0.03 ± 0.01 
Trp 42 ± 17 0.07 ± 0.01 0.04 ± 0.01 
Glucose 0.15 ± 0.05 0.67 ± 0.23 0.03 ± 0.02 
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5. Cumulative amount of 13 amino acids and glucose extracted in the four 
subjects (mean ± SD) at the cathode and by passive diffusion as a 
function of time. The quantities in the SC determined by tape-stripping are 
shown for comparison. 
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5. Cumulative amount of 13 amino acids and glucose extracted in the four 
subjects (mean ± SD) at the cathode and by passive diffusion as a 
function of time. The quantities in the SC determined by tape-stripping are 
shown for comparison. (continued) 
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5. Cumulative amount of 13 amino acids and glucose extracted in the four 
subjects (mean ± SD) at the cathode and by passive diffusion as a 
function of time. The quantities in the SC determined by tape-stripping are 
shown for comparison. (continued) 
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